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Since 1996 there have been 226 cases of variant Creutzfeldt-Jakob disease (vCJD) in the 
UK following dietary exposure to bovine spongiform encephalopathy (BSE) in the late 80s to 
early 90s. A recent study on archived appendix tissue has suggested that up to 1/2000 of the 
UK population may be silent carriers of infection. This is a significant portion of the UK 
population who may be incubating the disease and thus potentially passing it on to others via 
blood transfusion. As there is currently no effective screening method to test donated blood 
this is a major public health concern. The aim of this project was to utilize archived blood 
samples from transfusion experiments performed with BSE infected sheep, identify protein 
expression differences between uninfected and infected blood and discover potential 
diagnostic markers besides the abnormal prion protein (PrPSc). 
 
Infected samples were taken from sheep 10 months after oral inoculation with BSE, when 
their blood was proven to be infectious but the sheep lacked clinical signs. Uninfected 
samples were taken from the same sheep prior to BSE exposure. Samples from 9 sheep 
were pooled to control for genetic and metabolic differences. The plasma was processed 
using ProteoMiner columns to deplete highly abundant proteins while simultaneously 
enriching for low abundant proteins. Subsequently, isotopic labelling was used to distinguish 
between the two samples and levels of protein expression were compared by mass 
spectrometry. Initially 153 proteins were identified based on one unique peptide match. The 
extent of differential expression was assessed by filtering the median H/L (heavy/light 
isotopes) and proteins between >1.5 and <0.666 were retained, leaving a dataset of 44 
proteins. Elimination of the most common proteins reduced this to 37 proteins and after 
considering the current literature a candidate shortlist of 8 proteins were chosen to validate 
by western blotting and LI-COR imaging. The buffy coat fraction of blood from the same 9 
sheep were similarly processed. The original dataset of 1148 proteins was cut down to 124 
and Ingenuity Pathway Analysis (IPA) employed. This highlighted 191 biological processes 
of potential interest, including LXR/RXR activation, acute phase response signalling, 
leukocyte extraversion signalling and mitochondrial dysfunction. A shortlist of 8 candidate 
proteins were then determined for validation. These findings are the basis for a  proposed 
biomarker panel for an effective preclinical diagnostic blood test.  
 
Additionally, in order to investigate how cells pass infection by the human blood transfusion 
route, blood components from the natural scrapie flock were utilised to infect the Rov9 cell 
line. The aim of this work was to develop a system to study the processes by which live 
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white blood cells (WBCs) transfer infection to other cells. A cell culture model to study 
infectivity from scrapie infected WBCs of the Roslin Scrapie Flock was achieved. Further 
work is needed to examine whether membrane based cellular interactions are essential for 






























Compared to other neurodegenerative diseases, prion diseases are unique in that some 
forms are infectious. Following exposure of the UK population to bovine spongiform 
encephalopathy (BSE) there have been 226 cases of variant Creutzfeldt-Jakob disease 
(vCJD), the human form of BSE. It has been suggested that 1 in 2000 people in the age 
relevant population may be silent carries of vCJD. This figure has been estimated from 
detection of abnormal prion protein (PrPSc) in appendix tissue samples. It means that a 
substantial portion of the UK population may be incubating the disease and thus potentially 
passing it on to others via blood transfusion. This is a major health concern as there is 
currently no effective screening method to test for these individuals and thus it is a possibility 
that infected blood will be unknowingly given to a naïve recipient.  
 
The aim of this project was to utilize archived blood samples from transfusion experiments 
performed with BSE infected sheep and screen for differences in protein expression between 
uninfected and infected blood to identify diagnostic markers besides PrPSc. Donor sheep 
were orally infected with BSE, their blood collected and transfused to recipient sheep. Since 
it is established which of the recipients developed BSE, donors with infectious blood can be 
identified. Infected samples were taken when blood was proven to be infectious but the 
sheep lacked clinical signs (mimicking the human silent carrier status). Uninfected samples 
were taken from the same sheep at a time point prior to their exposure to BSE. Samples 
from 9 sheep were pooled to control for genetic and metabolic differences. A signature of 
protein expression in the blood of animals that transmitted disease may be of potential 
significance for diagnostics. This can be determined by use of mass spectrometry and 
isotopic labelling to distinguish the two groups.  
 
Before mass spectrometry samples were treated. Blood is a highly complex and may be 
separated into distinct fractions by centrifugation. Within plasma around twenty proteins 
(including albumin, transferrin and fibrinogen) constitute more than 98% of protein. Their 
presence can obscure detection of low abundant proteins. ProteoMiner technology utilizes a 
highly diverse library of hexapeptide ligands bound to beads within a small column. Each 
bead has an affinity for a specific protein. When samples are applied to the column high 
abundant proteins are concentrated on their beads while simultaneously, low abundant 
proteins are concentrated on theirs. This creates a final output that is more homogeneous. 
Following mass spectrometry, 35 proteins were identified as differentially expressed in 
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plasma. From this list candidate proteins were chosen to validate (confirm up or down 
expression in infected blood) based on previous literature on proteomics of prion diseases.  
 
The buffy coat layer of blood contains most of the white blood cells. Pooled buffy coat 
samples from the same 9 sheep were processed in the same manner, and 122 proteins 
were identified by mass spectrometry. This larger dataset was then placed into Ingenuity 
Pathway Analysis (IPA) to investigate the biological context of changes in protein expression. 
From the suggested disease pathways of IPA and current literature, a shortlist of candidate 
biomarkers were chosen to follow up on. In total 4 biomarkers for plasma and buff coat 
samples were validated. Results from pooled samples show confirmation of the mass 
spectrometry predictions, thus providing preliminary data on determining a protein biomarker 
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Chapter 1: Introduction 
 
1.1 Prion diseases and prion biology 
 
1.1.1 Prion diseases  
 
Prion diseases are rare, fatal, neurodegenerative conditions that have arisen in a large range 
of mammalian species (see Table 1.1). They are characterised by long incubation periods 
but are typically progressive once clinical symptoms commence. Prion diseases are also 
referred to as ‘transmissible spongiform encephalopathies’ (TSEs) due to the typical sponge 
like appearance taken on by the brain from neuronal loss during the course of disease. All 
prion diseases are characterised by the accumulation of misfolded prion protein (PrPSc). 
Although the topology or folded composition of each prion is unique, the principles governing 
aggregation and propagation are considerably distinctive (Hu and Huang 2013).  
Table 1.1: Prion diseases. There are over 20 different types of prion disease, this table 
lists some examples (Mabbott 2017).  





Human Accidental medical exposure to CJD-
contaminated tissues or tissue products 
Sporadic Creutzfeldt–
Jakob disease 
Human Unknown. Theories include somatic mutation or 
spontaneous conversion of PrPC to PrPSc 
Variant Creutzfeldt–Jakob 
disease 
Human Ingestion of BSE-contaminated food or 
transfusion of blood or blood products from CJD-
infected blood donor 
Familial Creutzfeldt–Jakob 
disease 
Human Germline mutations of the PRNP gene 
Gerstmann–Sträussler–
Scheinker syndrome 
Human Germline mutations of the PRNP gene 
Kuru Human Ritualistic cannibalism 
Fatal familial insomnia Human Germline mutations of the PRNP gene 
Bovine spongiform 
encephalopathy 
Cattle Ingestion of contaminated food 
Scrapie Sheep, goats, 
mouflon 
Acquired. Ingestion, horizontal transmission, 
vertical transmission unclear 
Chronic wasting disease Elk, deer, 
moose 
Acquired. Ingestion, horizontal transmission, 
vertical transmission unclear 
Transmissible mink 
encephalopathy 





Ingestion of BSE-contaminated food 
Exotic ungulate 
encephalopathy 
Nyala, kudu Ingestion of BSE-contaminated food 
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Human prion diseases can occur sporadically, be hereditary or be acquired. Thus far, there 
are seven subtypes that constitute human prion diseases: Kuru, Gerstmann-Sträussler-
Scheinker syndrome (GSS), fatal insomnia (FI), sporadic Creutzfeldt-Jakob disease (sCJD), 
familial (fCJD) and variant CJD (vCJD). The subtypes are distinguished by defined 
differences in cause, clinical phenotype, brain histopathology, and critically, in the structure 
of pathogenic PrPSc. GSS is a slow but progressive hereditary autosomal dominant disease. 
It was the first human prion disease in which a mutation in PRNP was discovered as the 
cause. The rarest is fatal and sporadic familial insomnia (Sikorska and Liberski 2012).  
 
 
The most common form is sporadic (sCJD) which occurs in Europe with a frequency of 1 
case per million of the general population per year (Sikorska and Liberski 2012). Acquired 
forms of disease account for only 5 % of cases of human prion disease and include kuru, 
iatrogenic CJD and vCJD (Imran and Mahmood 2011). Kuru is a unique geographical 
isolate, found exclusively in the Fore linguistic group of Papua New Guinea Eastern 
Highlands. It arose from the ritualistic practice of consuming the dead bodies of relatives as 
a mark of respect. It has seen a decline since a ban on ritualistic cannibalism was introduced 
in the mid-1950s (Manuelidis et al. 2009). Iatrogenic CJD was initially observed in 1974 in a 
patient who received cadaveric corneal transplant from a donor with sporadic CJD (Duffy et 
al. 1974). Since then there have been several cases of human prion disease associated with 
iatrogenic transmission by the use of neurosurgical instruments, cadaveric dura mater grafts 
and intramuscular injections of cadaveric pituitary-derived human growth hormone (hGH) 
and gonadotrophin hormone. Most cases of treatment with hGH have occurred in France 
and those linked to treatment with dura mater grafts have mainly occurred in Japan (Nozaki 
et al. 2010). vCJD was first reported 1996 in 10 United Kingdom (UK) patients (Will et al. 
1996). Caused by transmission from cattle infected with bovine spongiform encephalopathy 
(BSE), it is a major problem faced by Europe for the last 30 years.  
 
 
BSE was first diagnosed in southern England in 1986 (Wells et al. 1987). The initial clinical 
signs include changes in temperament, aggressive behaviour, the development of a head 
tremor and exaggerated startle reflexes. Late clinical signs include ataxia, stumbling and 
recumbency and can typically extend over several weeks (Wilesmith et al. 1992). As the 
incubation period is about 5 years, presumably the start of the epidemic in the national herd 
was exposure to food borne infection in the early 1980s. During this time changes occurred 
with the industrial rendering processes, where livestock carcass waste was converted to 
tallow and meat and bone meal. This is a likely cause for increasing survivability of prion 
infectivity in meat and bone meal where previously sufficient inactivation was applied to 
prevent recycling of infection (Wilesmith, Ryan, and Atkinson 1991). It has been shown that 
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experimental oral infection of cattle can be achieved with as little as 1 mg of BSE infected 
bovine brain (Wells et al. 2007). Another example of where a similar process of infection has 
taken place is in the appearance of prion disease in big cats and exotic ungulates (antelope, 
nyala and kudu) in zoo collections (Cunningham et al. 2004); (Lezmi et al. 2003); (Jeffrey 
and Wells 1988); (Kirkwood and Cunningham 1994). Strikingly, there have been no cases in 
domestic dogs (Kirkwood and Cunningham 2007). As well as the classical form of BSE, 
atypical BSE are potentially sporadic or genetic forms of prion diseases in cattle. Two forms 
of atypical BSE were identified mostly in older animals and were named according to the 
electrophoretic migration of their PrPSc on Western blots (Casalone et al. 2004); (Biacabe et 
al. 2004). High or H type BSE PrPSc is larger thus migrates at a slower rate and is detected 
in a higher position than classical BSE. Low or L type BSE PrPSc is smaller and migrates at a 
faster rate than classical BSE so is detected in a lower position during electrophoresis 
(Langeveld et al. 2011). Along with the differences in size, there are also different 
biochemical properties, transmission characteristics and PrPSc distribution (Priemer et al. 
2013).  
 
In the case of other animal prion diseases, classical scrapie is considered the archetypal 
prion disease as it has been known to fatally affect adult sheep (aged 2-4 years) in Britain 
since the early 18th century. Sources of infection include the placenta (Schneider et al. 2015) 
and milk (Konold et al. 2013) as well as environmental contamination such as bedding, 
pasture, fencing and housing. Studies have shown shedding of infection in urine, faeces and 
saliva, hence facilitating spread and maintenance within flocks (Terry et al. 2011); (Gough 
and Maddison 2010). Due to the stability of abnormal prion proteins, attempt to cleanse and 
disinfect housing have limited effect (Konold et al. 2008). Furthermore, prions may persist in 
the soil for at least 18 months, they can also retain their infectious properties even when 
bound to plants (Maddison et al. 2010); (Pritzkow et al. 2015). This is a big issue for disease 
control within the farm environment. In contrast with BSE, where no apparent changes in the 
biological phenotype of BSE isolates have been identified through the epidemic (Green et al. 
2005), several agent strains are recognised with classical scrapie (Bruce et al. 2002). A 
major distinction between the classical scrapie strains that are readily spread within 
susceptible sheep population and the atypical form of scrapie, is that atypical scrapie has 
unique molecular and phenotypic characteristics and is thought to perhaps occur 
spontaneously in older sheep (Greenlee 2018). Furthermore it transmits very poorly under 
natural conditions (Fediaevsky et al. 2010). Asymptomatic scrapie has worldwide distribution 
with similar incident rates which support a separate aetiology from classical scrapie (Cook et 
al. 2016); (Mitchell et al. 2010); (Dagleish et al. 2008).  
 
Chronic wasting disease (CWD) is a prominent prion disease affecting various cervid 
species. Originally described in captive mule deer in 1967 (Williams and Young 1980), CWD 
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has since been reported in both farmed and wild cervids, including white-tailed deer, mule 
deer, elk and moose. Surveillance has established presence in many central and eastern 
states of the US, as well as in 5 provinces of Canada (Gilch et al. 2011). The prevalence in 
cervids in Scandinavia is very low with 1 in 2,500 cervids (0.04%) in Finland and 23 in 
41,125 cervids (0.05%) in Norway. However these numbers may increase with further testing 
detecting more cases (Gale 2018). Characterisation of European isolates is currently being 
pursued, however preliminary data suggest that CWD strains identified in Europe and North 
America are different and that there is strain diversity in the European cervid population 
(EFSA et al. 2019). CWD has been described as the sole prion disease truly endemic in wild 
animal populations (Windl and Dawson 2012). Clearly contagious, CWD infectivity has been 
found in the lymphoreticular systems as well as in blood and urine (Mathiason et al. 2010). It 
cannot be said for sure if CWD is a danger to public health. However, there are some interim 
results from a study where CWD was transmitted to macaques that were fed infected meat 
(muscle tissue) or brain tissue from both clinical and asymptomatic CWD infected deer and 
elk (CDC 2018). Various schemes have been employed for control and limiting geographical 
range. In an attempt to eradicate CWD in Norway and prevent its spread to the rest of 
Europe, culling of herds has taken place in 2018 (GSSO 2018). In the United States (US), 
there has been limited success achieved with attempts to manage CWD. Control measures 
include surveillance, carcass regulations (banning importation of brain or spinal tissues), 
bans on baiting stations, as well as non-selective hunting and culling of deer (Conner et al. 
2008). Within endemic areas, such as the state of Colorado, management programmes 
focus on containing CWD prevalence in localised areas, thus reducing risk of spread along 
putative movement corridors (Blanchong 2010).  
 
1.1.2 Prion protein chemistry, function and misfolding  
 
The gene PRNP encodes prion protein (PrP), it is illustrated in Figure 1.1. It is a glycosylated 
membrane protein of about 230 amino acid residues, depending on species. Ubiquitously 
expressed across tissues in all mammalian species, it is predominantly associated with 
neurons, non-neuronal cells in the nervous system (glia and Schwann cells) and the lympho-
reticular system. PrP is able to adopt two confirmations, either a native α-helix rich structure 
(PrPC) or a misfolded, disease associated β-sheet abundant complex (PrPSc). The latter is 
self-propagating. It is able to recruit and convert PrPC, aiding assembly of PrPSc oligomers 
and amyloid plaques in the brains. PrPSc is less soluble than PrPC but more resistant to 
protease digestion (Choi et al. 2009). In the infectious or acquired forms of prion disease the 
refolding of PrPC to PrPSc is initiated by the uptake of misfolded PrPSc. In the genetic forms of 
the disease, PRNP polymorphisms predispose individuals to the formation of a misfolded 
prion protein which in turn promote further misfolding (Bagyinszky et al. 2018). The process 
whereby PrPSc is the only disease-causing agent, is described as the ‘protein-only 
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hypothesis’ (Prusiner 1998). It is puzzling that a protein underlying such fatal 
neurodegenerative disorders is highly conserved. This suggests that the existence of PrPC 
has some important beneficial, physiological activities. The function of PrPC however, is as 
yet unresolved.  
 
PrPC is synthesised in the rough endoplasmic reticulum (RER) and transits the Golgi 
apparatus as it moves to the cell surface (Riesner 2003a). Following translation and 
extrusion into the lumen of the endoplasmic reticulum, PrPC undergoes several 
posttranslational modifications to adopt the distinctive structure of a C-terminal globular 





Figure 1.1: (A) Organisation of human PrP. Unprocessed PrP is 253 amino acid 
residues in length and consists of an octarepeat region (OR), a hydrophobic region, one 
disulphide bond, two N-linked glycosylation sites at positions 181 and 197 and a 
glycosyl phosphoinosityl (GPI) anchor at position 230 attached to the C-terminus. N-
terminal (N1) is 23 to 110. C-terminal (C1) is 111 to 253 SP = signal peptide, PC = 
positively charged region, CC = charged cluster region, HC =hydrophobic core region 
(Yusa et al. 2012). (B) Normal and pathogenic prion protein. As represented in the 
diagram PrPC is composed of predominantly α helixes, while PrPSc is mainly made up of 
β sheets. The western blot shows expected band pattern before after treatment with 
proteinase K (PK) (Brown and Mastrianni 2010). 
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CC2), an octarepeat region (OR) and a hydrophobic domain make up the N-terminal tail. 
Additionally, there are two N-glycosylated sites at positions 181 and 197 and a glycosyl 
phosphoinosityl (GPI) anchor at position 230 of the C-terminus. Both N-glycosylation 
sequons can be variably glycosylated, resulting in unglycosylated, mono-glycosylated and di-
glycosylated species (Rudd et al. 1999); (Stimson et al. 1999). After transportation to the cell 
membrane, the GPI anchor allows PrPC to reside extracellularly in lipid rafts (Naslavsky et al. 
1997). Here it is a potential candidate for ligand uptake, cell adhesion or membrane 
signalling. It undergoes rapid constitutive endocytosis and subsequent recycling or 
degradation (Morris, Parkyn, and Jen 2006). 
 
PrPC is actively expressed in both neurons and glial cells of the central nervous system 
(CNS). Immunocytochemical studies by light and electron microscopy in both primate and 
rodent brains indicate its location in the pre- and post-synaptic compartments of nerve 
terminals in neurons (Sales et al. 1998). Due to this, one possible function of PrPC is in 
preserving normal synaptic structure and function through regulation of synaptic 
transmission and plasticity (the ability of synapses to change their strength based on 
previous activity) (Jeffrey et al. 2000). Studies of PrPC deficient mice show that they display 
weakened inhibitory GABAA (gamma-aminobutyric acid type A) receptor-mediated synaptic 
transmission and impaired long-term potentiation (LTP) (Collinge et al. 1994). This can be 
rescued by a human PRNP transgene (Whittington et al. 1995). LTP in the hippocampus 
underlies learning and memory formation, thus any defects in LTP may result in cognitive 
defects. This is exemplified in the reduction in spatial learning and memory in PrPC deficient 
mice (Criado et al. 2005). PrPC has also been suggested to play a key role in sleep 
homeostasis. With prolonged sleep deprivation PRNP knockout mice were found to have 
reduced slow wave activity and altered hormonal reactivity to stress (Sanchez-Alavez et al. 
2007). Coincidently, deterioration of slow wave activity was also found to contribute to sleep 
deficits in Alzheimer’s disease (AD) was reversed by enhancing GABAAergic inhibition 
(Busche et al. 2015) 
 
As PrPC is expressed a few days after embryonic implantation and thus has been proposed 
to play a role in development (Manson et al. 1992). It has been found that PrPC deficient 
mice exhibit reduced proliferation rates of neuronal progenitor cells in the embryonic, new 
born and adult CNS (Bribian et al. 2012). Another suggested function of PrPC is in 
neuroprotection. PrPC is also able to bind metal copper ions and thus it has been proposed 
to participate in resistance to oxidative stress by preventing reactive oxygen species (ROS) 
generation via free copper mediated redox reactions (Xu and Zhu 2012); (Brown et al. 1997). 
Copper binding may also inhibit prion disease propagation. Neuroblastoma cells cultured in 
the presence of copper have reduced accumulation of PrPSc and a significant delay in PrPC 
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conversion was observed when scrapie infected hamsters were treated with copper (Hijazi et 
al. 2003).  
 
A number of hypotheses have been proposed for the sequential events involved in 
conversion of healthy PrPC to abnormal PrPSc. Such processes are depicted in Figure 1.2.  
Early ideas for the underlying molecular mechanism formulated in the ‘prion hypothesis’ 
proposed that PrPSc acted as a template for PrPC to misfold (Prusiner 1998). Studies in the 
mid-90s demonstrated that the mixing of immune-isolated PrPC with PrPSc in a suitable buffer 
system caused the PrPC to take on PrPSc characteristics (Kocisko et al. 1994). The formation 
of aggregates or new ‘seeds’ are also thought to be critical to the misfolding cascade.    
 
 
1.1.3 Genetic susceptibility to prion diseases 
 
The single nucleotide polymorphism (SNP) at codon 129 of PRNP is a known genetic risk 
factor for the development of human prion diseases. It either encodes methionine (M) or 
valine (V) and has a profound effect on susceptibility. For vCJD in the UK, all pathological 
 
Figure 1.2: Potential pathways of protein misfolding. A) conversion of PrPC to PrPSc 
does not occur spontaneously but instead requires interaction of both molecules. The 
formation of this heterodimer then catalyses the conversion of PrPC to PrPSc and 
subsequent addition of PrPC to create fibrils. Alternatively, a cofactor may unfold PrPC to 
an intermediate PrP* which facilitates heterodimer formation. B) another possibility is that 
PrPC to PrPSc exist in equilibrium but a cofactor may shift this in favour of PrPSc. For both 
pathways amyloids may fragment resulting in additional seeds further driving the process 
of conversion (Gill and Castle 2018) 
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positive cases that had undergone genetic testing were homozygous M/M at codon 129 
(Saba and Booth 2013). The exception was one heterozygous (M/V) individual identified in 
2016 (Mok et al. 2017). Thus it is unknown whether codon 129 heterozygosity confers 
resistance to prion disease or whether it results in elongating the incubation period. Sporadic 
CJD also predominantly affects methionine (M/M) homozygous individuals, with MV 
heterozygosity reported to confer resistance (Palmer et al. 1991). For iatrogenic CJD 
following administration of cadaver-sourced pituitary derived growth hormone, an excess of 
valine (V/V) homozygotes were first reported in early UK cases as a marker of susceptibility. 
The V/V genotype has now greatly decreased while M/M genotype increased, suggesting 
contrasting conferred incubation times (up to 40 years after treatment). These discrepancies 
may potentially be explained by the compatibility of host genotype and the strain of the 
infecting prion, whereby different prion strains are preferentially propagated by prion proteins 
of different primary sequence (Collinge and Clarke 2007). 
 
A clear relationship between sheep host genetics and susceptibility to scrapie is well 
established. Susceptibility is strongly modulated by polymorphisms in PRNP. In sheep PRNP 
encodes alanine (A), arginine (R) and glutamine (Q) at codons 136, 154 and 171. 
Polymorphisms at these codons are mainly responsible for changes in resistance or 
susceptibility of a sheep to scrapie, as measured by attack rate or incubation period 
(Goldmann 2008). Having a valine (V) at codon 136 is associated with increased 
susceptibility, while R at codon 171 is associated with increased resistance. Hence, 
VRQ/VRQ sheep are the most susceptible and ARR/ARR sheep the most resistant (Hunter 
et al. 1996). Additionally, substitution of methionine (M) by threonine (T) or of leucine (L) by 
phenylalanine (F) at codons 112 and 141 respectively have been shown to result in longer 
scrapie incubation periods (González et al. 2014); (Laegreid et al. 2008). This relationship 
between PRNP and scrapie susceptibility has served as the basis for implementation of a 
scrapie control programme to breed sheep based on genetic selection. The National Scrapie 
Plan (NSP) was launched in 2001, with cost of blood sampling, laboratory genotyping and 
scheme administration met by the government. It required negative selection of the VRQ 
allele (rams with VRQ allele were killed or castrated) and became well established 
throughout the pure breeding sector of the sheep industry, with membership of over 12,000 
flocks by 2006. A comparison of ram lambs born in 2002 with those of 2006 depict distinct 
changes in PrP genotype (Dawson, Moore, and Bishop 2008).  
 
1.1.4 Peripheral pathogenesis 
 
In relation to prion diseases, peripheral pathogenesis refers to the accumulation and 
replication of prions within secondary lymphoid organs (SLO) before their spread to the brain 
where they ultimately cause neurodegeneration and death. Peripheral pathogenesis is 
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dependent on prion strain, affected host animal species, age, genetics and route of infection 
(oral, peritoneal, subcutaneous or intravenous [IV]). In many prion diseases, such as scrapie, 
CWD and vCJD, infection is acquired by the oral route.  
 
Following initial tissue entry, prion agents replicate in follicular dendritic cells (FDCs) of the 
small intestine Peyer’s patches and there is subsequent dissemination to peripheral 
lymphoid tissues (spleen, tonsils and peripheral lymph nodes) (Manuelidis et al. 2000). 
Studies have shown that prion accumulation within SLO is important for efficient 
transmission of the disease to the CNS subsequent to peripheral exposure. Survival times 
were extended in mice that lacked spleens after the intraperitoneal injection of scrapie prions 
(Fraser and Dickinson 1970). Additionally, the absence of Peyer’s patches also prevented 
neuroinvasion of scrapie prions from the gut lumen (Glaysher and Mabbott 2007); 
(Donaldson, Else, and Mabbott 2015).  Prions exploit key cells of the SLO in order to 
efficiently infect the host. Mice that lack mature B and T cells (severe combined 
immunodeficient or SCID mice) are protected from peripheral infection with prions (McFarlin 
et al. 1971); (Klein et al. 1997). However, T cells appear to lack the cellular requirements to 
sustain prion infection alone as their deficiency does not affect prion disease pathogenesis 
(Raeber 1999). Although in the absence of B cells, the accumulation of prions in the spleen 
and subsequent neuroinvasion are significantly impeded, B cells alone are unable to support 
prion replication. Prion replication does not occur in transgenic mice which express high 
levels of PrPC only on B cells (Montrasio et al. 2001). This highlights that the role of B cells in 
prion pathogenesis is likely to be indirect, perhaps in the homeostatic support of other 
cellular subpopulations within the lymphoreticular organs or because they play a critical role 
in the normal development of FDC. Moreover, Mok et al. (2012) have shown that deficiency 
in recirculating B cells prevented the spread of prion infection between SLO. Their data 
suggests that the actions of B cells, interacting with and acquiring surface proteins from 
FDCs, recirculating between SLO via the blood and lymph, mediate initial propagation of 
prions from the draining lymphoid tissue to peripheral tissues. Hence, B cells are required for 
prion propagation as in their absence FDC function is impaired. 
 
FDCs are non-haematopoietic cells that are present within the B cell follicles of SLO. Tumour 
necrosis factor-α (TNF-α) and lymphotoxins (LT) are cytokines produced by B cells. TNF-α 
and LT maintain FDCs in their differentiated state, in their absence FDCs rapidly de-
differentiate (Mackay and Browning 1998). It has been shown that prion accumulation in 
SLO and neuroinvasion are significantly impeded in mice deficient in TNF-α and LT 
stimulation thus hinting at the significant role played by FDC in establishing prion infections 
(Mabbott, Williams, et al. 2000); (Glaysher and Mabbott 2007). To determine that FDCs were 
the essential sites of prion replication within SLO, experiments have been performed with 
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transgenic mice. When expression of PrPC was switched off on FDCs, prion replication in the 
spleen was blocked. In contrast, when PrPC expression was switched on only on FDCs, this 
was enough to sustain high levels of replication in the spleen (McCulloch et al. 2011).  
 
Although PrPSc has been detected in the small intestine Peyer’s patches of cattle infected 
with BSE (Hoffmann et al. 2011), BSE prions are thought to have little involvement with SLO 
during the preclinical phase of infection (Kaatz et al. 2012). However, the transmission of 
BSE prions to other species (humans, sheep and mice) is distinctively characterised by their 
accumulation in lymphoid tissues (Hill et al. 1997); (Foster et al. 2001). Following oral 
exposure, prions must cross the gut epithelium before establishing infection upon the FDC 
within the gut-associated lymphoid tissues (GALT). This is done by exploiting specialist 
phagocytic epithelial M cells as depicted in Figure 1.3. M cells line gut associated lymphoid 
tissues and are important for efficient mucosal immune responses against certain pathogenic 
bacteria (Hase et al. 2009). A number of studies show that prions make use of M cells in 
order to establish infection within the host (Miyazawa et al. 2007); (Takakura et al. 2011); 
(Donaldson et al. 2016). Antigens that have been transported across the gut epithelium by M 
cells are released into the basolateral pocket beneath where they are sampled by 
mononuclear phagocytes. After antigen uptake these cells undergo maturation and migrate 
to local SLO to initiate an immune response. Conventional DCs also transport antigens 
within Peyer’s patches and towards the mesenteric lymph nodes (Cerovic et al. 2014); 
(Mabbott et al. 2011). FDCs do not travel in blood or lymph fluid, thus, circulation of 
infectivity in the body is thought to involve other key cells (such as dendritic cells, B 
lymphocytes and platelets) (Mabbott, Mackay, et al. 2000). As B cells recirculate between 
SLO for several weeks they often acquire antigens from FDCs within the germinal centres 
(Schmidt et al. 2013); (Suzuki et al. 2009). It has been shown that when the migration of B 
cells between SLO was blocked, the dissemination of prions from these tissues were also 
blocked (Mok et al. 2012). Hence, recirculating B cells appear to mediate the initial spread of 
prions via blood and lymph.  
 
The distribution of PrPSc in the brains of BSE infected sheep with signs of disease have 
proven to be similar irrespective of the route of inoculation being IC, IV or oral (Gonzalez et 
al. 2005). This suggests a common pattern of neuroinvasion and CNS spread. The presence 
of vascular amyloid PrPSc deposition in the basement membrane of endothelial cells of the 
hypothalamus, give an indication that infectivity may reach the brain from the blood (van 
Keulen et al. 2000). However, these plaques are rare in prion diseases, thus they do not 
justify haematogenous neuroinvasion being a frequent event or even having an important 




Figure 1.3: The movement of prions (PrPSc). Diagram depicting the spread of prions 
from the intestine to the CNS (Mabbott 2017).  
Following amplification in lymphoid tissue, prions travel via the sympathetic and 
parasympathetic pathways to ultimately infect the brain. From abdominal lymphoid organs, 
nerve fibres spread along splanchnic nerves to the spinal cord as part of the sympathetic 
nervous system. The enteric nerve plexus of the gut wall connects to the vagus nerve, which 
is part of the parasympathetic arm of the nervous system (Jeffrey and Gonzalez 2007). 
Alternatively, some cells may carry prion agents from the bloodstream to the CNS by 
crossing the blood-brain barrier (a specialised layer of endothelial cells joined by tight 
junctions). DCs and T cells are capable of breaching this barrier during the pre-clinical 
stages of prion disease (Mabbott and MacPherson 2006). Once the infectivity enters the 
CNS, it spreads to particular brain areas. The exact localisation is dependent on the 
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particular prion strain. The circumventricular organs (CVO) are specific organs in the brain 
which have fenestrated capillaries and are more permissive than other areas of the brain to 
the passage of large molecules. They provide a two way communication between the CNS 
and the rest of the body (Siso, Gonzalez, and Jeffrey 2010). It has been shown that PrPSc 
accumulation in CVOs of sheep is an early, consistent event that is not affected by route of 
challenge or disease strain. This suggests that CNS entry of infectivity can occur through 
these structures (Siso, Jeffrey, and Gonzalez 2009). There is no evidence that the arrival of 
PrPSc in the CVOs is cell mediated, as WBCs are not observed in these organs at preclinical 
or clinical stage of disease. PrPSc is thus likely to be present in plasma, as cell free soluble 
molecules. Once infection is established in the CVOs, there is potential for further spread to 
neighbouring neural structures through efferent connections. Neuroinvasion may occur via 
the vagus nerve from the blood. If blood enters the area postrema or through CVOs, the 
neurons here would start to accumulate PrPSc immediately. It is also possible that the 
neurons of neighbouring structures, such as the dorsal motor nucleus of the vagus (DMNV) 
or the hypothalamus, to which CVOs are connected, amplify infectivity or accumulate PrPSc 
more rapidly hence, leading to their detection in these structures first.  
 
Accumulation of PrPSc can be demonstrated in placenta (Andreoletti et al. 2002), mammary 
gland (Ligios et al. 2005), salivary gland (Vascellari et al. 2007) and kidney (Siso et al. 2006) 
of prion disease affected sheep. In both scrapie and BSE, PrPSc can be detected in the 
mesenchymal cells between collecting ducts and loops of Henle in the renal pelvis in the 
absence of inflammation. This indicates that the mesenchymal cells become infected from 
blood after filtration in the glomeruli or by extravasation from the vasa recta (Siso et al. 2008). 
Furthermore, PrPSc in the mammary gland and infectivity in milk is likely to derive from blood 
(Lacroux et al. 2008); (Konold et al. 2008). In the case of sheep with classical scrapie, prion 
protein may be detected in biopsies of accessible lymphoid tissue (third eyelid, tonsil, rectal 
mucosa) (O'Rourke et al. 2002). Infectivity and deposition of prion protein is widely found 
throughout lymphoreticular tissues in the preclinical phases of disease before neuroinvasion 
takes place (Jeffrey, Martin, et al. 2001); (Gonzalez et al. 2008); (Foster et al. 1996). In the 
case of sheep experimentally infected with BSE, it was possible to detect PrPSc in the spleen 
and Peyer’s patches of ileum at 16 months post inoculation. PrP of the lymphoreticular, 
alimentary tract tissues and CNS could be detected at 20 months, coinciding with clinical 
onset (Jeffrey, Martin, et al. 2001). In cattle evidence of infection is restricted to the CNS and 
not shown to include lymphoid tissue (Wells et al. 1998). The pattern of neuropathological 





1.2 vCJD and blood borne infectivity 
 
1.2.1 BSE epidemic and zoonotic transmission  
 
While sCJD has been prevalent and recognised for over 100 years, vCJD was first reported 
in 1996 as a result of food-borne transmission of BSE. BSE or ‘mad cow disease’ was a 
direct result of continued exposure of farmed animals to feedstuffs containing infected meat 
and bone meal (MBM) derived from rendered carcases. The evidence for a connection 
between vCJD and BSE was first suggested based on epidemiology, later studies indicated 
that the responsible agents were identical (Bruce et al. 1997). This was shown by 
experimental work with mice. BSE produces a characteristic pattern of disease in mice that 
is retained after experimental passage though intermediate species (Fraser et al. 1992); 
(Bruce et al. 1994); (Foster et al. 1996). Bruce et al. (1997) was able to show this distinct 
pattern was exhibited by both mice with vCJD and mice with BSE, they displayed similar 
neuropathology, incubation periods and lesion profiles. The link between vCJD and BSE was 
also demonstrated by similarities in the histopathological pattern of the disease transmitted 
to macaques (Lasmezas et al. 1996). This demonstrated that vCJD is a unique prion disease 
since is it an acquired infection across a species barrier. The most likely primary source of 
vCJD is by the oral route with BSE contaminated meat products. A number of laws were 
introduced as safety precautions, including bans on specified bovine offal (SBO) in 1989. 
Legislation ended UK production of mechanically recovered meat (MRM), in December 1995 
and of head meat in March 1996 (Cooper and Bird 2003).  
 
There have been 230 vCJD cases reported in 12 countries, with the majority in the UK (178) 
and France (27) (Seed et al. 2018); (NCJDRSU 2017). In the UK, the median age at the 
onset of the disease was 26.5 years and the median age at death 28 years (compared to 67 
years and 68 years respectively for sCJD). The youngest case was aged 12 years at onset 
while the oldest case was aged 74 years. From year to year the numbers of new cases of 
vCJD fluctuate. Data from the National CJD Surveillance Unit suggest that since 2001 
incidences of vCJD in the UK are declining (with no cases reported in 2014 and 2015), thus 
indicating that the epidemic may be limited. Until 2015, all cases were methionine 
homozygous (MM) at codon 129 (Mok et al. 2017). The exception and new incidence in a 
heterozygous (MV) individual raises concerns about a new wave of incidence in a population 
of people previously thought to be resistant. It raises the question of whether vCJD infection 
of heterozygous individuals can establish a permanent subclinical carrier state. Although this 
may be not be a problem for infected individuals it could be potentially disastrous 
epidemiologically, leading to an unrecognized yet self-sustaining epidemic (Aguzzi and 
Glatzel 2006).   
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To date, there have been 4 instances of vCJD as a result of transmission of prion infection 
by blood transfusion. These were identified through follow-up of the 66 traceable recipients 
of blood components from 18 UK blood donors who went on to develop vCJD (Hewitt et al. 
2006). All 4 cases resulted in transmission following transfusion of non-leucodepleted red 
cells. The first recipient (Case 1) developed symptoms of vCJD 6 years after receiving a 
transfusion of blood donated 3 years before the donor (Donor 1) developed symptoms of 
vCJD (Llewelyn et al. 2004). The second recipient (Case 2) died from a nonrelated cause 5 
years after receiving blood from a donor (Donor 2) who subsequently developed vCJD. This 
was the first recorded case of autopsy detected subclinical infection in the UK (Peden et al. 
2004). The third recipient (Case 3) developed vCJD symptoms 7 years after receiving a 
transfusion of blood donated around 21 months before the donor (Donor 3) developed 
symptoms of vCJD (Wroe et al. 2006). The fourth recipient (Case 4) developed vCJD 
symptoms 8 years after receiving blood donated about 17 months before the donor (Donor 
3) developed symptoms of vCJD (NCJDRSU 2013). Another case, identified by testing the 
spleen post mortem, was a haemophiliac patient who received plasma derivatives from a 
donor who developed vCJD 6 months after donating blood. The patient had the 129 MV 
genotype and died from an unrelated cause (Calizzani et al. 2014).  
 
1.2.2 Subclinical prevalence of vCJD 
 
It may be the case that a vast number of asymptomatic vCJD carriers exist in the UK 
population. The existence of a chronic, asymptomatic carrier state is an unavoidable 
consequence of the typically long incubation periods of prion diseases, which vary from 
months to decades. Anyone who contracted the infection but failed to exhibit clinical signs 
and symptoms may be considered as a ‘silent carrier.’ It is conceivable that they will develop 
the disease in due course (perhaps being triggered by a specific event) or that the carrier 
state would persist for an indefinite period of time in which case they may be regarded as 
‘permanent subclinical carriers.’ Thus, ‘subclinical’ implies that a patient will never develop 
clinical disease. Contrastingly, the term ‘preclinical’ refers to a person (or animal) before they 
start to show signs of disease.  
 
Studies in rodents, where immune deficient mice are exposed to prions, indicate that the 
permanent subclinical carrier state may be a common phenomenon (Frigg et al. 1999). 
However, mice do not have to be immunodeficient to exhibit this subclinical carrier state (Hill 
and Collinge 2003). Zlotnik and Rennie (1963) have shown that transmission of scrapie to 
mice via the intragastric route resulted in no clinical signs (as observed after 13 months). 
Passaging of brain and spleen pools from these subclinical cases into further mice, resulted 
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in their development of clinical disease at 6 months. The existence of human hosts 
incubating the infectious agent for months to decades without exhibiting any symptoms is a 
significant challenge for diagnosis and surveillance. The possibility that such patients may be 
unknowingly passing the infection on to others is a major public health concern. Attempts to 
accurately judge the magnitude of this issue are hindered by it being impossible to quantify 
the number of subclinical individuals without a durable preclinical test and thus, the level of 
risk to recipients of blood transfusion. This also impacts on implementation of effective 
hazard management strategies. Consequently, the vCJD epidemic may be prolonged, or in a 
much worse scenario, vCJD may become endemic and self-sustained (Aguzzi and Glatzel 
2006).  
 
The prevalence and geographical distribution of subclinical vCJD is still unknown. The age of 
disease onset has not changed across the last 2 decades. This suggests that there has been 
a cohort of individuals exposed to infection over a specific time frame. This suggests an 
existence of age related susceptibility or exposure between the ages of 10-20 years, 
individuals who would now be between 30 and 55 years (Cooper and Bird 2003). Studies on 
archived, paraffin embedded appendix tissue samples (looking for abnormal prion protein) 
give an indication of the carrier status of the UK population. This was deemed a suitable test 
based on the knowledge that extensive lymphoreticular involvement is a characteristic of 
symptomatic vCJD (Hill et al. 1999); (Ironside et al. 2002). PrPSc was also detected in 
appendectomy samples removed from two patients prior to the onset of vCJD symptoms 
(Hilton et al. 1998; Hilton et al. 2002). The first retrospective study reported an estimated 
prevalence in 1 in 4000 individuals with abnormal PrP in their appendixes (with 3 positive 
specimens identified) (Hilton et al. 2004). Another study was implemented between 2007 
and 2011 to analyse tonsils by two independent immunoassays, immunohistochemistry and 
Western blot. Here 150,000 tonsils were tested and none were positive (de Marco et al. 
2010). The appendix study was repeated between 2000 and 2012, with samples being 
screened by immunohistochemistry. Out of 32, 441 samples from patients born between 
1941 and 1985, 16 were positive. Patients in this time period were tested as they would be 
the generation potentially exposed to BSE in the food chain. (Gill et al. 2013a). A weakness 
of this study however, is that the period of human exposure to BSE may be more extended 
than previously thought. Additionally, although vCJD occurs more commonly in the younger 
age groups, reactive appendix samples were found across all age groups. From this it may 
be hypothesised that many healthy people could exhibit peripheral PrPSc accumulation in 
their appendix. Thus a third appendix tissue study was initiated to look at samples outside of 
the presumed BSE exposure period (before 1980 and after 1996) (PHE 2016 ), (Gill et al. 
2020). As positive samples were found in both groups examined it does not clearly answer 
the question of whether abnormal prions detected by immunohistochemistry in the British 
population is limited to those exposed to the BSE epidemic. It may actually be that there is a 
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low background of PrPSc in appendices unrelated to intensity of exposure to BSE or that 
human exposure began in the late 1970s and continued until the mid-90s (Seed et al. 2018).     
 
1.2.3 Prevention of infection  
 
In the UK about 2.1 million units of blood components are transfused each year. This 
includes red cell concentrates for patients with haemorrhage or anaemia and platelet 
concentrates for patients with acute or chronic thrombocytopenia at risk of bleeding. To 
implement risk minimization for spread of vCJD, as of 1998 all blood donations are filtered to 
remove white blood cells (WBCs), leaving < 1x106 leucocytes per pack. This was based on 
the detection of leucocyte associated infectivity in prion disease rodent models (Brown et al. 
1998). It has been demonstrated that leucodepletion of red blood cells (RBCs) provides a 
major reduction in disease transmission. Lacroux, Bougard, et al. (2012) demonstrated that 
with the PG127 sheep infection model transfusion of standard RBCs (prepared from 400 mL 
of blood) transmitted the disease with 100% efficiency. In comparison, only one out of the 
five recipients of the leucodepleted RBCs had any evidence of infection when culled. 
However these results are in contrast to the findings by McCutcheon et al. (2011). In this 
study sheep were orally infected bovine BSE infected brain homogenate. Blood and blood 
components were then prepared with commercially available leucodepletion filters to the 
same specifications as required for routine transfusion medicine. It was demonstrated that all 
blood components could support prion disease transmission by blood transfusion. Strikingly, 
following leucodepletion, infectivity titres were still sufficient to transmit BSE. Little difference 
was seen in the incubation period in recipients of paired non-leucodepleted plasma and red 
cells with their leucodepleted equivalents. 
 
Further studies have demonstrated that positive transmission can be achieved in non-human 
primates from blood products from both symptomatic and non-symptomatic infected donors. 
Nineteen macaques were transfused with leucodepleted blood products (RBCs and plasma) 
from primate donors with high levels of peripheral PrPSc after being exposed to vCJD. Five of 
the macaques developed typical vCJD phenotype and had detectible PrPSc in lymphoid 
organs as confirmed by Western blot detection. The results confirmed the transmissibility of 
vCJD by transfusion in primates (Comoy et al. 2017). 
 
As well as implementing leucodepletion of all blood used for transfusion, a number of other 
precautionary measures were taken to limit the risk of potential vCJD transmission and 
protect the UK blood supply. In 1997, blood components or tissues obtained from any 
individual who later developed clinical vCJD were withdrawn from use. In 1999 it was 
ensured that all plasma derivatives used in the UK were manufactured using only donations 
from countries with a low risk of vCJD. In 2004, following the first case of vCJD by blood 
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transfusion, individuals who had themselves received a transfusion since 1980 were 
excluded from donated blood (SaBTO 2015).  
 
Novel diagnostic strategies, including the use of surrogate markers of prion infection 
alongside use of prion reduction strategies, may help to control the risk of iatrogenic prion 
spread through blood transfusions. A sensitive and specific, high through-put screening test 
would inevitably lead to disease mitigation by identifying subclinical carriers. Substantial 
efforts are required to make this happen. Although the initial outbreak of vCJD appears to be 
over, subsequent epidemic waves among those already infected are a considerable concern. 
Furthermore, not clearly knowing the size or extent of the subclinical population leaves a 
continued risk to blood safety. Thus, precautionary measures remain in place for transfusion 
of blood components and on going surveillance is necessary (Seed et al. 2018).  
 
1.2.4 Transfusion study experiments  
 
Following confirmation of CJD transmission from human blood to laboratory animals, it was 
suggested that extreme caution would be appropriate when blood is used for transfusion 
purposes. The infectivity of blood components that had been spiked with scrapie infected 
hamster brain cells as well as blood from mice infected with a mouse adapted GSS strain 
were investigated by Brown et al. (1998). Both the exogenous spike and the endogenous 
infectivity experiments determined that infectivity was present in plasma as well as white 
blood cells. Furthermore, Brown (1999) showed that in mice infected with a mouse adapted 
stain of GSS infectivity in the buffy coat fraction of blood was present during the preclinical 
phase of disease. However, 5 x more buffy coat (and 7 x more plasma) was required to 
transmit disease by the IV route than by the IC route. 
 
From the human vCJD cases acquired following blood transfusion it is known with certainty 
that a single unit of vCJD prion infected red cell concentrate is sufficient to cause 
transmission of disease. This indicates that the concentration of ID50 units in blood is 
substantially high. ID50 is measured by end point dilution titration in mice by the IC route, it is 
the dilution at which 50% of mice become infected. The infectious titre of vCJD isolates in 
transgenic mice expressing bovine prion protein is 106.33 (Douet et al. 2014). It is unknown 
whether the virulence of BSE prions are enhanced when passaged from human to human, 
compared to the original bovine to human situation (Aguzzi and Glatzel 2006). Passaging 
experiments of scrapie infectivity between mice and hamsters indicate that this is possible. 
Shi, Xiao, et al. (2015) determined that the passage of mouse adapted scrapie strains (ME7-
ha and 139A-ha) into hamsters resulted in markedly shortened incubation times compared to 
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their parent mouse strains. Alternatively, Bishop et al. (2008) found no difference in 
transmission efficiency when inoculating HuTg mice with BSE and vCJD. 
 
One of the first indications that prion diseases might be transmissible by blood transfusion 
arose from experiments performed with sheep experimentally infected with BSE or with 
natural scrapie (Houston et al. 2008); (Houston et al. 2000); (Hunter 2002). Sheep are a 
good model for this process due to the similar pathogenesis of sheep BSE and human vCJD. 
As is the case with vCJD infection, BSE infected sheep also harbour infection in peripheral 
tissues, PrPSc deposition is extensively found in the lymphoreticular system (Foster et al. 
1996); (Hill et al. 1997). Another limiting factor for successful transmission of prion diseases 
by blood in rodent models is the small volumes of blood that can be injected. However, with 
sheep the volumes of blood that can be transfused are comparable to those used in human 
transfusion practice. Houston et al. (2008) collected blood and/or buffy coat (450-500 mL 
which is equivalent to 1 unit in transfusion medicine) from donors (orally infected with BSE or 
naturally infected with scrapie) at different time points during infection. Overall efficiency of 
transmission was high, 36% of recipients of blood from BSE donors and 43% of recipients of 
blood from scrapie infected donors became infected. The incubation period of those that 
received blood from preclinical or clinical donors were similar. This highlighted the possibility 
that disease could be transmitted from symptom free vCJD infected humans, risking the 
spread among the UK population. 
1.2.5 Blood infectivity: Distribution of infectivity in blood components 
 
The animal bioassay of infectivity is the only method available to directly measure the 
presence of the infectious agent (Ingrosso et al. 2002). Cervenakova et al. (2003) IC 
inoculated mice with mouse adapted strains of vCJD or GSS, blood was collected 
fractionated and blood components inoculated into groups of healthy mice. Brains and 
spleens of these mice were harvested and tested for PrPSc presence by Western blot. They 
found that levels of 20-30 infectious doses per mL were present in buffy coat and plasma 
during both the incubation and symptomatic stages of disease. Platelet pellet infectivity was 
lower (10 ID/mL) and RBCs were not infectious. 
 
Transmission by infected blood and WBCs in sheep was confirmed by Andreoletti et al 
(2012). Andreoletti et al. (2012) determined the minimum infectious dose (ID50) able to 
transmit prion infection in sheep by transfusion using VRQ/VRQ recipient sheep that were 
transfused with whole blood which had been spiked with successive 1/10 dilutions of brain 
homogenate prepared from sheep orally inoculated with the classical scrapie strain PG127 
(Andreoletti et al. 2012). Previously brain homogenate had been titrated by end point dilution 
in tg338 mice, and had a titer of 106.6 ID50 IC/g (Andreoletti et al. 2011). The lowest dose 
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resulting in transmission was observed in sheep (1 infection out of 2 challenged individuals) 
that were transfused with blood containing 103 ID50 IC in tg338 mice (Andreoletti et al. 2012).  
 
This high efficiency of transmission by blood transfusion contrasts with the very low 
infectious titer measured by IC inoculation of blood into transgenic mice expressing ovine 
PrP. Infectious titre of whole blood ranged between 3 -16 ID/mL as estimated from IC 
inoculated into tg338 mice. Plasma and RBCs, expressed as the equivalent volume of whole 
blood, were estimated to have 8.6 and 2.7 ID IC in tg338 per mL of blood respectively. The 
infectivity in WBC was measured by end point dilution titration by IC inoculation of ten folds 
serial dilutions in tg338 mice and the titre determined as between 4.5 - 13.4 ID per mL 
(Andreoletti et al. 2012). In another experiment performed at the same time by Andreoletti et 
al. (2012), VRQ/VRQ sheep were orally challenged with 106.7 ID50 IC in tg338 of the same 
PG127 brain homogenate stock. Whole blood samples were collected at the last stage of the 
incubation period, between 2-5 weeks before clinical onset. IV administration of 0.2ml of 
blood from these asymptomatic infected donor sheep was sufficient to infect the transfusion 
recipient with 100% efficacy. Since 0.2ml produced 100% transmission, Douet et al. (2016) 
performed further experiments to extend this study and further titrate scrapie infected whole 
blood by IV transfusion in sheep. It was then established that 0.1 mL of whole blood (but not 
0.01 mL) from an asymptomatic scrapie infected donor sheep can transmit the disease 
(Douet et al. 2016).  
 
Furthermore, Andreoletti et al. (2012) were able to show that freshly prepared WBCs from 
the same sheep have a comparable capacity to whole blood to infect prion disease free, 
VRQ/VRQ transfusion recipient sheep. Incubation periods of recipient sheep receiving whole 
blood or WBC preparations were similar, thus hinting at comparable infectious dose in both 
products. While all recipients of fresh WBCs succumbed to clinical disease, the IV 
administration of PFA fixed WBCs only resulted in infection of two out of four recipient 
sheep. Contrastingly, IV administration of crude plasma (100 mL) resulted in infection of only 
three out of four of the recipient sheep and the incubation periods were longer than those 
sheep who received whole blood. None of the sheep that received plasma prepared from 20 
mL of whole blood were infected. The incubation periods of sheep administered PFA fixed 
WBCs exceeded those observed for plasma recipients. Hence, this outcome suggests that 
the PFA fixation partially inactivates WBC infectivity. However, when IC inoculated into tg338 
mice, the same fresh and PFA WBC homogenates produced 100% attack rates with similar 
incubation periods.  
 
The level of prions in blood vary in different species as well as with different prion strains 
(Weissmann et al. 2002). Identifying the cell phenotype or cell free protein fractions that 
harbour prion infectivity may contribute to greater understanding. PrPC has been identified 
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on human lymphocytes, monocytes, granulocytes, platelets and red cells by flow cytometry 
and Western blotting (Holada and Vostal 2000). The normal cellular prion protein is strongly 
expressed by myeloid dendritic cells (Burthem et al. 2001). In humans, it has been shown 
that the majority of blood PrPC is present in the plasma and platelet fraction (MacGregor et 
al. 1999). In terms of infectivity, Douet et al. (2014) have reported infectivity in erythrocytes, 
leukocytes, and plasma of an individual with vCJD. This was confirmed by IC inoculation of 
tgBov mice.  
 
Infectivity of WBC subpopulations were further investigated in subsequent studies. Douet et 
al. (2016) showed that the IV administration of 105 WBCs from scrapie infected donor sheep 
is sufficient to cause disease in recipient sheep. Cell sorted CD45R+ (predominantly B 
lymphocytes), CD4+/CD8+ (T lymphocytes), and CD14+ (monocytes/macrophages) blood cell 
subpopulations were shown to contain prion infectivity as determined by bioassays in ovine 
PrP transgenic mice. However, although the IV administration of 106 CD45+ or CD4+/8+ living 
cells was able to transmit the disease, similar numbers of CD14+ cells failed to infect the 
recipients. Hence, mononucleated blood cell populations display different abilities to transmit 
prion disease by the transfusion route. Furthermore, Dassanayake et al. (2016) were able to 
show that scrapie prions are associated with monocytes and T lymphocytes circulating in the 
peripheral blood of sheep naturally infected with classical scrapie through 
immunohistochemistry and PMCA.  
 
Bioassays of white tailed deer have demonstrated that all body fluids (saliva, urine, faeces 
and blood) contain infectious prions. Both clinical and preclinical CWD infected deer were 
able to cause CWD in naïve white tailed deer following transfusion of whole blood 
(Mathiason et al. 2009). In deer with CWD, cellular (mononuclear leukocytes and platelets) 
but not cell free plasma fractions of blood were shown to transmit infection. B cells from 
blood or retropharyngeal lymph nodes and platelets (but not CD14+ monocytes or plasma) 
contained PrPSc capable of transmitting CWD. This suggests a significant role for B cells and 
platelets in trafficking CWD infectivity (Mathiason et al. 2010). In contrast, no infectivity has 
been detected in blood of cattle with natural BSE or of cattle with experimental BSE (Bradley 
1999).  
 
1.3 Diagnosis of prion diseases 
 
1.3.1 Current diagnostic methods  
 
The clinical and pathological manifestations of genetic prion diseases can be broadly 
segregated into distinct phenotypes fCJD, GSS, FFI. The recognition of phenotypes is 
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essential for diagnosis and care. Diagnosis of genetic prion diseases require a combination 
of clinical feature observations (dementia, motoric incoordination, myoclonus, visual 
disturbances, weakness, seizures). Neuropathological findings are distinct between the three 
diseases. Spongiform degeneration and astrogliosis distributed throughout the cortex and 
deep nuclei of the brain is found in the case of fCJD. There will be multiple amyloid plaques 
bound by antiprion protein antibodies in GSS. While in FSS there is a lack of spongiform 
degeneration and presence of neuronal dropout and gliosis primarily within the thalamus and 
inferior olivary nucleus of the brain stem (Gambetti et al. 2003). For the genetic forms of 
prion disease, a family history consistent with autosomal dominant inheritance would also be 
indicative. Hence molecular genetic testing for a PRNP disease causing mutation is used.  
 
In the case of nongenetic prion disease (sCJD) other options include use of 
electroencephalogram (EEG), brain imaging (magnetic resonance imaging [MRI] or position 
emission tomography [PET] scans) (Demaerel et al. 1999). While these tests can support 
diagnosis, definitive confirmation is only made by post-mortem histological and biochemical 
analysis of brain tissue (Galeno et al. 2017). Increases in the levels of 14-3-3 protein, 
neuronal specific enolase and total tau (nonphosphorylated) proteins which accompany 
progressive neuronal death are considered markers for nongenetic prion disease, hence, 
examination of cerebrospinal fluid (CSF) is considered useful (Satoh et al. 1999); (Huang et 
al. 2003). Clinical features of vCJD are strikingly different to that of sCJD. Most commonly, 
persistent and early psychiatric signs and symptoms are expressed including anxiety, 
withdrawal, depression or emotional lability. Sensory disturbances such as paraesthesia and 
painful limbs are also typical. Neurological signs appear around 6 months after the 
psychiatric symptoms, they include dysarthria, dysphasia, severe ataxia with falls and 
involuntary movements. vCJD also lasts longer than sCJD at 6-39 months and median death 
at 14 months (Will et al. 2000). Microscopic examination and immunohistochemistry for PrP 
of the brain reveals and abundance of ‘florid plaques’ in the cerebral and cerebellar cortices 
(Ironside and Head 2004). Unlike sCJD, PrPSc is also distributed in lymphoid tissues all over 
the body, from lymph nodes, tonsils and the spleen (Liberski and Ironside 2004). Tonsil 
biopsy using immunohistochemistry for detection of PrPSc, is additionally considered for 
individuals in whom vCJD is suspected (Zeidler et al. 1999). 
 
In the case of detection for animals with prion diseases, there are a number of commercially 
available kits for post mortem testing. In Europe, the most widely used BSE tests typically 
performed on brain samples are the Prionics-Check Western test (Western blot for PK 
resistant prion protein) and the BioRad Platelia test (ELISA detection). In total, about 8 
million BSE tests are performed per year, however the requirement to test healthy 
slaughtered cattle for BSE in the UK ended in 2013 (FSA 2017).  
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One difference between sheep scrapie PrPSc and bovine BSE PrPSc is in the proteinase K 
cleavage sites and thus the size of PrP27–30 (with scrapie PrPSc having a slightly larger 
fragment). Detection of this has been established by development of an antibody against the 
sequence lying between the two proteinase K cleavage sites. The presence of a signal, 
using this antibody on Western blot suggests sheep scrapie PrPSc while the absence 
suggests the presence of BSE PrPSc (Stack, Chaplin, and Clark 2002). Furthermore, scrapie 
PrPSc is deposited in the rectoanal mucosa-associated lymphoid tissues (RAMALTs) of 
infected sheep relatively early in the course of infection (Espenes et al. 2006). Hence, 
samples from this site can be used to diagnose preclinical scrapie in sheep (Gonzalez et al. 
2008). The examination of RAMALT biopsy specimens for the diagnosis of prion disease has 
been described in elk, and small numbers of mule and white tailed deer too (Keane et al. 
2009). Ante-mortem evaluation of tonsil biopsy specimens have also been used to determine 
preclinical CWD in deer (Schuler et al. 2005).  
 
1.3.2 Blood screening methods 
 
A validated screening test for preclinical vCJD carriers is much sought after for the significant 
protection it would offer. However, there are major challenges that exist. For instance, there 
is a lack of samples from subclinical vCJD individuals to validate assays. Animal models are 
the only means by which preclinical samples may be generated (Sawyer et al. 2015). 
Additionally, there is a need to detect the very low concentration of PrPSc likely to be present 
at the preclinical stage of disease. For methods based on PrPSc detection, PrPSc needs to be 
detected against a high background of PrPC. However, most antibodies do not discriminate 
between them. Some example initiatives include use of a 15B3 prion specific antibody 
developed by Prionics and a Seprion resin manufactured by Microsence. Both methods 
concentrate PrPSc so it can be detectable by ELISA and flow cytometry (Korth, Streit, and 
Oesch 1999). Grosset et al. (2005) also designed fluorescent labelled palindromic peptides 
to discriminate between PrPC and PrPSc, when binding occurs the shift in confirmation 
modified the fluorescent properties of the label.  
 
As well as the low concentration of PrPSc in blood, a possible reason for poor detection is 
aggregate size, solubility, and protease resistance. In comparison to blood, the brain is a 
solid organ that permits aggregate accumulation on and within infected nerve cells. It has 
been proposed that the large amyloid fibrils that characterize prion diseases are protective, 
rather than pathological, by sequestering more hazardous subfibrillar oligomers into 
comparatively innocuous deposits (Treusch, Cyr, and Lindquist 2009). Hence, the small 
subfibrillar oligomers are actually the principal causes of disease, probably by providing an 
increased number of multiplication seeds. Silveira et al. (2005) assessed PrPSc containing 
 41 
aggregates by their size, infectivity and converting activity. To do this they disaggregated 
PrPSc from scrapie-infected hamster brain, sonicated and separated by size through filtering 
and asymmetric flow field fractionation. The samples were then analysed by light scattering 
and non-denaturing gel electrophoresis. Their results suggested that the most efficient 
initiators of prion diseases are non-fibrillar particles, 14-28 PrP molecules in mass. If this is 
the case and smaller aggregates are the predominant form of PrPSc found in the blood, it 
would indicate that PrPSc of the blood is more infectious than brain derived PrPSc.  
 
Thus, while blood is highly infectious the amount of PrPSc in the blood is very low and 
additional amplification steps are required for efficient detection (Saa, Castilla, and Soto 
2006). Such procedures include protein misfolding cyclic amplification (PMCA) and real time 
quaking induced conversion (RT-QuIC). PMCA relies on a small amount of abnormal PrPSc 
(the seed) to convert excess normal PrPC (the substrate) following incubation. Repeated 
rounds of sonication break down the growing chains giving rise to a rapidly increasing 
amount of abnormal protein available to trigger conversions. PMCA has been reported to 
have great sensitivity and specificity. Following one round of 96 PMCA cycles (2 days) PrPSc 
at up to 100 million-fold (108) dilution of vCJD brain tissue was detectable. After two rounds, 
10 billion-fold (1010) dilution could be reached (Moda et al. 2014). PMCA is a highly efficient 
technique, which has been used to identify PrPSc in the blood of early preclinical to terminally 
ill stages of disease in scrapie and BSE infected sheep (Halliez et al. 2014; Lacroux et al. 
2014). Furthermore, Concha-Marambio et al. (2016a) used PMCA to analyse blood from 12 
cases of vCJD and 153 controls (including healthy control as well as patients with sCJD and 
other neurodegenerative conditions). There results show PrPSc could be detected with 100% 
sensitivity and specificity in blood samples from vCJD patients. Bougard, Brandel, 
Belondrade, et al. (2016) were able to identify 18 patients with clinical vCJD among 256 
French and British plasma samples with 100% sensitivity and specify. Importantly, this 
method was also accurate for blood samples from two individuals 1.3 and 2.6 years before 
development of clinical symptoms.  
 
RT-QuIC employs multiwall plates and a thioflavin T (ThT) based fluorescence detection of 
the prion-seeded amyloid. The assay involves cycles of vigorous shaking and incubation, 
during incubation PrPSc acts as a seed inducing conformational changes in E.coli expressed 
recombinant PrP (recPrP) substrates integrating them into a growing amyloid fibril. These 
aggregates may then be detected with fluorescent plate readers using the amyloid sensitive 
ThT dye. One advantage of RT-QuIC over PMCA is that the agitation can be performed 
more easily and consistently than sonication, which has varied delivery of the vibrational 
energy to samples (Atarashi et al. 2011). A major difference between the two techniques is 
that PMCA amplifies prion infectivity, while RT-QuIC products do not appear to be infectious 
(Groveman, Raymond, et al. 2017). RT-QuIC has been used to analyse whole blood 
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collected from deer and hamsters inoculated with CWD brain material, throughout disease 
incubation in time course studies. PrPSc could be detected in the blood of animals, within 
minutes following exposure to the inoculum. Detection dropped at the middle stage of 
infection but rose again during the late stage, coinciding with neuroinvasion (Elder et al. 
2015). Orrú et al. (2011) is another study of RT-QuIC on blood, here an additional antibody 
based immunoprecipitation step was used to enhance detection. This method allowed for 
detection in 1014 fold serial dilutions of brain material spiked into plasma.  
 
The Direct Detection Assay (DDA) is an alternative to both PMCA and RT-QuIC, with the 
potential to be sufficient for clinical sensitivity at the early stages of preclinical prion disease. 
It works with the use of a solid state, steel binding matrix to capture and concentrate PrPSc 
which is then detected immunologically using ELISA. Through rodent studies, Sawyer et al. 
(2015) have shown that DDA has an analytical sensitivity equivalent to a 109-fold dilution of 
prion infected brain material. Edgeworth et al. (2011) was able to detect PrPSc in blood from 
15 symptomatic patients with 70% sensitivity and 100% specificity, which is almost as 
effective as diagnosing sCJD using CSF samples (Atarashi et al. 2011). Jackson et al. 
(2014) detected PrPSc in a study of blood samples from national blood collection and prion 
disease centres of the US and UK. This is coupled with direct immunodetection giving 
specificity of 99% for vCJD infected blood samples.  
 
1.3.3 Detection of preclinical infectivity in blood 
 
In terms of identifying preclinical prion disease, PMCA is the most widely accepted technique 
for research purposes, although it is not currently being used as a diagnostic test. The 
method is highly specific for the detection of PrPSc with a several million fold increase in 
sensitivity compared to that of standard Western blot assays (Castilla, Saa, and Soto 2005).  
After amplification, PrPSc was detectable in the blood of hamsters experimentally infected 
with scrapie at the early preclinical phase of the disease (Saá, Castilla, and Soto 2006); 
(Soto et al. 2005). Sawyer et al. (2015) were able to use DDA to consistently detect 
preclinical infection using wild type CD1 mice experimentally infected with the Rocky 
Mountain Laboratory (RML) scrapie strain. In both studies, the methods showed higher 
detection sensitivity early in the preclinical stage of the incubation period when blood was 
less infectious. Thus, it is important to note that PrPSc levels do not always reflect the titre of 
infectivity in blood. 
 
Lacroux et al. (2014) tested the sensitivity of PMCA with the vCJD/BSE model of disease. In 
both sheep and primates, the assay enabled identification of infected individuals in a very 
early stage of the asymptomatic incubation phase. Bougard, Brandel, Belondrade, et al. 
(2016) further proved the sensitivity of PMCA by using the technique to detect silent carriage 
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of prion 1.3 and 2.6 years before clinical onset in two donors who later developed CJD. This 
was performed on archived plasma. It has also been suggested that WBCs are the most 
appropriate targets for preclinical detection by PMCA. Lacroux et al. (2014) were able to use 
buffy coat samples from macaques IV challenged with vCJD brain homogenate or blood 
from a clinically affected vCJD macaque to seed PMCA reactions. When using WBCs as a 
template, the method enabled identification of vCJD/BSE in asymptomatic experimental 
animals in the early phase of the incubation period. Concha-Marambio, Chacon, and Soto 
(2020) also used PMCA to detect prions in blood during the preclinical stage of infection in 
vCJD infected macaques, as early as 2 months postinoculation, without false positives from 
noninfected animals. Additionally, Halliez et al. (2014) investigated blood components as 
PMCA seeds, the seeding ability of platelets was weaker than that associated with WBCs, 
hence WBCs are potentially more infectious.  
 
The detection of PrPSc varies at different times throughout the incubation period. Peripheral 
administration of prions results in initial replication in lymphoid tissues and the spleen 
(Kimberlin and Walker 1979); (Glatzel and Aguzzi 2000). Thus, the rise of PrPSc in blood 
during the early preclinical phase is considered to coincide with the time of its replication in 
lymphoid organs. The reduction of PrPSc in blood occurs when infectivity in peripheral tissues 
has reached a plateau and starts to migrate to the brain. It is possible that the proportion of 
PrPSc carrying lymphocytes in circulation is much higher during the exponential phase of 
peripheral replication than during the stationary phase. Studies on the pathogenesis of 
mouse scrapie show that high quantities of PrPSc appear in the brain only a few weeks 
before onset of clinical signs (Kimberlin and Walker 1979). In comparison, Jeffrey, Ryder, et 
al. (2001) orally infected sheep with brain tissue from BSE infected cattle. The results 
suggested that in some BSE infected sheep, neuroinvasion occurred in the absence of 
detectable PrP accumulation in visceral tissue or peripheral nervous system. The detection 
of PrPSc in blood at the symptomatic phase of the disease may also be due to disruption of 
the blood-brain barrier resulting in leakage of cerebral proteins into the blood (Banks 1999). 
Prion disease causes extensive brain degeneration by neuronal death, synaptic alterations 
and changes to the brain (Castilla, Hetz, and Soto 2004). All of which may impact on the 
blood-brain barrier, allowing movement of PrPSc, which at this time would be highly abundant 
in the brain (Saá, Castilla, and Soto 2006). 
 
As the incubation period may last several decades, it is unknown how many people may be 
in an asymptomatic phase of vCJD. Additionally, it is possible that some infected patients 
may never develop clinical symptoms but will remain in a carrier status with potential to 
transmit to other individuals. The ideal blood based diagnostic test for prion diseases would 
be specific, efficient and reliable. It would need to be able to detect individuals premortem, 
throughout the incubation period and have the ability to be vastly scaled up to screen the 
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large numbers of blood donations. Within the UK approximately 2.5 million units of blood are 
transfused each year (NICE 2015); (NHS 2018). Screening with PMCA is not feasible. It a 
technically challenging technique, with a long incubation time, which limits its routine use. 
The absence of screening tests and effective therapies to treat this disease are barriers in 
preventing further infections. A possible alternative to detection of prions in blood is looking 
at alternative biomarkers for infection. 
 
1.3.4 The search for alternative biomarkers of prion infection 
 
The European Medicines Agency (2001) defines ‘biomarkers’ as measurable characteristics 
that reflect physiological, pharmacological or disease processes. There are genomic, 
transcriptomic, proteomic and metabolomic models for biomarker discovery. Omic 
investigations lend themselves to biomarker discovery as they investigate multiple molecules 
simultaneously. Surrogate markers that are currently in use for patients with clinical signs of 
CJD, include 14-3-3, tau, apolipoprotein E and cystatin C (Van Everbroeck, Boons, and Cras 
2005); (Otto et al. 2002); (Burkhard et al. 2001). High levels of 14-3-3 proteins present in 
patient CSF is a criteria for suspected sCJD to be upgraded to probable sCJD (Herbst et al. 
2009). Additionally, neurofilament light polypeptide (Nfl) has been shown to be elevated in 
serum of patients with sCJD but further work is required for its potential role in monitoring 
disease progression (Thompson et al. 2018); (Mok and Mead 2020). 
 
1.3.4.1 Transcriptomic studies 
 
Transcriptomics is the study of the transcriptome or total messenger RNA (mRNA) within a 
cell or organism. The transcriptome reflects those genes that are actively expressed at a 
given time point as the mRNA (with the noncoding introns spliced out) is the template for 
protein synthesis during translation. Transcriptional profiling has enabled the more precise 
characterization of cell lineage and cell state genetic profiles (Lowe et al. 2017). In regards to 
prion disease biomarker research, many studies focus on gene expression in brain tissue 
using DNA microarrays and subtraction hybridization, but it likely that any subtle transcription 
alterations that occur in neurons at the onset of disease are masked. For example, Almeida 
et al. (2011) identified 966 differentially expressed genes in the medulla following oral 
infection of cattle with bovine spongiform encephalopathy. Analysis of 14 genes revealed 
that prion infection may cause dysfunction of several different networks. These networks 
include extracellular matrix, cell adhesion, complement and coagulation cascades, MAPK 
signalling and the transforming growth factor (TGF) beta signalling pathways.  
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Riemer et al. (2004) identified 114 genes with altered expression patterns in the diseased 
brains of scrapie infected mice. The data demonstrated the presence of a strong 
inflammatory reaction and stress response, which also relate to gene expression patterns 
found in brains of individuals affected by AD and aging (Zhang et al. 1999). Xiang et al. 
(2004) analysed the gene expression profiles from brains of mice IC inoculated with scrapie 
strains ME7 and RML. They discovered 121 genes with a twofold increase in expression in 
both ME7 and RML infected mouse brains. These genes encode proteins involved in 
proteolysis, protease inhibition, cell growth and maintenance, the immune response, signal 
transduction, cell adhesion as well as molecular metabolism. A further study by Xiang et al. 
(2007) revealed altered cholesterol metabolism during the neurodegeneration in mouse 
scrapie (ME7) model. Functional analysis showed that the most affected biological process 
was cholesterol metabolism and that this was indicated to be inhibited in diseased brains. 
Brown et al. (2005) identified 78 genes that were differentially expressed greater than 1.5-
fold within the preclinical ME7 infected hippocampus prior to the late stage glial cell 
activation. Further analysis revealed oxidative and endoplasmic reticulum (ER) stress, 
activated ER and mitochondrial apoptosis pathways, and activated cholesterol biosynthesis 
were involved at this stage of the disease.  
 
Sawiris et al. (2007) identified 296 differentially expressed genes in brain tissue from mice 
with late stage BSE. The genes were found to be associated with ubiquitin function, 
lysosomal function, molecular chaperoning of protein folding, apoptosis, calcium ion binding, 
zinc ion binding or regulation of transcription. Skinner et al. (2006a) investigated cDNA 
microarray to profile gene expression changes in the brains of mice infected with two strains 
of scrapie (ME7 and RML). They highlighted a core group of 349 prion related genes that 
consistently showed altered expression in mouse models. Functional analysis revealed 
protein synthesis, inflammation, cell proliferation and lipid metabolism pathways. They found 
that the key interaction partner for these prion related genes was the regulatory cytokine 
TGFB1. They also discovered that the majority of genes expressed in neurons were down 
regulated and involved in regulatory pathways such as synapse function, calcium signalling, 
long term potentiation and ERK/MAPK signalling. Hwang et al. (2009) determined gene 
expression throughout disease progression in the brains of eight distinct mouse prion strain 
combinations. They identified 333 differentially expressed genes and mapped them into 
functional pathways and networks in an attempt to reflect the definitive neuropathological 
events taking place. The novel functions shared by the differentially regulated genes include 
leukocyte extravasation, androgen metabolism, phospholipid metabolism, microglial 
activation, calcium signalling pathways and haematopoiesis.  
 
Barbisin et al. (2014) conducted large-scale transcriptional profiling of brains from BSE 
infected cynomolgus macaques. They found 300 transcripts with expression changes greater 
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than twofold. Out of the 86 genes with known functions, bioinformatics analysis showed most 
were involved in cellular development, cell death and survival, lipid homeostasis, and acute 
phase response signalling. The microarray analysis of brain tissue from patients with sCJD 
by Xiang et al. (2005) resulted in identification of 79 upregulated and 275 downregulated 
genes, which showed at least 1.5- and 2-fold changes, respectively. Major alterations 
included prominent upregulation of the genes encoding immune and stress response factors 
and significant downregulation of genes encoding synaptic proteins. However, further 
characterization of these genes are crucial in understanding the basis of prion disease 
pathological processes. The common feature of these prion disease transcriptomic studies 
on brain tissue is the identification of changes occurring in pathways to go with immune 
response, acute phase response and metabolism. 
 
In place of studying brain tissue for potential genetic changes relating to prion disease, some 
studies have focused on other tissues. This is because studying changes in lymphoid tissues 
or blood is also more likely to be useful for identifying potential biomarkers related to 
preclinical infection, while identifying changes in the brain may result in detecting changes 
due to neurodegenerative processes that are not specific to prion disease. Kim et al. (2008) 
identified 14 genes with altered expression prior to the onset of clinical symptoms in spleens 
of mice infected with ME7, 22L and RML-Chandler scrapie strains. The function of these 
genes included cellular process of immunity, the endosome/lysosome system, hormone 
activity, and the cytoskeleton. Following oral inoculation of lambs with scrapie, cDNA from 
the ileal Peyer's patch were used to study gene expression profiles by Skretting et al. (2004). 
They were able show differential expression of 23 genes, the genes shared homologies with 
genes encoding proteins involved in the mitochondrial ATP production. Filali et al. (2014) 
performed gene expression profiling of mesenteric lymph nodes from sheep with natural 
scrapie. They found a total of 105 genes that were differentially expressed with a twofold 
change in expression. Of these, 43 were upregulated and 62 downregulated. The genes 
were largely associated with focal adhesion, PPAR signalling and ECM-receptor interaction. 
 
There is a highly diverse cell population circulating within blood, a potential route to 
overcome the hurdles of biomarker discovery when examining blood is to isolate specific cell 
populations and use these as a basis for gene or protein profiling studies. Brown et al. 
(2007) analysed blood by qPCR from sheep experimentally infected with scrapie to 
investigate the extent of differential expression of ERAF (erythroid-associated factor) in order 
to explore the role of erythrocytes in prion disease. However, the results revealed that the 
extent of differential expression of erythroid genes within peripheral blood is not sufficient to 
provide a discriminatory diagnostic test. After exploring the gene expression profiles of 
WBCs from cattle orally infected with atypical BSE, Panelli et al. (2011) discovered that there 
was significant modification of genes linked to T and B cell development and activation. 
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Identifying other biomarkers associated with prion infectivity in blood may help in 
understanding the molecular mechanisms underlying prion disease pathogenesis and the 
pathways critical for disease progression. This would allow for a more rigorous and specific 
blood test to be developed and may reveal potential targets for intervention. Xerxa et al. 
(2016) performed microarray analysis in whole blood of atypical BSE infected cattle and 
revealed 32 differentially expressed genes to be in common between clinical and preclinical 
stages of disease. The study highlighted that immune response and metabolism pathways 
may play an important role in peripheral prion pathogenesis. 
 
Additionally, microglial transcriptional changes and upregulation of interferon sensitive genes 
have been detected at the very early stages of CJD infection, well before the PrPSc and 
clinical signs (Baker, Lu, and Manuelidis 2004). In another study, (Huzarewich et al. 2011) 
found that a total of 1753 transcripts exhibited fold changes greater than three in FDCs, 
dendritic cells, and macrophages isolated from the spleens of prion infected versus 
uninfected mice. The gene for leucine-rich proteoglycan decorin (DCN) was found to be one 
of the genes most overexpressed in infected mice, furthermore the levels were mirrored in 
mice infected with scrapie as well as BSE and vCJD. Genes related to iron metabolism and 
homeostasis were significantly decreased in infected spleens, these pathways have been 
previously implicated in prion pathogenesis of the brain (Singh et al. 2009); (Greenough, 
Camakaris, and Bush 2013); (Andersen, Johnsen, and Moos 2014). The common pathways 
identified as important in prion disease of these transcriptomic studies on non-brain tissue 
are the immune response and metabolism.  
 
1.3.4.2 Proteomic studies 
 
Proteomics is the large-scale study of all the proteins expressed in a cell, tissue or organism 
with the aim to understand their functional relevance by studying biological pathways and 
networks (Cho 2007). Proteomic studies for prion disease often focus on brain tissues, the 
biomarkers found highlight neuropathogenesis mechanisms. Moore et al. (2014) identified 
1,567 proteins from RML mice infected and uninfected brain homogenates. Ingenuity 
pathway analysis (IPA) of the top 100 ranked proteins show the molecular and cellular 
functions affected in disease state. This includes elevated lipid transport and metabolism, 
fatty acid metabolism, molecular transport and cell-to-cell signalling but disruption in vesicle 
transport and metal binding. Choi et al. (2016) identified152 differentially expressed proteins 
in ME7 scrapie-infected mouse brains. Biological analysis of upregulated proteins reveal 
major functions that relate to neuronal processes (cell-to-cell signalling, synaptic 
transmission) as well as metabolic pathways (acyl-CoA synthetase, glycolysis, oxidative 
reduction processes). The hippocampal proteome of ME7 mice was investigated by Asuni et 
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al. (2014), out over 200 proteins individual proteins 8 were identified based on a 2-fold 
change cut off, 4 were components of astrocytes. In human prion disease the brain 
proteome was analysed by Shi, Chen, et al. (2015) who identified 379 commonly 
differentially regulated proteins in cerebellum tissues of CJD, FFI and genetic CJD patients. 
The significant biological categories affected include oxidative phosphorylation and 
metabolism. 
 
Chen et al. (2014) assessed the differential protein expression in CSF of sCJD patients. 
They found 437 proteins, 49 proteins within the 95% confidence interval. Of these 12 were 
upregulated and 13 were downregulated significantly. The most affected pathways of the 
differentially expressed proteins in CSF of the sCJD patients were complement and the 
coagulation cascade, followed by metabolism (glycolysis and gluconeogenesis). Proteomic 
studies have also been performed on easily accessible body fluid. Simon et al. (2008) 
identified disease-induced biomarkers in the urine of BSE infected cattle (from a range of 
time points during disease progression). Five unique proteins were identified including 
clusterin and cathelicidin1. Plasma samples from asymptomatic RML infected mice were 
investigated by Wei et al. (2011a) in a quantitative proteomic approach. Overall 708 proteins 
were identified, 53 with a 2-fold increase and 58 exhibiting 2-fold decrease. Proteins that 
were significantly upregulated included those to do with the immune system and metabolism. 
Metabolism is a reoccurring theme of these proteomic studies on prion disease. 
 
1.3.4.3 Metabolomic studies 
 
Metabolomics is the study of metabolites (low molecular weight compounds that participate 
in metabolic reactions) present in a cell or organism under a given set of conditions (Liu 
2019). Bourgognon et al. (2018) analysed the brains of mice infected with RML scrapie 
revealing disease related alterations in neuronal metabolism, 141 biochemicals (out of 498) 
were significantly altered by prion infection. Those functions affected included glucose 
tolerance, glycolysis, sphingolipid signalling and inflammation signalling. Although there have 
not been many published metabolomic studies performed on prion disease biomarker 
discovery there has been a considerable amount of research done on the influence of the 
microbiome in pathogenesis of neurological disorders (Sampson et al. 2016); (Minter et al. 
2016); (Donaldson and Mabbott 2016). The gut microbiome has proven crucial for several 
metabolic and immunological functions, as well as involvement in brain development and 
specific interactions with the enteric and central nervous systems (Ogbonnaya et al. 2015); 
(Fung, Olson, and Hsiao 2017). In one study, Xu and Wang (2016) showed a positive 
correlation between around 50 microbial metabolites and AD early age of onset and 
cognitive decline. They identified a total of 27 genetic pathways associated with AD 
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biomarkers, including pathways related to axon guidance, immune systems, neurone 
signalling and lipid metabolism.  
 
1.3.4.4 Challenges of Omic studies 
 
The key aspect of genomic, transcriptomic, proteomic and metabolomic studies is that a 
complex system can be understood better if considered as a whole. They differ from 
traditional hypothesis driven studies, by instead using holistic approaches where no 
hypothesis is applied but all data acquired is analysed to generate and define hypothesis 
that may be further tested (Kell and Oliver 2004). Although advances have been made in 
omic fields, this non-targeted and non-biased manner results in datasets on expression 
levels of thousands of genes, proteins or metabolites. Clearly this is a huge challenge for 
commonly used statistic methods, in subtraction of background noise and normalisation of 
data (as well as reproducibility) to allow comparison between different experiments. However 
technology and software are still evolving, holding promise for progression.  
 
One great challenge of genomic research is to enable mechanistic dissection of biological 
processes on a high through-put scale. Transcriptomics by microarray or RNAseq (RNA 
sequencing) is now in frequent use. Analysis of mRNA provides direct insight into cell 
specific gene expression features by recognising the presence or absence of a transcript 
and quantifying it, but also by identifying single nucleotide polymorphisms (SNPs), allele 
specific expression and gene fusions. Such information is fundamental for understanding the 
cellular dynamics and how changes in the transcriptome profiles affect health and disease 
(Manzoni et al. 2016). However, the process is not without limitations. Specifically gene 
expression microarrays measure the changes seen in mRNA abundance and not the 
corresponding protein, thus there are restrictions over the interpretation of such data. 
 
The proteome is a dynamic reflection of both genes and the environment. Proteins are 
ubiquitously affected in disease and disease response, hence it is thought that the proteome 
holds particular promise to the discovery of biomarkers. This is reflected in the protein 
disease biomarkers already in use. An important consideration when comparing proteomic 
studies to those of the genome or transcriptome is the vast increase in potential complexity. 
The 4-nucleotide code of DNA and mRNA are translated into a complex code of 20 amino 
acids. To form a final functional protein the primary sequence of peptides (of varying lengths) 
may be folded into a large number of possible confirmations with chemical modifications 
(such as phosphorylation, glycosylation and lipidation). Additionally, multiple isoforms of the 
same protein can be derived from alternative splicing (Manzoni et al. 2016). These degrees 
of variation contribute to the heterogeneity of the proteome (at any given time) and while a 
 50 
great deal of information may be obtained through proteomic investigations analysis is 
challenging. Furthermore there are technical issues, such as the inability to accurately detect 
low abundant proteins, mass spectrometry bias towards identification of peptides with high 
concentrations, the lack of uniformity across research groups can lead to differences in 
protein fragmentation or differences in algorithms used to run analysis and integration with 
genomics data (Bell et al, 2009).  
 
The advantage of studying the global metabolite profiles in a cell tissue or organism in 
metabolomics is that the metabolome is the final downstream product of gene transcription. 
Therefore, changes in the metabolome are amplified relative to changes in the transcriptome 
and the proteome. While the metabolome contains the smallest domain (~5000 metabolites), 
it is more diverse with many different molecules making it physically and chemically complex 
(Wilson’s 2008). Since metabolic pathways are largely conserved between species, is a key 
tool for translating results from cellular and animal models to human (Bourgognon and 
Steinert 2019). However, there are some critical limitations to this field such as the need to 
improve analytical techniques to detect and process results, the on going production of 
population specific reference metabolomes and the incomplete understanding of the 
biological role of all detectable metabolites (Manzoni et al. 2016).  
 
In the case or prion diseases, they are unique in that they may arise in a few different ways. 
Spontaneous or genetic forms of the disease arise and progress within the brain, with 
minimal replication in non-central nervous system tissues. However, the opposite is found of 
diseases associated with ingestion of the infectious agent or owing to blood transfusion. 
There are a number of drawbacks from studies on biomarkers of different prion infected 
tissues. For example, samples are highly diverse in regards to cellular complexity and stage 
of disease. It is difficult to find diagnostic biomarkers, especially for preclinical stages of 




Following the exposure of the UK population to BSE there are an estimated 1/2000 of the 
age relevant population that may be subclinical carriers of vCJD. This means that they may 
be unknowingly incubating the disease and potentially passing it on to others via blood 
transfusion or even through use of contaminated surgical or dental instruments. It is 
important to identify such individuals as they pose a public health concern. Furthermore, 
there are currently limited diagnostic tools for preclinical disease available on easily 
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accessible samples. The hypothesis is that preclinical prion infection results in altered 
expression of blood proteins.  The blood proteome will be investigated for detectable 
changes in protein composition during disease progression. Identifying and validating a 
signature of differentially expressed proteins in infected blood may reveal valuable 
biomarkers for potential use in diagnostics. It may be possible to utilise these proteins as an 
alternative to detecting PrPSc for diagnosing prion disease. This may provide the bases for 
development of a preclinical, ante-mortem screening test for suspected individuals. 
 
There are many unresolved queries in prion science regarding blood infectivity. It is unknown 
why blood is so infectious (as little as 100 µL can transmit the disease) despite the presence 
of such a low level of PrPSc. It is possible that blood PrPSc has different characteristics to 
brain derived PrPSc, or that co-factors in the blood are equally important in passing infection. 
Within blood, live WBCs seem to be important for transmission of disease via the IV route. 
The hypothesis is that the nature of prion infectivity in blood differs fundamentally from brain 
derived infectivity, and relies on interactions between living cells for efficient transfer of 
infection to a new host. The differential treatment of WBCs may hint at the features 
necessary for optimal infection to occur or show that there are factors involved that simply 
cannot be replicated ex vivo. For instance, freeze-thawing cells disrupts the integrity of the 
cellular membrane and paraformaldehyde (PFA) fixation chemically bonds surface proteins 
thus restricting cell to cell interactions (Andreoletti et al, 2012). Investigating these scenarios, 
in comparison to fresh or untreated WBCs, may shed light on the mechanisms involved in 





1. To determine differential protein expression in plasma and WBC enriched-buffy coat 
blood fractions from BSE-infected sheep. 
2. To validate candidate protein biomarkers for prion infection on blood samples 
collected from BSE-sheep. 
3. To use an in vitro cell culture model to study the molecular and cellular interactions 












Chapter 2: Materials and Methods 
 
2.1 Identification of protein biomarkers that distinguish prion-infected blood 
from uninfected blood 
 
2.1.1 Preparation of samples of sheep blood components 
 
Blood samples were taken from BSE infected sheep used in previous blood transfusion 
experiments (McCutcheon et al. 2011). Prion disease free donor sheep were sourced from 
the DEFRA scrapie free flock. All sheep were of the susceptible ARQ/ARQ PRNP genotype. 
This genotype confers disease susceptibility and also has the shortest incubation time 
following experimental infection with BSE. Sheep were orally infected with 5 g of bovine BSE 
infected brain homogenate (TSE archive, APHA Weybridge), their blood (2 units, 1 unit = 
450 mL in blood packs containing 63 mL anti-coagulant CPDD.A1) was collected 10 months 
after infection and blood components (whole blood, red blood cells, buffy coat, plasma and 
platelets) were prepared for transfusion to recipient sheep. Mock-infected donors were 
inoculated with 5 g normal bovine brain homogenate at similar time as the infected cohort. At 
regular intervals (and prior to both inoculation and transfusion), 10 -20 mL of each blood 
component were sampled for analysis and archive storage. The sheep were monitored for 
clinical signs of prion disease. Brain and lymphoid tissues (spleen, tonsil, distal ileal Peyer’s 
patch, prescapular and mesenteric lymph nodes) were collected from each animal (whether 
or not clinically positive) for detection of PrPSc by IHC and Western blot to confirm or rule out 
the presence of infection.  
 
From nine donor sheep (ID numbers: N257, N236, N233, N251, N261, N189, N231, N232, 
N157) 1 mL aliquots of uninfected plasma (time point 0, pre-challenge) were thawed at room 
temperature, then combined and vortex mixed to create a pooled sample. These sheep were 
chosen because they all transmitted infection (the sheep that received their blood came 
down with disease). The pooled plasma was stored in 1 mL aliquots at -80 oC for later use. 
The procedure was repeated for infected plasma (time point 12 months, after blood 
collection for transfusion to recipient sheep) from the same sheep. Similar uninfected and 
infected pools were prepared using buffy coat samples (250 µL aliquots) from the same nine 
sheep. Individual plasma and buffy coat samples taken at different time points from the same 
nine sheep, and three negative control donors (N239, N170, N217) were also used in 
Western blot validation experiments. Figure 2.1 illustrates pooled plasma and individual 





For Western blot validation of mass spectrometry data, 1 mL of previously prepared 
uninfected or infected plasma/buffy coat pools or individual plasma/buffy coat samples were 
taken from -80 oC storage and thawed at room temperature. 200 µL of plasma was diluted in 
250 µL of Extraction buffer (RIPA Lysis and Extraction Buffer, ThermoFisher Scientific 89900 
and 1 % Halt™ Protease Inhibitor, ThermoFisher Scientific 1858566), vortex mixed and 
stored at -80 oC in aliquots of 100 µL for later use.  
  
2.1.2 Measurement of total protein by Micro bicinchoninic acid assay (BCA) 
 
The Pierce™ Biotechnology Microplate BCA Protein Assay Kit –Reducing Agent Compatible 
(ThermoFisher Scientific, 23252) is stored at room temperature. Reagents, protein standards 
and controls were prepared following kit instructions. BSA standards were prepared in Milli-Q 
water (2000 µg/mL, 1500 µg/mL, 1000 µg/mL, 750 µg/mL, 500 µg/mL, 250 µg/mL, 125 
µg/mL) and 9 µL of each concentration dispensed into a 96 well plate in triplicate. Plasma 
and buffy coat samples were diluted to fit within the BCA assay linear range of 125-2000 
µg/mL. A 1/20 stock solution was prepared followed by two-fold serial dilutions (1:2, 1:4, 1:8, 
 
Figure 2.1: Pooled and Individual plasma samples from nine sheep. From nine sheep 
plasma samples were taken at both an uninfectious, prechallenge time point (before 
exposure to BSE) and infectious, 12 month time point (where their donated blood caused 
infection when transfused to recipient sheep). A pooled plasma sample which was used in 
initial experiments was created by mixing all nine sheep samples, individual sheep plasma 
samples from the same two time points were used in follow up experiments. The same 
procedure was repeated for buffy coat samples of the same nine sheep at these two time 
points. Similarly, plasma and buffy coat samples from three age-matched sheep (not 
exposed to BSE) with blood collected at the same time points were also prepared as 
negative controls.  
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1:16, 1:32 and 1:64). 9 µL of sample at each dilution was pipetted directly to the centre of the 
microplate well followed by 9 µL of Reconstitution Buffer and 4 µL of Compatibility Reagent. 
The Standard Control is the working constitution buffer without reducing agent (it does not 
contain protein). The Sample Control is the working constitution buffer with reducing agent 
(also does not contain protein). To evaluate and avoid random error by using the average 
value, triplicates of each standard and test sample were used. The plate was incubated at 37 
oC for 15 mins. 260 µL of Working Reagent was added to all wells and the plate further 
incubated at 37 oC for 30 minutes. After cooling at room temperature, absorbance at 570 nm 
was determined by Spectrophotometer Pharmacia LKB.Ultraspec3 and absorbency readings 
saved to Excel. In Excel the mean value for the absorbance reading of the Sample Control 
replicates was subtracted from all sample replicates. Using the Standard Control as the 
blank, a standard curve was prepared by plotting the average blank-corrected absorbance 
value for each BSA standard versus its concentration. This was used to determine the 
protein concentration of the unknown sample by rearranging the equation of the line. 
 
2.1.3 ProteoMiner Enrichment Kit for enriching low abundant proteins  
 
The BioRad ProteoMiner Kit (Small-Capacity kit 1633006, Large-Capacity kit 1633007) 
contains a vast library of hexapeptide ligands bound to beads pre-packaged in mini-spin 
columns. The columns were prepared as per the manufacturer’s guidelines. The column 
storage material (nondisclosed solution) was collected and discarded following centrifugation 
at 1000 x g for 60 seconds. 600 µL of wash buffer was used to wash the column through 
centrifugation. The pooled plasma  and pooled buffy coat samples were diluted to give a total 
protein load of 45 mg, so as not to exceed the column total protein capacity of the Large 
Capacity kit (50 mg). Binding to beads was facilitated by addition of 900 µL of sample to the 
column and continuous stirring by a rotary platform for 2 hours at room temperature. The 
column was centrifuged at 1000 x g for 60 seconds to remove unbound high-abundant 
protein. The column was washed by centrifugation four times with 600 µL of wash buffer to 
remove any remaining material (sample washes), and washed once with 600 µL of Milli-Q 
water to remove any traces of wash buffer (water wash). The enriched elution samples were 
obtained by sequential addition of urea buffer (8 M Urea in 50 MM HEPES) as opposed to 
the kit provided elution buffer so as to be compatible with mass spectrometry. 100 µL of urea 
buffer was added to the column and the column incubated at room temperature for 15 
minutes with intermittent vortex mixing. The first eluate (Elution 1 or E1) was collected after 
centrifuging at 1000 x g for 60 seconds. This was repeated to generate enriched elutions 2 




2.1.4 Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS PAGE) to 
separate proteins by molecular weight 
 
Samples were retrieved from the freezer and thawed at room temperature. A second BCA 
assay was performed following protein enrichment with ProteoMiner. Two dilutions (1:3 and 
1:6) of the Enriched Elutions E1, E2 and E3 were prepared. E1, E2 and E3 were pooled to 
generate E4 and the same dilutions (1:3 and 1:6) were prepared. For the column Flow 
Through a 1:20 stock solution was made followed by a series of two fold dilutions (1:2, 1:4, 
1:8, 1:16, 1:32 and 1:64). Two-fold serial dilutions were prepared for the Sample Wash and 
Water Wash. Samples were loaded onto a 96 well plate in duplicates and the procedure 
repeated as previously described.  
 
Prior to protein identification by mass spectrometry, SDS-PAGE was used to visualise 
depletion of high abundant proteins in the eluted samples. Using the results of the second 
BCA assay, the volume of each sample containing 10 µg of protein was calculated for 
comparison. Samples were diluted with 10 X Reducing agent (500 mM dithiothreitol, or DTT; 
ThermoFisher Scientific) and 4 X NuPAGE® Lithium dodecyl sulfate (LDS) Sample Buffer 
then heated at 100 oC for 10 minutes and centrifuged at 1000 x g for 1 minute. Samples 
were loaded on a 12 % Bis-Tris (BioRad) gel, along with a molecular weight marker (BioRad 
Precision Plus Protein Kaleidoscope™ Standards 1610374), and electrophoresis performed 
at 180 V for 50 minutes (or until the dye front reached close to the bottom of the gel), using  
1 X SDS Running Buffer and NuPAGE® Antioxidant (according to the manufacturer’s 
instructions). The gel was removed from its cassette and left to stain on a shaking platform 
with 3 mL of undiluted BioRad Coomassie Blue Stain (161-0436) for at least 1 hour. The gel 
was rinsed in Milli-Q water and images were captured with the LI-COR C-DiGit scanner.       
 
2.1.5 Reduction, Alkylation and Tryptic Digestion to prepare samples for mass 
spectrometry  
 
The pooled Enriched Elution samples (E4) for both infected and uninfected plasma and buffy 
coat were removed from the -20 oC freezer and thawed at room temperature. Volumes of each 
sample corresponding to 200 µg of protein were pipetted into proteomic grade aliquot tubes 
(Sigma-Aldrich). 5.8 µL of freshly prepared 250 mM DTT (in 50 mM HEPES, 1 M NaOH, pH 8) 
was added and the aliquots were placed on a shaking platform in an incubator set at 37 oC for 
1 hour. After cooling at room temperature, 6.6 µL of 375 mM iodoacetamide (in 50 mM HEPES, 
1 M NaOH, pH 8) was added. The aliquots were covered with aluminium foil and incubated in 
darkness at room temperature for 40 minutes with intermittent vortexing. Following this, 5.6 µL 
of 250 mM DTT (in 50 mM HEPES, 1 M NaOH, pH 8) was added and samples incubated at 
room temperature for a further 20 minutes with intermittent vortexing. Samples were diluted 
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with addition of 950 µL of 50 mM HEPES (1 M NaOH, pH 8). Trypsin (Promega Sequencing 
Grade Modified V5111) was added to give a ratio of 1 µg of trypsin to 20 µg of protein. After 
overnight incubation at 37 oC the samples were stored at -20 oC. 
 
Samples were then forwarded for isotopic labelling and mass spectrometry analysis performed 
by Dominic Kurian. The procedure was repeated for buffy coat samples. 
 
2.1.6 Mass spectrometry  
 
To distinguish between infected and uninfected sample peptides were labelled using stable 
isotopic reductive dimethylation (ReDi) on OASIS HLB columns. Raw spectra data was 
processed by DataAnalysis (Bruker) software and the resulting peaklists were searched 
using Mascot 2.4 server (Matrix Science) against UniProt Bovine sequence database.  
 
Methods performed by Dominic Kurian: 
 
Protein digestion, dimethyl-labelling and liquid chromatography-tandem mass spectrometry 
The ProteoMiner depleted samples were resuspended in a buffer containing 8 M Urea, 0.1% 
SDS, 50 mM ammonium bicarbonate (pH 8.0). Aliquots containing 100µg of proteins each of 
infected and uninfected samples were digested with trypsin following standard methods of in-
solution digestion. The resulting peptides were cleaned up and labelled by reductive di 
methylation on Solid Phase Extraction cartridges. 
 
Stable isotopic reductive dimethylation of the resulting peptides was performed on OASIS 
HLB columns (Waters) following standard methods (Boersema et al. 2009). The peptides 
were acidified by addition of trifluoroacetic acid to 0.1 % (v/v) before loading onto conditioned 
OASIS HLB columns. Peptides from uninfected and infected samples were labelled with 
‘light’ and ‘heavy’ labelling reagents, respectively. The ‘light’ buffer consisted of 0.8 % (w/v) 
formaldehyde and 0.12 M sodium cyanoborohydride carrying hydrogens in their natural 
isotopic distributions in triethyl ammonium bicarbonate (TEAB) buffer. ‘Heavy’ buffer consists 
of 0.8 % (w/v) deuterated formaldehyde and 0.12 M sodium cyanoborohydride in TEAB 
buffer. The bound peptides were washed and eluted with 0.1 % (v/v) trifluoroacetic acid in 
70 % (v/v) acetonitrile. The eluted peptides were concentrated using a speed vacuum 
concentrator. The labelled ‘light’ and ‘heavy’ peptides were mixed together before 
fractionation by strong cation exchange chromatography on a Polysulphoethyl A column 
(PolyLC Inc USA). Fractions were desalted on Stage-Tip columns (Rappsilber, Mann, and 
Ishihama 2007). Each fraction of peptides was loaded on to a Acclaim PepMap100, C18, 3 
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μm, 100 Å, 75 μm (internal diameter) × 50 cm column using an UltiMate RSLCnano LC 
System (Dionex).  
 
The peptides eluted by reversed-phase chromatography were analysed by a micrOTOF-Q II 
mass spectrometer (Bruker) which was operated in data-dependent mode, automatically 
switching between MS and MS2 mode. The m/z values of tryptic peptides were measured 
using a MS scan (300-2000 m/z), followed by MS/MS scans of the six most intense peaks. 
Rolling collision energy for fragmentation was selected based on the precursor ion mass and 
a dynamic exclusion was applied for 60 seconds  
 
Raw spectral data were processed by DataAnalysis (Bruker) software and the resulting 
peaklists were searched using Mascot 2.4 server (Matrix Science) against UniProt Bovine 
sequence database containing 24,480 entries. Mass tolerance on peptide precursor ions 
was fixed at 25 ppm and on fragment ions at 0.1 Da. The peptide charge states were set as 
2+ and 3+. Carbamidomethylation of cysteine was used as a fixed modification and oxidation 
of methionine and light and heavy dimethylation of N-terminus and lysine were chosen as 
variable modifications.  False discovery rate was limited to < 1% for peptide IDs after 
searching decoy databases. Dimethyl quantification was performed by using WARPLC 
plugin on Proteinscape 3.1 software (Bruker) to integrate extracted ion chromatogram of 
every precursor. Peptide ratios were normalized based on setting overall peptide median 
ratio at one, which corrects for unequal protein sampling and a coefficient of variability of 
peptide ratios were also determined for each of the quantified proteins. 
 
2.1.7 Validation of biomarkers by Western blot and LI-COR imaging 
 
For quantitative, Western blotting infected and uninfected samples (diluted in Extraction 
buffer) were thawed from -80 oC in the derogated cat 3 lab. Following addition of 2 X Sample 
Buffer (4 % SDS, 34 % glycerol, 0.1% Bromophenol blue, 0.1 M DTT, 1 X Glycine), the 
samples were denatured at 100 oC for 5 mins and resolved by electrophoresis on 
commercial 12 % Bis-Tris (BioRad) gels in 1 X SDS Running Buffer at 180 V for 50 minutes. 
Two duplicate gels were resolved by electrophoresis in parallel in the same electrophoresis 
tank at the same time. One gel was incubated in InstantBlue™ (Expedeon) protein stain at 
room temperature for 1 hour on a rotating platform. Visualisation and quantification of the 
whole protein signal per lane was carried out using the LI-COR Odyssey scanner and 
software (Infrared Imaging System Scan, 700 channel). The other gel was used to transfer 
protein on to 0.2 µm Nitrocellulose membrane (BioRad 162-0112) at 18 V, 0.06 A for 1 hour. 
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This was performed using the BioRad transfer block (170-3940). Following this, the 
membrane was washed in Phosphate-buffered Saline (PBS)- 0.1 % Tween (0.1 % PBS-T) 
three times for 5 mins at room temperature on a rotating platform, blocked (in 10% Roche 
commercial blocking solution) for one hour and then incubated overnight in primary antibody 
diluted in 0.1 % PBS-T (see Table 2.1 for individual working dilutions). The primary 
antibodies used were: Fibulin1 (Abcam 192417), Vitamin D Binding Protein (Invitrogen PA5-
29082), Hemopexin (Invitrogen PA5-29521), Moesin (Novus NB1 1-90372), working dilutions 
listed in Table 2.1.  
 
The following day the membrane is washed thrice in 0.1 % PBS-T and then incubated in 
secondary antibody (Donkey anti-rabbit IgG ThermoFisher Scientific 31238, diluted 1/5,000 
in 0.1 % PBS-T). After three more washes in 0.1 % PBS-T the membrane was submerged in 
BM Chemiluminiscence Western Blotting substrate (Roche). Detection and quantification of 
protein by measuring the western blot band signal was subsequently performed using a 
second LI-COR imaging machine, the C-Digit LI-COR Blot Scanner and Image Studio Lite 
software (12 minute exposure). In order to calculate a normalised western blot signal, the 
western blot band signal is divided by the ratio. The ratio for the pooled samples was the 
average whole LI-COR total protein signal per InstantBlue™ stained gel for either uninfected 
or infected time point. The ratio for the individual samples was calculated by dividing a 
sample’s whole protein signal by that of the highest whole protein signal of all the samples 
run on the same gel.  
Table 2.1: Working dilutions for primary antibodies. 




































Novusbio NBP1-90372 Rabbit Human, 
mouse, rat 
1:2500 
All antibodies were optimised for use with either sheep plasma or buffy coat samples.  
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2.1.8 Statistical analysis 
 
Two sample T tests were performed to test the statistical significance of the normalised 
western blot results (described in Figure 2.2). This was done to analyse if the average 
difference between groups is significant of due to random chance. The diagram illustrates 
the comparison tests performed. Graphs were plotted and T-tests calculated using 
GraphPad Prism 7.  
 
2.2 Rov9 cell line infection experiment  
 
Rov9 cells are rabbit kidney epithelium cells modified to overexpress VRQ sheep PrP. They 
were developed as a quantitative assay to assess prion infectivity by (Arellano-Anaya et al. 
2011). The stocks used here were provided by Didier Vilette and stored at -80 oC. 
 
2.2.1 Passage of Rov9 cells  
 
In order to keep cells alive and growing under cultured conditions confluent cells were 
passaged every 7 days. To initially establish the cultures from frozen stock, medium was 
warmed to 37 oC in a water bath. 10% Opti-MEM medium (Reduced Serum Medium, 
ThermoFisher Scientific 31985062) was prepared with 10 % Foetal bovine serum (Gibco, 
15392402), and Penicillin-Streptomycin (PS) antibiotics (100 X ThermoFisher Scientific 
15140122). The vial was thawed and cells were added directly into the T25 flask containing 
Opti-MEM medium. The next day, medium was changed and cells left in incubator until 
confluence. For passage cells were washed twice with pre-warmed sterile PBS, trypsinated 
with 400 µL of 1 X Trypsin-EDTA (Sigma) to each T25 flask and flasks were incubated at 37 
oC for 5 mins. Cells were then disrupted by forceful tapping of flasks. 3.6 mL of fresh medium 
 
Figure 2.2: Diagram of comparison T tests performed. To analyse the significance of 
the normalised western blot data of each potential biomarker protein T tests were 
performed comparing each group at each time point and the difference between time 
points (prechallenge subtracted from 12 months). 
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(1/4 split) was added to the flask. Dissociation of the cellular clumps was achieved by up and 
down movements with the stripette. 1 mL of cell suspension was added to new flasks 
containing 3.6 mL of fresh medium which were placed into incubator at 37 oC. Doxycycline 
was added once the medium is prewarmed at 37 oC. Since Rov9 cells have an inducible 
promoter and they express ovine PrPC in a doxycycline-dependent manner, doxycycline 
(Sigma-Aldrich, D3447) was prepared in a stock of 5 mg/mL (5000 X) in absolute ethanol 
and added to Opti-MEM medium at a concentration of 1µg/µL only when the PrPC 
expression was required for infection with infected brain homogenate. 
 
2.2.2 Peripheral Blood Mononuclear Cell (PBMC) isolation  
 
PBMCs were isolated from blood collected from sheep in the Roslin Scrapie Flock. Two 
genotypes denote susceptibility or resistance to disease. VRQ/VRQ sheep are highly 
susceptible to scrapie and were the source for infected blood, while ARR/ARR sheep are 
resistant, and were used as negative controls (Hunter 1997). 100 mL of blood in EDTA 
anticoagulant were collected by jugular venepuncture from the sheep. Sterile scissors were 
used to cut blood bags and divide the blood between 50 mL falcon tubes. To separate blood, 
the falcon tubes were balanced and centrifuged at 3000 x g with brake off for 15 mins at 
room temperature. Once this initial spin was completed, buffy coats (containing leucocytes) 
were removed from the interface between red cells and plasma by use of stripette, placed in 
50 mL falcon tubes and diluted up to 50 mL in PBS and carefully layered over 20 mL of 
Lymphoprep (STEMCELL Technologies). Buffy coats and Lymphoprep were centrifuged for 
30 mins at 3000 x g with brake off. PBMC were harvested from the interface of the density 
gradient and supernatant, diluted in PBS and spun at 1500 x g for 15 mins at room 
temperature with brake on to remove residual Lymphoprep. Supernatant was then discarded 
ensuring not to disturb the pellet. This was followed by three consecutive PBS washes of the 
PBMCs at 1500 x g for 15 mins at room temperature. Cells were suspended in 10 mL of 
Opti-MEM medium and a 1 mL 1/10 dilution of cells in 0.2 % Trypan blue (ThermoFisher 
Scientific) was used to count cells in the haemocytometer.  
 
2.2.3 Infection of Rov9 cell line with PBMC  
 
To compare the infection of Rov9 cells with differentially treated PBMC, aliquots of 1 x 107 
infected PBMC pellets and aliquots of 1 x 107 uninfected  PBMC pellets were used. Rov9 
cells were first grown to confluency in a 12 well plate. To inoculate the Rov9 cells with fresh 
PBMCs, cells were resuspended in warm media and added to individual plate wells directly 
after isolation from whole blood. Next, both infected and uninfected pellets were 
freeze/thawed three times to lyse cells before Rov9 cell inoculation (10 mins on ice, 10 mins 
at room temperature thrice). Additionally, paraformaldehyde (PFA) fixation was performed by 
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treating infected and uninfected cell pellets with 2% filtered PFA. Aliquots of cell pellets in 
PFA were placed on ice for 10 mins, washed twice with PBS. The differentially treated 
PBMC pellets were added to Rov9 cells in the 12 well plate and left for 4 days before 
addition of fresh medium and weekly passaging (Salamat et al. 2011). Rov9 cells with no 
PBMC inoculation was used as a negative control, while inoculation of Rov9 cells with 1% 
brain homogenate of SSBP1 infected sheep or 1% brain homogenate from natural scrapie 
sheep provided a positive control. At each passage, cells were split 1/4 for storage, 1/4 for 
passaging, 1/4 for processing by western blot and 1/4 discarded. More detail is provided 
within Chapter 5. 
 
2.2.4 Processing of cell lysate for western blot 
 
The cell lysate was collected using TL1 Lysis buffer (0.5% Sodium Deoxycholate, 0.5% 
Triton X-100, 50 mM Tris-HCL). Following removal of medium, and after two washes in cold 
PBS, 1.5 mL of TL1 buffer was added to each T25 flask. Flasks were then placed at 4 oC for 
10 mins. Cell lysate was extracted by collection of T25 flask content in 15 mL falcon tubes 
and centrifugation at 2000 x g, 4 oC for 2 mins. The pellet (cell debris) was discarded and the 
supernatant (containing the cell membrane protein) was stored at -20oC or digested using 
proteinase K (PK) for detection of PrPSc by western blot. Total protein of the cell lysate was 
measured using microBCA as per suppliers guidelines and the cell lysate was diluted to 1 
mg/mL. For PK digestion, 2 µg of Proteinase K Solution (ThermoFisher Scientific AM2546) 
was added per 500 µL of cell lysate (for a final concentration of 4 µg PK/mg protein) and the 
samples placed at 37 oC for 2 hours. PK was then inactivated by addition of 4 µL of 4 mM 
Pefabloc protease inhibitor, and pellet obtained by centrifugation at 13000 x g for 30 mins. 
Pellets were resuspended in 20 µL 2 X Sample Buffer (Sodium Dodecyl Sulfate 4 %, 
Glycerol 34 %, Bromophenol Blue 0.1 %, Dithiothreitol 0.1 M, Tris-Glycine 1 X) and after 
denaturing at 100 oC for 5 mins resolved by electrophoresis and western blot (Salamat et al. 
2011) performed to visualise presence of PrPSc. After migration, the protein gels were 
transferred to nitrocellulose membrane and blocked with blocking reagent. The membranes 
were revealed with ROS-BC6 primary antibody (McCutcheon et al. 2014) at 0.25 µg/mL 
concentration in PBS-Tween (0.1%) overnight. After three washings with PBS-T, they were 
incubated with goat-antimouse secondary antibody (1 ng/mL) before immunodetection using 
BM Chemiluminiscence Blotting Substrate (Roche). 
 
2.2.5 Preparation of brain homogenate  
 
Scrapie/Uninfected brain homogenate was prepared into 10 % as required for Western blot 
by first thawing frozen brain samples on ice. 1-2 mL of sterile PBS was pipetted into a 
universal tubes. 1 g of brain tissue (frontal cerebral cortex, cerebellum and thalamus) was 
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cut into small pieces with sterile scalpels and placed into the tube of PBS. Using an Omni 
electronic homogenizer (Camlab) the tissue was homogenised until no clumping was 
observed (any fibrous tissues were removed). The brain tissue was diluted into a total of 10 
mL of PBS and thoroughly mixed. Aliquots of 500 μL brain homogenate were stored at  -80 
oC in 1.5 mL screw topped Eppendorf tubes.  
 
Brain homogenate was removed from storage and thawed before use. Brain homogenate 
was PK digested (for a final concentration of 4 µg PK/mg protein at 37 oC for 2 hours), 
processed in 2 X Sample Buffer and resolved by western blot in the same manner as 
described for Rov9 cells (2.2.4). 
 
2.2.6 recPrP Protein Purification: Full length Mouse PrP (flMoPrP) production  
 
RecPrP was purified to a high level following methodology previously described by Makarava 
and Baskakov (2008) and (Barron et al. 2016). Glycerol stocks (GATC-FML-Sam.000000.2 
Mo rPrP Wt S7 23-230 E.coli Rosetta 08/10/10) were used to grow large numbers of 
bacterial cell. These were induced to produce recPrP by addition of 1 M Isopropyl β-D-1-
thiogalactopyranoside (IPTG). Inclusion bodies were then harvested, resolubilised and 
protein purification performed by Ni-NTA Immobilized Metal Affinity Chromatography (IMAC) 
on the AKTA FPLC machine. IMAC fractions containing the most protein were combined and 
loaded on to a super loop using a syringe. Desalting (using a HiPrep 26/10 Desalting column 
on the AKTA FPLC) was conducted for buffer exchange and removal of low molecular 
weight substances.  
 
To achieve a level of high recPrP purity, Reverse Phase High Performance Liquid 
Chromatography (RP-HPLC) on the Dionex Ultimate 3000 was completed on the desalting 
fractions. The peak was collected as one fraction (shown in Figure 2.3 A and western blot in 
Figure 2.3 B), protein concentration was estimated using NanoDrop, 1 mL aliquots 
lyophilised using a SpeedVac (45 oC, HPr 5.4 vac for 3 hours) and stored at -80 oC. .  
 
To use the recPrP, aliquots were removed from storage and samples resuspended in PBS. 
Following NanoDrop confirmation of protein concentration, the recPrP was diluted in PBS, 


















Figure 2.3: Examples of RecPrP purification. A high level of protein purification was 
achieved through Immobilized Metal Affinity Chromatography (IMAC), Desalting and 
Reverse-phase chromatography. (A) is a snapshot of the reverse-phase chromatogram, 
the UV peak indicates protein eluted from the column. (B) is a SDS-PAGE gel of Desalting 
and Reverse Phase fractions. The intense band at ~25kDa indicates a large amount of 
flMoPrP; there are fewer impurities (non-specific bands) in the Reverse Phase fraction.  
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The blood borne transmission of vCJD is a major concern for blood transfusion banks, 
plasma derived product manufacturers and public health authorities. A significant challenge 
for diagnosis and surveillance is that hosts may incubate the infectious agent for months to 
decades without exhibiting any symptoms. Hence, a method for identifying donors or blood 
donations that pose a risk is highly desirable (Lacroux et al. 2014). An ideal preclinical test 
would have the ability to identify an individual throughout the incubation period. The test 
would have high levels of sensitivity and specificity, be able to be performed on easily 
accessible samples and have the ability to scale up for high throughput. Sensitivity is the 
ability of a test to correctly classify an individual as ‘diseased,’ it is also called the true 
positive rate or probability of detection. While specificity refers to the ability of a test to 
correctly classify an individual as ‘disease free,’ also known as the true negative rate (Parikh 
et al. 2008). 
 
Immunohistochemistry of the obex brain region exploiting anti-prion protein antibodies has 
long been seen as the ‘gold standard’ for prion diagnostics for animal prion diseases 
(Schaller et al. 1999). Other antibody specific diagnostics (such as Prionics or BioRad tests) 
utilise western blot or ELISA techniques. However, detection of PrPSc has to be performed 
against the background of PrPC. This is an issue as most antibodies bind both PrPSc and 
PrPC. Furthermore, since the current detection method of PrPSc is dependent on its 
resistance to PK digestion, it is not suitable for detection of PK sensitive PrPSc (Rubenstein 
2012).  The major issue with most of these tests is that they can only be applied to post 
mortem samples, not live animals or individuals.  
 
A key reason for the difficulties faced in constructing a reliable premortem diagnostic test is 
the low level of PrPSc present in body fluids. Protein misfolding cyclic amplification (PMCA) is 
an exception to other diagnostic methods. It is a technique whereby detection sensitivity is 
increased through amplification of PrPSc. It works by utilising the ability of the misfolded 
protein to convert a pool of normal PrPC to a PK-resistant form thus ‘amplifying’ the original 
entity. The detection of PrPSc from blood of vCJD patients is 100% sensitive and specific 
using this technique (Concha-Marambio et al. 2016b). Additionally, Bougard, Brandel, 
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Bélondrade, et al. (2016) identified preclinical blood from two individuals 1.3 and 2.6 years 
before they developed and displayed vCJD symptoms. The assay was also able to detect 
vCJD infection in the early preclinical stage in primates (Lacroux et al. 2014). Real-time 
quaking induced conversion (RT-QuIC) also exploits the ability of PrPSc to induce PrPC to 
misfold. The formation of PrPC aggregates is monitored in real time by their ability to bind to 
a fluorescent dye (thioflavin T) (Wilham et al. 2010); (Atarashi et al. 2011). The use of RT-
QuIC on the cerebrospinal fluid (CSF) of suspected patients with sCJD is commonly used to 
confirm diagnoses. The reported sensitivity is between 69% -89% for neuropathologically 
confirmed sCJD and specificity between 99%-100% (McGuire et al. 2012); (Park et al. 2016); 
(Bongianni et al. 2017); (Groveman, Orrú, et al. 2017). 
 
Alternative, ‘surrogate’ protein biomarkers to complement PrPSc in detection would be 
invaluable and perhaps overcome the hurdles in preclinical diagnostics (Rubenstein 2012). 
The modern day trend in clinical research for biomarkers is not to find a single factor but 
instead a panel of biomarkers in which the total diagnostic performance tends towards 100% 
sensitivity coupled with 100% specificity (Piubelli et al. 2006). Clinical analysis of blood is a 
widespread diagnostic procedure in medicine. The integral role blood plays in human 
physiology implies that it should be a universal reflection of a patient’s state. The cellular 
components are erythrocytes, thrombocytes, lymphocytes, monocytes and granulocytes and 
the liquid portion is called plasma (Geyer 2017). In regards to proteinaceous biomarker 
discovery, the most challenging feature of the plasma proteome is the exceptionally wide 
concentration range of proteins. In fact, more than 10,000 proteins have been identified in 
human plasma (www.plasmaproteomedatabase.org accessed on November 2018) making 
the plasma proteome the most heterogeneous and complex sub-proteome of the human 
body (Hortin, Sviridov, and Anderson 2008). Hence many studies on plasma proteomics 
involve a step in minimising sample complexity whilst reducing protein dynamic range. 
 
Once a biomarker candidate has been discovered it requires confirmation and validation. 
This is an issue in addressing preclinical human prion diseases due to the availability of 
samples and disease being confirmed either at a late stage or after death. To overcome this 
issue and address the unmet need for blood based prion disease biomarkers, samples used 
here are from an archive collected during previous transfusion experiments in BSE infected 
sheep. This reflects the real life scenario where three individuals developed vCJD following 
transfusion of infected blood from donors who later succumbed to vCJD themselves. Sheep 
are a good model for what occurs in humans as they share similarities in disease 
pathogenesis. BSE infected sheep harbour infection in peripheral tissues, PrPSc deposition is 
extensively found in the lymphoreticular system (Jeffrey, Martin, et al. 2001). This is similar 
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to humans infected with vCJD (Hill et al. 1999). In contrast, BSE infectivity in cattle does not 
have widespread tissue distribution (Buschmann and Groschup 2005); (Espinosa et al. 
2007). Additionally, the relative size of sheep and humans allow for volumes of blood 
comparable to those used in human transfusion practice to also be transfused in sheep 
studies.  
 
3.1.1 Aims of work 
 
The aim of this chapter is to identify differences in protein expression between uninfected 
and infected plasma samples from BSE infected and uninfected sheep. Through mass 
spectrometry comparison it may be possible to identify changes in protein expression that 
indicate disease status. Predicted proteomic differences must be tested to ensure correct 
identification and reproducibility of results. Up or down regulation of particular proteins in the 
original plasma samples will be verified to confirm the mass spectrometry data. This will 
provide preliminary data on determining a protein biomarker panel associated with prion 
infection in blood of asymptomatic patients. To elaborate on the viability of a particular 
protein as a potential diagnostic marker, comparison of its detection in human samples is 
















3.2.1 Use of ProteoMiner to deplete highly abundant proteins in plasma 
 
The samples used in this study are from a previous transfusion study of BSE infected sheep. 
Since it is established which of the recipients developed BSE, donors with infectious blood 
can be identified. Infected samples were taken when blood was proven to be infectious but 
the sheep lacked clinical signs (mimicking the human silent carrier status). Uninfected 
samples were taken from the same sheep at a time point prior to their exposure to BSE brain 
material. Hence, the two time points investigated were prechallenge (uninfected) and 12 
months after (infected). The plasma from nine sheep were pooled to control for genetic or 
metabolic differences between sheep. This was done for samples at both time points. Before 
performing mass spectrometry the plasma went through an initial processing step.   
 
Around twenty proteins (including albumin, transferrin and fibrinogen) constitute more than 
98% of protein mass in plasma (Geyer et al. 2016). Their presence can obscure detection of 
less abundant proteins. In order to enrich the plasma samples for less abundant proteins the 
ProteoMiner enrichment kit was employed. Due to conventional antibody mediated depletion 
methods being specific to human or mouse proteins thus potentially not recognising sheep 
antigens, ProteoMiner was chosen as the method for these samples. To decrease highly 
abundant proteins and enrich less abundant proteins in complex biological samples 
ProteoMiner technology utilises a vastly diverse library of hexapeptides bound to beads held 
within the column. There are a total of 64 million unique beads. Each bead features a 
distinctive hexapeptide ligand with affinity for a specific protein. When the sample is applied 
to the beads, hexapeptide ligand bind to their particular protein by interacting with exposed 
amino acid sequences. Simultaneously, highly abundant proteins saturate their high affinity 
ligands (excess proteins is washed away) and less abundant proteins are concentrated on 
their high affinity ligands as illustrated in Figure 3.1. Proteins bound to the beads 
(representatives of all original components) are eventually eluted. Thus the dynamic range of 
protein concentrations in the samples is greatly reduced. Table 3.1 indicates the source of 
samples collected from completion of ProteoMiner.  
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Table 3.1: Description of the origin of samples obtained from the ProteoMiner 
column.  
Flow Through Sample with excess levels of high abundant proteins.  
Sample Wash Wash Buffer used to remove excess unbound protein. 
Water Wash MilliQ water used to remove surplus Wash Buffer from column.  
Enriched Elution Elution Buffer used to elute protein from column. 
 
The table highlights names and describes the source of the samples that were collected 
from the column and run on a SDS-PAGE gel to monitor efficiency of technique following 
repeat experiments. 
 
Figure 3.1: Flowchart explaining the process of the ProteoMiner technology. The 
ProteoMiner columns contain vast libraries of hexapeptide ligand beads. Each bead is 
unique to an individual protein. Once a complex sample is applied to the column, 
proteins within that sample bind to their specific beads of the column. Less abundant 
proteins are retained while highly abundant proteins saturate their high affinity ligands. 
With subsequent washing of the column excess protein is removed (in Flow Through). 
Finally a more homologous sample is recovered by addition of an elution buffer. The 
result is depletion of a significant portion of the high abundant proteins within the sample 


























Figure 3.2: Results following use of ProteoMiner on pooled plasma. A portion of 
Coomassie Instant BlueTM stained gel is shown in (A). The Enriched Elution is obtained 
from eluting the final sample off of the ProteoMiner column; the Original Sample is before 
ProteoMiner is performed. The image illustrates that bands on the gel become visible (in 
Enriched Elution lane); representing low abundant proteins that are no longer obscured 
and are now detectable (compared to Original Sample lane). The bar chart (B) shows 
protein concentration of the plasma before and after ProteoMiner, it is an average from 
four repeat experiments. As determined by microBCA the Original Sample concentration 
fluctuated between 80 – 68 mg/mL while the concentration Enriched Elution ranged from 
2.5 - 4 mg/mL. Thus a 95 % reduction in plasma protein concentration was achieved 




Figure 3.3: SDS-PAGE comparison of ProteoMiner samples from plasma in two 
different anti-coagulants (EDTA and Sodium Citrate). The archived samples used in 
this study had been stored in either EDTA or Sodium Citrate anti-coagulant. In order to 
evaluate if this had an affect on ProteoMiner performance, comparison experiments were 
performed. This figure shows samples where a total of 10 µg of protein was loaded per 
gel lane. Following this, the gel was stained with Coomassie Instant BlueTM. The results 
are fairly similar for samples in both anticoagulants. Bands within the boxes indicate 
enhanced detectability of Enriched elution low abundant proteins. Thus it was decided 
that moving forward only samples collected in EDTA (the current anticoagulant used in 




The results from ProteoMiner on the pooled plasma samples from sheep before and 12 
months after infection with BSE indicate that a large proportion of highly abundant proteins 
have been removed, facilitating an enhanced detection of less abundant proteins. Figure 3.2 
A depicts the substantial reduction in amounts of 60 kDa albumin protein (from the Original 
sample, before ProteoMiner) on the SDS-PAGE gel for uninfected pooled plasma and is 
representative of results for infected pooled plasma too. At the same time there is an 
appearance of a multitude of fine bands (in the Enriched Elution, after ProteoMiner) 
representing the presence and detectability of less abundant proteins. In order to determine 
the protein content of the samples before and after ProteoMiner, microBCA assays were 
performed. There is a 95 % reduction in protein concentration (bar chart in Figure 3.2 B). 
 
The results from using the ProteoMiner enrichment kit highlight the importance of 
ProteoMiner in expanding the visibility of less abundant protein in complex solutions. 
Uninfected pooled plasma was initially used to optimise the technique in the category 2 lab. 
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These tests included analysing plasma collected in two different anticoagulants, EDTA and 
Sodium Citrate. Figure 3.3 shows that there is depletion of abundant samples prepared in 
both anticoagulants. The boxes highlight the areas of the gel which illustrate this most clearly. 
The Original Sample has been run next to the Enriched Elution and for both plasma in EDTA 
and plasma in Citrate, the strong band for albumin (60 kDa) has been replaced with many 
bands for less abundant proteins. Since the ProteoMiner is viable with both types of 
anticoagulant, it was decided that moving forward only plasma collected in EDTA would be 
used (as there were more samples collected in EDTA available from infected sheep and it is 
the current anticoagulant used for blood collection). Furthermore, the best denaturing 
temperature and protein loading concentrations for resolving proteins by SDS-PAGE were 
determined. It was concluded that denaturing of proteins at 100 oC and loading 10 µg of 
protein per sample gave the best results for comparison. 
  
Proteins are eluted from the ProteoMiner column using a Commercial elution buffer 
containing 8 M Urea and 2 % CHAPS. Urea is a strong denaturant. As binding affinity 
required proper three dimensional folding of a protein, reagents that weaken interactions 
 
Figure 3.4: Use of two different elution buffers (Urea buffer and Commercial 
elution buffer) with ProteoMiner on uninfected plasma. The ProteoMiner kit 
provides a Commercial elution buffer that contains CHAPS. CHAPS is not 
compatible with mass spectrometry. For this reason, a substitute Urea based 
buffer was tested and the results compared to the Commercial buffer. Plasma 
was added to two ProteoMiner columns simultaneously and 10 µg of protein from 
each collected sample resolved on the same gel. The figure shows that low 
abundant protein bands become evident in the enriched fraction with use of the 




Figure 3.5: Testing the ProteoMiner large capacity kit with pooled uninfected plasma.  
Following optimisation of the technique using the small capacity ProteoMiner kit, work was 
scaled up to the large capacity kit. The small capacity ProteoMiner kit is able to 
simultaneously concentrate low abundant proteins and deplete the concentration of high 
abundant proteins in samples with a total protein load of ≥ 10 mg, while the large capacity kit 
has a protein loading capacity of ≥ 50 mg. Plasma has a protein concentration of 50 – 80 
mg/mL, thus 1 mL of undiluted plasma can be used with the large capacity ProteoMiner kit. 
The gel in this image shows a practice run with the large capacity kit. Unlike with the small 
capacity kit, the final sample is eluted three times. The signal of low abundant protein species 
have been amplified in the three enriched elutions. 
 
between protein and ligand can be used for elution. CHAPS is a detergent used for 
solubilizing proteins. Detergents are not compatible with mass spectrometry. Whilst 
surfactants are commonly used in protein preparation, their presence can affect enzymatic 
digestion and the subsequent analysis of the resulting peptides by mass spectrometry. Since 
the ProteoMiner kit provided elution buffer includes CHAPS, the enriched elution eluted in 
this buffer may not be compatible with mass spectrometry and this would thus interfere with 
analysis. To avoid this issue other buffers were trialled. The change from the commercial 
elution buffer to a Urea based buffer (8M Urea in 50MM HEPES without CHAPS) achieved 
the same level of highly abundant protein reduction and enhanced detection of less 
abundant protein. This is depicted in Figure 3.4. The boxes on the gel highlight a comparison 
between the Enriched Elution and Original Sample. Many bands appear in the Enriched 
Elution following the use of ProteoMiner thus highlighting the detection of less abundant 
proteins that were previously masked for both samples eluted in Urea buffer and the 
Commercial elution buffer. 
A 
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Table 3.2: Total protein amount of samples before and after ProteoMiner.  
 
Total protein (µg) 
Uninfected 
Plasma pool 
Original  82373 
Enriched Elution 4 5874 
Infected Plasma 
pool 
Original  78039 
Enriched Elution 4 4575 
 
1 mL of undiluted pooled plasma is added to the ProteoMiner large capacity kit column. 
(separate columns for uninfected and infected plasma). The procedure results in three 
rounds of 100 µL eluted sample from the column (Enriched Elution 1, 2 and 3), these are 
combined to obtain Enriched Elution 4. The table indicates the protein concentration of 
the original plasma sample (before ProteoMiner) and Enriched Elution 4 (after 
ProteoMiner). There has been a 94-93% reduction in protein concentration for the 
uninfected and infected pooled plasma samples.  
After testing the reproducibility of the results, work was scaled up to use the large capacity 
kit (Figure 3.5). The large capacity ProteoMiner columns works best with samples of a 
protein content greater than 50 mg/mL, hence 1 mL of undiluted sample could be applied to 
the column. Three rounds of sample elution are required (Elution 1, Elution 2, Elution 3). 
Following experimental trials in the containment level 2 lab (and containment 3 lab training), 
the large capacity ProteoMiner kit was used on pooled infected and uninfected samples in 
the category 3 lab.. Table 3.2 provides the protein concentration of samples before and after 
ProteoMiner as obtained by microBCA assay. Figure 3.6 are the final gels where the 
depletion of highly abundant protein in the samples may be observed. Figure 3.7 depicts the 
workflow involved. The three elutions were combined to give Elution 4. After reduction and 
alkylation (to break protein disulphide bonds and prevent disulphide bonds reforming, 
improving peptide yield and sequence coverage) and tryptic digestion (to digest proteins into 




Figure 3.6: Samples from pooled uninfected and infected plasma that were 
depleted on separate ProteoMiner columns were resolved on separate gels. After 
fully optimising the use of ProteoMiner and performing a practice run using the large 
capacity kit, samples for mass spectrometry were prepared in the derogated containment 
level 3 lab. 1 mL of uninfected plasma and 1 mL of infected plasma were applied to 
individual ProteoMiner columns simultaneously. Samples of the three elutions were taken 
before they were combined to create Elution 4 (to determine protein concentration by 
microBCA assay and to resolve on gel). Following reduction, alkylation and tryptic 






























Figure 3.7: Flowchart depicting sample preparation. This is an overall summary of 
the steps involved to prepare samples prior to mass spectrometry. First, 1 mL aliquots of 
uninfected plasma from nine sheep were pooled to control for differences between 
sheep. A sample of the original pool was taken for microBCA analysis to determine 
protein concentration. 1mL of pooled sample was applied to a large capacity 
ProteoMiner column. Samples from the ProteoMiner column were microBCA assayed to 
calculate 10 µg of protein to resolve on comparison gels with the original sample. 
Following a check of SDS-PAGE results (to ensure a reduction in the most abundant 
proteins), the enriched elution was taken through reduction, alkylation and tryptic 
digestion steps. The exact same procedure was performed simultaneously with pooled 
infected plasma (taken from the same nine sheep but at a different time point during the 
transfusion study experiment, when their blood was proven to be infectious). Finally, both 
uninfected and infected samples were forwarded for isotopic labelling and mass 
spectrometry analysis. 
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3.2.2 Mass spectrometry of plasma and identification of potential biomarkers 
 
Liquid chromatography-tandem mass spectrometry (LC-MS) is a powerful and robust 
analytical technique. Liquid chromatography separates multiple components of complex 
mixtures while mass spectrometry delivers structural identify with high molecular specificity 
and detection sensitivity (Pitt 2009). The individual abilities of liquid chromatography and 
mass spectrometry are enhanced by their tandem combination, experimental error is 
reduced. 
 
The use of plasma in this study, a complex biological sample with a high protein dynamic 
range, meant that liquid chromatography fractionation was an essential step in the isolation 
and identification of target proteins. Liquid chromatography uses a column packed with 
porous, solid material known (the stationary phase), where the sample is injected and a 
solvent (the mobile phase) passes to transport the sample. Separation is achieved through 
exploiting the different affinities of chemical compounds in the sample for the stationary 
phase versus the mobile phase. After a sample is injected on to the column, it is adsorbed 
on the stationary phase and the solvent passes through the column separating compounds 
one by one. The component with the most affinity to the stationary phase is the last to 
 
 
Figure 3.8: Scatter plot of proteomics data showing protein expression obtained 
from mass spectrometry of pooled uninfected and infected plasma. Light and heavy 
isotopes were used to distinguish between the uninfected and infected samples 
respectively. The red lines indicate cut off points for the H/L ratio. The differentially 
expressed proteins are the outliers. The original dataset of 153 proteins was thus 
reduced to 44 proteins.   
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separate as the high affinity corresponds to more time taken to travel to the end of the 
column. The most commonly used liquid chromatography is reverse-phase chromatography 
(RP-LC). This is because it allows for precise control of variables such as organic solvent 
type, concentration and pH. In RP-LC the mobile phase is polar and the stationary phase is 
non-polar or hydrophobic. This means that polar molecules pass through the column at a 
faster rate than non-polar molecules. The separated compounds may then be determined by 
mass spectrometry.  
 
Mass spectrometers operate by three main processes: ionisation, separation and detection. 
First the sample is introduced to the ionisation chamber and analyte molecules are 
converted into an ionised or charged state. Subsequently, ions are separated according to 
their mass to charge ratio (m/z) by a mass analyser. A detector records the m/z and ion 
counts. The last step involves a post processing software that determines the species and 
quantity of each ion (within the resolution limit of the instrument). 
 
Proteins that are differentially expressed in infected plasma compared with uninfected 
plasma can be evaluated by isotopic labelling and quantitative LC-MS. Protein samples were 
first reduced and alkylated and subsequently digested into peptides using trypsin. The 
resulting peptides were labelled with stable isotopic reductive dimethylation strategy 
(Boersema et al. 2009). Reductive dimethylation labelling is performed using regular (light) 
or deuterated (heavy) forms of formaldehyde and sodium cyanoborohydride to add two 
methyl groups to each free amine. Peptides from uninfected and infected samples were 
labelled by reductive dimethylation (with light (L) and heavy (H) isotopic labels respectively). 
Upon LC-MS, extracted ion chromatograms of the light and heavy counterparts of each 
peptides, were calculated to derive relative peptides abundance and protein ratios were 
derived from the individual peptides ratios that belongs to each proteins. 
 
Spectral data was searched against the ENSEMBL sheep database. Originally 153 proteins 
were identified in the plasma samples based on one or more unique peptide match. The data 
was then filtered by setting the coefficient variation (%CV) to less than 100%. The %CV is 
calculated by dividing the standard deviation of peptide profiles by the mean, proteins 
with %CVs greater than 100 have expression ratios that are considered unreliable.  The 
extent of differential expression was assessed by filtering the median heavy/light (H/L chain) 
isotopes and retaining proteins between >1.5 and <0.666, leaving a dataset of 44 proteins 
(Figure 3.8). These stringent cut offs are applied to minimise the inclusion of false positives 
resulting from the lack of biological replication, removing proteins with potentially unreliable 
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expression ratios that would otherwise be classified as differentially expressed. The 
normalised fold change refers to the H/L ratio, hence proteins with a value <1 are down 
regulated in the infected sample. There is no change in expression for proteins with a value 
of 1, while upregulated proteins the number is >1. The most common plasma proteins 
already manipulated by ProteoMiner (such as albumin, transferrin and fibrinogen) were 
eliminated leaving 35 proteins (Table 3.3). A shortlist of 8 candidate proteins (Table 3.4) was 
established by comparison of the dataset with current literature. Validation of these proteins 
would reflect on the validation of the full list of proteins.  
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Table 3.3: List of 35 differentially expressed proteins identified by mass 




0.22 SERPINA3 serpin peptidase inhibitor 
0.27 HPX hemopexin 
0.27 IPSP serpin peptidase inhibitor 
0.36 SERPINA1 serpin family A member 1  
0.39 SAA1 serum amyloid A-2 protein  
0.39 TTR transthyretin  
0.39 IPSP serpin peptidase inhibitor 
0.47 IGLC6 immunoglobulin Lambda-6 Chain C Region 
0.53 A1BG alpha-1-B glycoprotein  
0.56 C1QB complement C1q B chain 
0.5 ATP6V1A ATPase H+ transporting V1 subunit A  
0.59 IGL immunoglobulin Lambda  
0.59 ATP5H ATP synthase, H+ transporting, mitochondrial Fo 
complex subunit D  
0.59 C5 complement component 5 
0.61 ITIH4 inter-alpha-trypsin inhibitor heavy chain family 
member 4 
0.63 GC GC, vitamin D binding protein 
0.63 MT-ND1  NADH-ubiquinone oxidoreductase chain 1 
0.64 CDH5 cadherin 5 
0.66 C3 complement C3  
      
1.55 GSN gelsolin 
1.55 SERPINF1 serpin family F member 1 
1.58 BPIA2 BPI fold-containing family A member 
1.61 APOD apolipoprotein D  
1.69 SHBG sex hormone binding globulin  
1.78 C1S complement component 1, s subcomponent  
1.80 F2 prothrombin precursor  
1.89 CONG conglutinin precursor 
1.91 HABP2 hyaluronan binding protein 2  
1.95 ITIH1 inter-alpha-trypsin inhibitor heavy chain 1 
2 FBLN1 fibulin 1 
2.02 ITIH2 inter-alpha-trypsin inhibitor heavy chain 2 
2.16 C4BPA complement component 4 binding protein alpha  
2.27 CD5L CD5 molecule like  
2.36 SERPINA5 serpin family A member 5  
2.73 PON1 paraoxonase 1  
To identify proteins, data was searched against the ENSEMBL Sheep database. Clear-
cut offs were applied to bring the original list of 153 proteins down to 35 proteins (full list 
in Appendix Table 1). Uninfected plasma was labelled with a light (L) isotopic label, and 
uninfected plasma with a heavy (H) isotopic label. The normalised fold change is a ratio, 
thus <1 signifies a decrease in protein expression in the infected sample while >1 relates 
to an increase. 
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Protein Protein function  Examples of relevant studies showing relation to 
neurodegenerative diseases 
0.27 HPX 
hemopexin Binds heme and transports it to the 
liver for iron detoxification and 
recycling.  
Yu et al. (2003); Sui et al. (2004); Castano et al. (2006); Moore et al. 
(2014). 
0.39 TTR 
transthyretin Transports thyroxin and retinol. Yu et al. (2003); Riemer et al. (2004); Castano et al. (2006); Piubelli et 
al. (2006); Brechlin et al. (2008); Perrin et al. (2011); Rubenstein 








Component of the C1q complex, 
involved in the complement system 
and innate immunity.  
Afagh et al. (1996); Botto et al. (1998); Dandoy-Dron et al. (1998); 
Klein et al. (2001); Riemer et al. (2004); Xiang et al. (2004); 
Gehlenborg et al. (2009); Flores-Langarica et al. (2009); Erlich et al. 
(2010). 
0.63 VDBP 
vitamin D binding 
protein 
Transports vitamin D metabolites. Bishnoi, Palmer, and Royall (2015). 
     
1.61 APOD 
apolipoprotein D Involved in lipid metabolism. Dandoy-Dron et al. (1998); Riemer et al. (2004); Xiang et al. (2004); 
Skinner et al. (2006); Moore et al. (2014); Muffat and Walker (2010); 




Binds hyaluronic acid and may play 
a role in coagulation. 
Nagga et al. (2014). 
2.00 FBLN1 
fibulin 1 Binds to fibrinogen and other 
extracellular matrix structures. 
Ahn et al. (2010). 
A light (L) isotope was used to label uninfected plasma, while a heavy (H) isotope was used to label infected plasma. The selection of potential plasma 
biomarkers was based on the current literature and previous association with prion diseases or other neurodegenerative conditions. Five show decreased 
expression in infected samples, while three are increased. This is highlighted by the normalised fold change (<1 decrease, >1 increase). The function of each 
protein was obtained from UniProt. 
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The infected plasma sample is a pool from samples collected from 9 sheep 12 months post oral 
challenge with BSE brain material. Previous studies on sheep similarly inoculated, indicate that at 
this preclinical stage the level of PrPSc is undetectable in lymphoreticular organs or the CNS (Jeffrey, 
Ryder, et al. 2001); (Bellworthy et al. 2005). Hence, investigating the changes occurring with other 
proteins circulating within the body at the preclinical stage of infection is important. These blood-
based proteins may give an indication of what is taking place during on going TSE infection. The full 
list of differentially expressed proteins suggests the changes occurring are involved in the immune 
system (particularly triggering and regulation of the compliment cascade), hemostasis (formation of 
fibrin and platelet activation), metabolism of lipids and signal transduction. The candidate biomarkers 
(Table 3.4) were selected by looking at publications where studies have suggested a connection 
between the protein (or corresponding gene) to either prion diseases or other neurodegenerative 
diseases.  
 
Hemopexin is closely involved in the maintenance of iron/redox homeostasis in mammalian tissues. 
Hemopexin has previously been determined as a potentially relevant marker for prion diseases. It is 
one of the molecular transport proteins shown to be increased in the brains of scrapie infected mice 
(Moore et al. 2014). In regards to other neurodegenerative disorders, hemopexin has been reported 
to display a six and a half-fold upregulation in sera from patients with Alzheimer’s disease (AD) (Yu 
et al. 2003). Significant upregulation was seen in serum of triple transgenic 
(PS1M146V/AβPPSwe/TauP301L) mice with AD (Sui et al. 2014). Additionally, hemopexin has been 
identified by mass spectrometry as increased in the CSF of AD patients (Castano et al. 2006). 
 
Transthyretin is one of three prealbumins. Its main role is in the transport of thyroid hormones in the 
plasma and CSF. Transthyretin has been identified at high levels in CSF from patients with CJD 
(Brechlin et al. 2008). It is associated with increased expression during disease and has previously 
been suggested as a relevant CJD marker (Piubelli et al. 2006).  It has been shown to be 
upregulated in the plasma of AD patients (Song et al. 2014) and early stage AD patients (Perrin et al. 
2011). Gene expression profiling of BSE infected macaque brains show upregulation of transthyretin 
(Barbisin et al. 2014). Upregulation of the transthyretin gene has also been observed in scrapie 
infected brain tissue as determined by RT-PCR analysis of terminally ill scrapie infected and mock 
infected mouse brains (Riemer et al. 2004). Transthyretin is commonly found in proteomic analysis 
of prion disease and AD samples, it is also one of proteins identified in the previously mentioned 
studies for hemopexin (Rubenstein 2012); (Sui et al. 2014); (Yu et al. 2003); (Castano et al. 2006). 
 
Alpha-1-B glycoprotein is of unknown function, however it has been linked to AD. In tracking plasma 
biomarkers using samples from AD patients, Song et al. (2014) suggested a upregulation of alpha-1-
B glycoprotein in three replicate experiments. A significant increase in A1BG expression was 
observed by Muenchhoff et al. (2016) in plasma of AD patients when investigating protein changes 
at the asymptomatic and symptomatic stages of disease. Additionally, when screening the serum of 
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AD mice to identify potential novel protein biomarkers for early AD alpha-1-B glycoprotein was 
shown to be significantly upregulated (Sui et al. 2014). This upregulation is in contrast to our dataset 
where these proteins were downregulated 
 
Among the proteins detected by mass spectrometry analysis were components of the complement 
system. C1q is the first component of the classical complement pathway. The C1q complement 
consists of 18 protein chains: six A, six B and six C.  C1q binds to fibrillar β-amyloid (Aβ) found as 
extracellular deposits in tissues leads to activation of the classical complement pathway as well as 
pro-inflammatory events. An increase of C1qB-chain immunoreactivity was reported in neurons of 
AD patients (Afagh et al. 1996). Hence, the presence of C1q with amyloid deposits in the brain has 
lead to it association with AD pathology. C1q B chain has been shown to be upregulated (Riemer et 
al. 2004) or at least altered (Xiang et al. 2004) in scrapie infected brain tissue. Additionally, a 4-5 fold 
increase was observed in the level of C1qB mRNA in scrapie infected mice brains at the terminal 
stage of disease (Dandoy-Dron et al. 1998). In a transcriptomic study of 8 mouse prion diseases, 
three genes coding for C1q were shown to be among the top 10 upregulated genes in the brain 
(Gehlenborg et al. 2009). Mice deficient in C1q or complement receptors have been shown to be 
partially or fully protected against spongiform encephalopathy upon exposure to prions. The 
reduction in splenic accumulation of prion infectivity and PrPSc indicates that activation of specific 
complement components is involved in the initial trapping of prions in lymphoreticular organs at the 
early stage of infection (Botto et al. 1998). FDCs are a major extracerebral prion reservoir. It has 
been speculated that signalling mediated by binding of complement triggers a specific state of 
differentiation or activation of FDCs that allow accumulation of prions (Klein et al. 2001); (Flores-
Langarica et al. 2009). C1q may also play a role in the PrP aggregation process. The interaction 
between C1q and PrP could represent an early step in the disease where elimination of the prion 
seed is prevented subsequently leading to further aggregation (Erlich et al. 2010). 
 
Vitamin D binding protein is encoded by a gene that belongs to the albumin gene family. Although 
multifunctional, its main role is in binding vitamin D and its plasma metabolites and transporting them 
to target tissues. Vitamin D binding protein has been found to be elevated in the CSF of 
neurodegenerative disorder cases such as AD and PD. Raised serum vitamin D binding protein has 
been suggested to be useful indicator of future AD, hence it has been implicated in the pathogenesis 
of AD (Bishnoi, Palmer, and Royall 2015).  
 
Apolipoprotein D is a high density lipoprotein, which unlike other lipoproteins (that are mainly 
produced in the liver) is mainly produced in the brain and testes. Its involvement in stress responses 
suggest it may have a neuro-protective role during ageing and neurodegeneration (Muffat and 
Walker 2010). Apolipoprotein D has previously been identified as a gene with upregulation in prion 
diseases from looking at scrapie infected brain tissue (Riemer et al. 2004). It has also been shown to 
be a differentially expressed gene in scrapie infected mouse brain, with  >1.5 fold enhanced 
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expression (Xiang et al. 2004). Apolipoprotein D was elevated, compared to uninfected age matched 
controls, in brains of mice infected with the RML mouse strain of scrapie (Moore et al. 2014). It was 
first reported to exhibit increased expression in the brains of scrapie infected animals only at the 
terminal stage of disease by Dandoy-Dron et al. (1998). Dandoy-Dron et al. (1998) found a 3-8 fold 
increase in the level of mRNA in brains of scrapie infected mice. Similarly, an average twofold 
change increase was observed in scrapie infected mice using cDNA microarray (Skinner et al. 
2006b). Apolipoprotein D has been found to be elevated in a variety of neurological disorders, 
including AD, schizophrenia and stroke (Dassati, Waldner, and Schweigreiter 2014).  
 
Hyaluronan binding protein 2 is part of the S1 family of serine proteases. Secreted by the liver it 
binds hyaluronic acid and may play a role in coagulation. Hyaluronic acid impairs the integrity of the 
blood brain barrier (Al-Ahmad et al. 2019) and has been suggested as a potential biomarker for 
patients with vascular dementia, due to the detection of elevated levels in their CSF (Nägga et al. 
2014). Both Hyaluronan binding protein 2 and Fibulin 1 were among the top upregulated proteins 
detected by the mass spectrometry. Fibulin 1 is found in association with the extracellular matrix and 
is involved in cell adhesion and motility. Fibulin 1 binds to fibrinogen and incorporates it into blood 
clots (Tran et al. 1995). Blood clots formed in the presence of Aβ peptide have an abnormal structure 
and are resistant to degradation. As its binding causes fibrinogen to oligomerize, it has been 
suggested that the interaction of Aβ with fibrinogen may contribute to the vascular abnormalities 
found in AD (Ahn et al. 2010). The vascular abnormalities that patients with AD may exhibit include 
altered cerebral blood flow, damaged cerebral vasculature and hemostasis impediments (de la Torre 
2004). Vascular diseases such as atherosclerosis correlate in severity with dementia and AD (Bell 
and Zlokovic 2009). Functional decreases in blood flow and/or metabolic rate have been detected 
prior to the development of abnormalities seen on structural imaging, EEG or level of 14-3-3 in CSF 
in prion disease patients (Taber et al. 2002); (Mathews and Unwin 2001); (Matsuda et al. 2001); 
(Staffen et al. 1997).  
 
The appearance of these proteins (or their genes) in other prion or neurodegenerative disease 
datasets in disease profiling studies give a strong indication of their usefulness as prospective 
biomarker candidates.  
 
3.2.3 Biomarker validation in pooled samples  
 
3.2.3.1 Testing and optimization of antibodies on sheep plasma 
 
The ability to confirm the extent of differential expression of the chosen protein biomarkers between 
uninfected and infected plasma is of critical importance if any are to be deemed suitable for potential 
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clinical use. To validate the mass spectrometry predictions and quantify specific proteins the western 
blot technique was used. This approach involves separating proteins by molecular weight through 
gel electrophoresis, their transfer (‘blotting’) to a membrane, which is then antibody probed, and their 
subsequent detection by chemiluminescent, fluorescent or colorimetric tools. The result is a specific 
protein band that may be visualised. The benefit of western blot over other immunoassay methods is 
that if the target protein is altered (downregulated or overexpressed) the pixel density of the band 
changes. This change can be measured by LI-COR technology.  
 
Following microBCA assay to calculate protein concentration, initial tests were performed on pooled 
samples of uninfected plasma. The plasma was diluted in RIPA buffer and aliquoted out for storage. 
This was done in an attempt to alleviate protease degradation, a potential problem for protein freeze 
thawed multiple times or stored at -20 oC. The samples differ from that used for mass spectrometry 
in that they had not been ProteoMiner treated. Antibodies for each potential biomarker were tested 
under various conditions (Table 3.5 and 3.6), however many showed cross reactivity (they were 
unable to recognise the intended target or resulted in non-specific binding and alternative protein 
bands). This was despite high percentage human and sheep amino acid similarity (protein identity) 
as established from comparing human and ovine peptide sequence identity on UniProt. This was 
done because the mass spectrometry data was searched against the ENSEMBL sheep database, 
while most antibodies are produced to react with human samples. Only three antibodies (fibulin 1, 
vitamin D binding protein and hemopexin) showed specific binding and were taken forward for 
further testing. The molecular weights for each biomarker are 26 kD (fibulin 1), 58 kD (vitamin D 
binding protein) and 56 kD (hemopexin). The molecular weights determined for vitamin D binding 
protein and hemopexin are as expected from predictions based on human or mouse data. Fibulin 1 
is predicted to have a molecular weight of 95 kD which is cleaved into 70 kD and 26 kD fragments 
(Sasaki et al. 1996). The antibody used here detects the 26 kD form (Aviva Systems Biology FBLN1 
Ab OACD03419). A large band with high fluorescent intensity may obscure any small changes 
between samples. Optimisation by testing different protein loading (while keeping western blotting 
conditions stringent) was performed for efficient quantification by LI-COR scanning (Figure 3.9).  
After further optimisation experiments, it was decided that both hemopexin and vitamin D binding 
protein antibodies worked best with 8 µg of protein, while the clearest bands seen for fibulin 1 was 









Table 3.5: Table of antibodies tested for the chosen protein biomarkers in order to validate the mass spectrometry data.   








Species Reactivity  
Hemopexin Polyclonal antibody, hemopexin Fisher Scientific 
UK Ltd 
13403677 73% Human 




12848892 72% Human, mouse, rat 
Alpha 1 B 
glycoprotein 
A1BG Polyclonal Antibody Thermo Fisher 
Scientific 
PA5-14207 68% Human 
Complement C1q B 
chain 
C1Q B Antibody Polyclonal Thermo Fisher 
Scientific/Life 
Technologies 
PA5-42554 74% Human, canine, equine 
Vitamin D binding 
protein 
Polyclonal antibody, vitamin D 
binding protein 
Fisher Scientific  
UK Ltd 
13413207 79% Human, mouse 
Apolipoprotein D Polyclonal antibody, apolipoprotein D Fisher Scientific 
UK Ltd 
13481377 73% Human, mouse 
Hyaluronan binding 
protein 2 
Anti-HABP2 Antibody Polyclonal Cambridge 
Biosciences/Atlas 
Antibodies 
HPA019518 82% Human 
Fibulin 1  
Anti-Fibulin 1 antibody 
Abcam EPR10913 93% Human, mouse, rat 
 
All antibodies were rabbit polyclonal. The human and sheep amino acid similarity (protein identity %) is a comparison of the human and ovine target 
peptide sequence, it is included as a probable indicator of antibody performance. Many antibodies are produced to react with human proteins, however 








Table 3.6: Optimization of antibodies to select proteins for Western blot. 
Protein Manufacturers Primary Secondary Protein Western blot result  
 recommended Antibody Antibody Load  
 dilution for primary dilutions dilutions tested tested  
 Antibody tested  (µg)  







1:10 000 2, 4, 6, 8, 10 Quantifiable band signal at 56 kD  
achieved with 8 µg of protein,1:2500 
primary antibody dilution and 1:5000 
secondary antibody dilution. 
 1:50 000 
1:100 000 
1:200 000 
7, 8, 9, 10 
  
 




1:10 000 2, 4, 6, 8, 10 Cross reactivity (multiple 
nonspecific bands).  1:50 000  
 1:100 000   
 1:200 000   




1:10 000 2, 4, 6, 8, 10 Cross reactivity. 
glycoprotein 1:50 000   
 1:100 000   
 1:200 000   





1:10 000 2, 4, 6, 8, 10 Non-target band identified. 
C1q B chain 1:50 000   
 1:100 000   


















  1:750 
  1:500 
 





2, 4, 6, 8, 10 
7, 8, 9, 10 
Quantifiable band signal at 58 kD 
achieved with 8 µg of protein 
Works with 1:750 primary 
antibody dilution and 








1:10 000 2, 4, 6, 8, 10 Cross reactivity. 
 D 1:50 000   
 1:100 000   
 1:200 000   




1:10 000 2, 4, 6, 8, 10 Cross reactivity. 
binding 1:50 000   
protein 2 1:100 000   
 1:200 000   













2, 4, 6, 8, 10 
4, 5, 6, 7 
Quantifiable band signal at 26 kD 
achieved with 5 µg of protein. 
Works with 1:750 primary 
antibody dilution and 1:5000 





The antibodies for the potential biomarkers were tested at a range of concentrations, combined with dilutions of secondary antibody (Donkey anti-
Rabbit IgG ThermoFisher Scientific 31238, manufacturer’s guide dilution 1:10 000 - 1:200 000) across multiple uninfected plasma protein 


















Figure 3.9: Optimisation of protein loaded before quantification for each biomarker 
antibody. A range of protein loads were tested (with the manufacturer’s suggested dilution of 
antibody) to obtain an appropriate western blot band signal required for quantification. As a 
large band signal may obscure any slight differences between the two samples (uninfected and 
infected plasma), a thinner band is more favourable for comparison and detection of minute 
changes. Shown here are example western blots for a range of protein concentrations loaded 




3.2.3.2 Quantification of proteins in pooled uninfected and infected plasma  
 
In order to determine specific protein expression of these potential biomarkers, western blot 
and LI-COR imaging was employed. Samples used here were equivalent to the plasma 
pools depleted by ProteoMiner prior and analysed by mass spectrometry. The difference in 
protein expression was measured in the infected sample compared to the uninfected sample 
(the uninfected sample was set as the norm).Two gels were run in parallel to resolve loading 
differences between lanes (where the same concentration of protein is loaded, as calculated 
through microBCA assay). One gel was stained with Coomassie Instant BlueTM and used to 
measure the whole protein content of each lane giving a ‘whole protein signal’. Thus small 
differences between loading of individual samples may be established (and accounted for) 
when calculating differences in specific protein expression (Eaton et al. 2013).  
 
A ‘ratio’ value is calculated for a particular sample by dividing that sample’s whole protein 
signal by the average whole protein signal for all samples (on the same gel) of the same 
protein concentration. A ‘normalised western blot signal’ can then be calculated by dividing 
the western blot band signal (detected from LI-COR scanning the antibody probed, 
chemiluminescence stained nitrocellulose membrane) by the ratio. These steps are depicted 
in Figure 3.10 A. Figure 3.11 gives example gels for each biomarker chosen for validation. 
To plot the graph in Figure 3.12 A a ‘comparison’ value is calculated from the normalised 
western blot signal by dividing the normalised western blot for the infected pooled plasma by 
that for the uninfected plasma.  
 
The results of the pooled plasma corroborate the mass spectrometry data, despite the mass 
spectrometry being performed on ProteoMiner manipulated pooled plasma samples (while 
pooled plasma used in the western blots for verification were not ProteoMiner treated). For 
fibulin 1 mass spectrometry suggested there would be an increase in expression in the 
infected plasma sample. From running 6 experiments comparing expression in uninfected 
and infected pooled plasma an upward trend in fibulin 1 expression may be observed (Figure 
3.12 A). There is not much variation from experiment to experiment, as illustrated by the 
table in Figure 3.12 B. The paired T test for the Comparison data (Normalised western blot 
signal for uninfected and infected pooled plasma) gives a P value of 0.0028. This means the 
result is significant. Both vitamin D binding protein and hemopexin were predicted by the 
mass spectrometry to decrease in expression from the uninfected to the infected pooled 
plasma. For vitamin D binding protein there is a clear decrease in expression. The P value 
for the Comparison data across 6 experiments is 0.007. This is highly significant. Similarly, in 
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the case of hemopexin there is also a downward trend in expression exhibited by the 
western blot results. The P value for the paired T test of the hemopexin Comparison results 









   
 
Figure 3.10: Steps involved in the LI-COR Western blot determination of protein 
expression. (A) is a flow diagram summarising the procedure performed with pooled 
plasma sheep samples. Volumes equivalent to the same protein concentration of 
pooled uninfected and pooled infected plasma were simultaneously loaded on to two 
gels. One gel (B) is taken through the full western blot procedure (arrow pointing to 
band of interest). The second gel (C) is stained with Coomassie Instant BlueTM to 
determine whole protein content of the lanes. Protein is transferred to a nitrocellulose 
membrane by blotting. Following blocking, application of primary antibody (here anti-
Fibulin1), secondary antibody and chemiluminescence solution the membrane is 






A.    
 
B.    
 
C.   
 
Figure 3.11: Example blots for the three biomarkers with uninfected (UN) and 
infected (IN) pooled plasma. Duplicate gels are run in parallel, one gel is stained with 
Coomassie Instant BlueTM to detect the whole protein content of the lane. The second gel 
passes through the full western blot procedure and a specific individual band is 
determined. The arrows indicate bands of interest (A) Fibulin 1 is at 26 kD, (B) Vitamin D 






B.   
Sample  
Comparison (Normalised western blot band signal) 













Fibulin 1 1.18 1.14 1.13 1.23 1.22 1.25 1.19 0.048 0.020 
Vitamin D 
Binding 
Protein  0.66 0.72 0.77 0.83 0.65 0.54 0.70 0.102 0.042 
Hemopexin 0.63 0.74 0.73 0.70 0.68 0.91 0.73 0.096 0.039 
 
Figure 3.12: Results for biomarker expression in pooled uninfected plasma compared to pooled infected plasma. Graph A illustrates the 
average difference in protein expression for the three biomarkers. The table (B) shows this data from 6 repeat experiments. Experiments are 















































Average change in protein expression in uninfected 
and infected pooled plasma for each potential 
biomarker protein 
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3.2.4 Biomarker validation in individual samples  
 
After confirming that the results for the change in expression between pooled uninfected 
plasma and pooled infected plasma for the potential biomarkers were reproducible by 
western blot it was decided to expand the work to look at results in individual sheep samples. 
The results for the potential biomarkers with the pooled plasma should be somewhat 
reflected by the results from individual sheep. It will also highlight if there is any single sheep 
that has skewed the data in a certain direction. These sheep were the same nine sheep that 
were used to make the pooled samples. To use as controls, three age matched negative 
control sheep from the same study, which had been orally dosed with uninfected cattle brain 
homogenate, were chosen. This was to ensure that any changes observed were not just age 
dependent. Furthermore, an aliquot of pooled plasma was used as a positive control, the 
results of which should be the same across all analyses. Unfortunately due to issues with 
sample storage, although this sample was run on each gel the data was not quantifiable 
across all time points. Seven time points that cover the transfusion study were selected for 
analysis, these time points represent different stages during the incubation period of infection 
(Prechallenge, 4 months, 8 months, 10 months, 12 months, 18 months post-infection and 
Clinical). Fewer samples were available at the 4 months and 18 months time points. For 18 
months, where only one negative control sheep had blood taken, control sheep from the 
closest time points (12 months) were used as substitutes and run on the same gel. Not all 
sheep had blood collected at these time points during the course of the transfusion study. 
Additionally, no samples for sheep N233 were collected at 10 months post-infection 






Samples from the twelve sheep at the seven time points were removed from -80 oC storage 
(Sheep IDs listed in Table 3.6), diluted in RIPA buffer and microBCA assays were performed 
to determine protein concentration. Following this, the protein load was further optimised to 
achieve to ensure the appropriate amount per lane needed in efficient quantification. Similar 
to the procedure used in determining differences in protein expression in the pooled 
uninfected and infected samples, the individual sheep samples for each specific time point 
were run on duplicate gels. One gel was stained with Coomassie Instant BlueTM for analysing 
whole protein content of the lanes. The second gel was taken through the western blot 
procedure and individual protein bands captured by LI-COR scanning. In order to calculate a 
normalised western blot signal, the western blot band signal is divided by the ratio (as done 
for the pooled samples). However, here the ratio is determined by dividing that sample’s 
whole protein signal by the highest whole protein signal (out of those from the twelve sheep 
run on the same gel). The procedure is depicted in Figure 3.13. 
 
Two gels were produced for each of the seven time point, with samples from control sheep 
interspersed between experiment sheep to avoid bias (one Coomassie Instant BlueTM 
Table 3.7: List of individual sheep and time points that plasma samples were 



















N257 1        
N236 2        
N233 3        
N251 4        
N261 5        
N189 6        
N231 7        
N232 8        
N157 9        
N239 10*        
N170 11*        
N217 12*        
* Control sheep 
The shading signifies the presence of samples available for data analysis. Not all sheep 
has samples taken at every time point. The control sheep are age-matched with the 
infected sheep but were not exposed to BSE.  
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stained for the whole protein signal, and one taken through the full western blot procedure to 
obtain a western blot band signal). This was done for the three different biomarkers (at least 
forty-two gels). Figure 3.14 shows example gels for the initial individual sheep blots. For 
technical reasons yielding poor results, the data could not be interpreted. Analysis of gels 
were inconsistent due to large discrepancies in whole protein band signal from Coomassie 
Instant BlueTM stained gels (when there should have been equal loading between lanes, 
across samples). This was possibly a consequence of inaccuracy in sample preparation, 
pipetting errors or resolving gels in different gel tanks. Western blot band signals were also 
implausibly variable. After performing these experiments, a fault was discovered with one of 
the transfer units this resulted in poor and inconsistent transfer of protein to membrane 
depending on equipment being used affecting certain time points more than others. In Figure 
3.14 much fainter signals can be seen on the second half of the gel (samples following the 
second marker for sheep 12, 7, 8, 9 and the uninfected pool). The transfer tank was then 
taken out of use. In an attempt to overcome the variation between running experiments on 
different days and using different equipment the experiment was altered. Further gels were 
processed for the specific biomarkers. This time, two gels were resolved for an individual 
sheep but with samples from multiple time points. Similar inconsistences were also observed 







Figure 3.13: Overview of individual plasma analysis. In order to determine the level 
of protein expression for each candidate biomarker in the individual sheep plasma, 
samples were resolved on gels and analysed by LI-COR. The flow chart shows the steps 
involved to run each gel. Plasma from nine sheep were individually diluted in RIPA buffer 
(to prevent protein precipitation). Samples were taken for microBCA assay to establish 
protein concentration. Following this 1 mg/mL stock solutions were prepared and 
appropriate quantities of protein (as optimised for use with each particular biomarker 
antibody) resolved in duplicate gels by SDS-PAGE electrophoresis. One gel is forwarded 
for the whole western blot procedure and membranes antibody probed to obtain specific 
bands that allowed for quantification. The second gel is stained over night in Coomassie 
Instant BlueTM and a signal for the whole protein content per lane (per sample) 
quantified. A ratio value is obtained by dividing the whole protein signal by the highest 
whole protein signal across the gel (as the same protein concentration for each of the 
nine sheep samples should have been loaded, thus taking into account loading 
discrepancies). The western blot signal is then divided by the ratio and this value plotted 
on graphs. Initially this was performed on samples that covered several time points 
across the transfusion study. Due to inconsistencies between experiments this was 
scaled back to compare the two time points used initially for uninfected and infected 










Figure 3.14: Representative Coomassie Instant BlueTM stained gel and western blot 
for individual sheep plasma samples at 8 months, probed for hemopexin (8 µg of 
protein loaded). The initial experiments on individual sheep plasma show uneven protein 
load across lanes (A). The uninfected pooled plasma (last lane of B) does not show up on 
the western blot and this may be a result of poor sample storage or handling. Additionally 
there is spill over from the marker lane into the neighbouring lane of the Coomassie 




Following on from the successful validation of the mass spectrometry data with the pooled 
samples, it was predicted that the changes seen in the pooled samples would also be 
reflected in the individual samples that made up these pools at their particular time points 
(prechallenge and 12 months post infection).  As the results from running the individual 
samples for different time points on different gels were not consistent with the mass 
spectrometry data or from validation with the pooled samples, it was decided to start again 
as well as redesign the experiment. First, microBCA assays of the original samples in RIPA 
buffer were performed again. Extra care was taken with calculations (ensuring not to include 
predicted values above or below the standard curve). Figure 3.15 shows a test run following 
this. There is improved loading and a more consistent whole protein signal. The validation of 
mass spectrometry data using individual sheep samples was then simplified.  
 
Only two time points were compared, the same two time points compared with pooled 
plasma (uninfected or prechallenge and infected or 12 months). Multiple sheep (including the 
same control sheep) were run on each gel. Ideally, using this method would overcome some 
of the obstacles encountered in the first experiment. A total of six gels were run for each 
biomarker (including 3 for whole protein staining).  
 
 
Figure 3.15: Preliminary test for even protein loading following repeat microBCA of 
individual sheep plasma samples at two time points (8 µg of protein loaded). The 
total protein loading is less variable after redoing microBCA assay for original samples 
and preparing stock dilutions and samples in loading buffer again. Uninfected and infected 
plasma (prechallenge and 12 months post infection) from the same sheep are resolved 
side by side, both control and infected sheep are shown here. 
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Figure 3.16 A shows fibulin 1 expression for individual sheep plasma samples at two time 
points, example gels are given in Figure 3.17.There is no change hence no statistically 
significant difference in fibulin 1 expression for control sheep at the two time points. The 
difference in fibulin 1 levels in BSE infected sheep between prechallenge and 12 months is 
highly statistically significant (paired T test P value = 0.0055). Figure 3.16 B shows the 
difference in fibulin 1 expression between the two time points (the normalised western blot 
values at prechallenge subtracted from the normalised western blot values at 12 months). 
Comparing difference between the control and infected sheep is significant (T test P value = 
0.0165). If there was no change in fibulin 1 expression between the two time points for  both 
infected and control groups of sheep, then it would be expected that the difference (12 
month expression – prechallenge expression) would be the same when comparing one 
group to the other. As this is not the case (indicated by Figure 3.16 B and the significant P 
value), it can established that the expression of fibulin 1 in infected sheep varies to that of 
control sheep.  
 
Vitamin D binding protein expression for control and test individual sheep are depicted in 
Figure 3.18 A, with representative gels shown in Figure 3.19. The paired T test result for 
comparing protein expression of infected sheep at prechallenge and infected sheep at 12 
months is significant (P value =0.0113). Comparing expression of vitamin d binding protein in 
control sheep and infected sheep at 12 months also gives a significant result (T test P value 
= 0.0222). The difference between normalised western blot signals (prechallenge subtracted 
from 12 months) for the two groups (control and infected sheep) can be seen in the second 
graph (Figure 3.18 B). It is almost significantly different (T test P value = 0.0763). 
 
In the case of hemopexin (Figure 3.20 A and Figure 3.21) although the average hemopexin 
levels at 12 months for infected sheep were lower compared to prechallenge levels, it is not 
a statistically significant difference. The reason for this is likely to down to the great variability 
seen in hemopexin levels across all sheep. The difference between 12 months and 
prechallenge normalised western blot results is shown in Figure 3.20 B. Comparing control 











Figure 3.16: Fibulin 1 expression in individual sheep plasma at Prechallenge 
compared to 12 months post infection. Graph (A) shows a clear increase in fibulin 1 
expression in infected sheep at the 12 months time point compared to at Prechallenge. 
The asterisk indicates a paired T test with a significant result (P=0.0055). The level of 
fibulin 1 expression for control sheep is consistent at both time points (there has been 
no change over time in control sheep). Graph (B) is the difference between 12 months 
and Prechallenge (the normalised western blot band signal at prechallenge subtracted 
from the normalised western blot band signal at 12 months) plotted for control sheep 
and infected sheep.The asterisk shows a significant value was calculated in the T test 








Figure 3.17: Representative gels are shown for individual plasma sheep samples 
at prechallenge and 12 months post infection probed for fibulin 1 (5 µg of 
protein loaded). Gel (A) is a Coomassie Instant BlueTM, LI-COR scanned gel for 
quantification of whole protein signal. This discussion should be in the text. The 
second image (B) is of the membrane post-western blot and LI-COR scanned (arrow 
points to band of interest). UN/uninfected (Prechallenge) and IN/infected (12 months) 
samples for each sheep were loaded next to one another for easy comparison. Control 






   
Figure 3.18: Vitamin D binding protein expression in individual sheep at 
Prechallenge compared to 12 months. The graph (A) shows the level of vitamin D 
binding protein expression has decreased from prechallenge to 12 months in infected 
sheep. This is in contrast to the control sheep where there is no change vitamin D binding 
protein expression from prechallenge to 12 months. There is a significant difference 
(Paired T test P=0.0113). A significant difference was also observed when comparing 
control sheep at 12 months to infected sheep at 12 months (T test P=0.0222). Graph (B) 
shows the difference between 12 months and Prechallenge normalised western band 
signal for control and infected sheep (the normalised western blot band signal at 
prechallenge subtracted from the normalised western blot band signal at 12 months). 
Comparing control and infected sheep shows an almost significant change in vitamin D 





 A.  
 
B.   
 
 
Figure 3.19: Representative gels are shown for individual plasma sheep samples at 
prechallenge and 12 months post infection probed for vitamin D binding protein (8 
µg of protein loaded). Two gels of the same samples were resolved at the same time, 
with UN or uninfected (Prechallenge) and IN or infected (12 month) placed side by side for 
easy comparison. The first (A) is Coomassie InstantBlueTM stained to obtain the whole 
protein signal. Protein on the second gel is transferred to a membrane that is antibody 
probed and LI-COR scanned (B). The arrow highlights the band of interest. Although, like 
the antibodies for the other biomarkers, the vitamin D binding protein antibody had been 
optimised for use, a new batch from the same manufacturer were used in these 
experiments. Hence, this antibody stock seems to be more sensitive than that used 








Figure 3.20: Hemopexin expression in individual sheep at Prechallenge 
compared to 12 months. Graph (A) shows data for expression of hemopexin in 
control and infected sheep at two time points. Although the level of hemopexin is 
unchanged between Prechallenge and 12 months for control sheep, there is a 
decrease in expression for infected sheep at the same time. The last graph (B) plots 
the difference between western blot signals at 12 months and Prechallenge 
(normalised western blot signal at prechallenge is subtracted from the normalised 
western blot signal at 12 months) for control and infected sheep. The difference is 












Figure 3.21: Representative gels are shown for individual plasma sheep samples at 
prechallenge and 12 months post infection probed for hemopexin (8 µg of protein 
loaded). Both (A) and (B) illustrate the method used to quantify the level of hemopexin in 
individual plasma samples. Samples are resolved on two gels simultaneously. One (A) is 
Coomassie Blue stained to obtain a whole protein signal per lane. Protein on the second gel 
is transferred to a membrane and antibody probed to acquire specific western blot band 
signals (B). The data is analysed to get a comparison in expression at different time points. 
The arrow on (B) identifies the protein of interest. Although optimisation of the antibody was 
performed and used on pooled sheep plasma samples, a new batch of antibody was used 





The aim of this work was to investigate the effects of preclinical prion disease on blood 
protein composition. This was done through use of archived plasma samples from 
transfusion studies performed on BSE infected sheep. It is of particular importance to identify 
any relevant changes in protein expression profiles between uninfected and infected time 
points to pick out information potentially relevant for use in diagnostics. It would be more 
efficient to implement a biomarker panel, alongside testing for PrPSc. As previously 
highlighted, there is a need for a test to clearly detect preclinical disease, distinguish these 
patients and prevent inadvertent cross-transmission.  
 
Samples from nine sheep were pooled to normalise protein expression differences caused 
by genetic or metabolic variation between outbred animals. A challenge in the proteomic 
analysis of plasma samples is that a small number of highly abundant proteins obscure less 
abundant proteins. To address this issue as part of the preparation of samples for mass 
spectrometry analysis ProteoMiner was utilised. This results in a partial depletion of highly 
abundant proteins in samples and concentration of less abundant proteins, thus a more 
equalised sample. Mass spectrometry highlighted a difference in the expression of 153 
proteins between uninfected and infected plasma pools, this list was refined to 35 proteins 
after filtering and removing the top common plasma proteins. From here 8 proteins were 
selected to validate mass spectrometry quantification and further explore their suitability for 
use as candidate biomarkers. Validation of these candidate biomarkers would reflect on the 
validation of the full list of 35 proteins. Out of these 8, only antibodies for 3 proteins cross-
reacted with a protein of the predicted molecular weight and showed low levels of non-
specific reactivity in Western blot and LI-COR analysis. After testing on pooled uninfected 
and infected samples, samples for the individual 9 sheep (as well as 3 negative controls) 
were investigated for differences in protein expression from 7 time points that covered the 
breadth of the transfusion study. Due to technical issues, this did not yield reliable results, 
and the analysis was not continued because of time constraints. Instead, to confirm the 
results of the pooled plasma samples, individual sheep samples from two time points 
(prechallenge and 12 months) were analysed.  
 
The trends predicted by mass spectrometry may be observed in the results of western 
blotting of the pooled infected and uninfected samples. The mass spectrometry analysis 
indicated twice as much fibulin 1 expression was found in infected compared to uninfected 
samples. This was the highest out of the 8 candidate proteins (Table 3.4) and the sixth 
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highest in the list of 35 proteins with differential expression between uninfected and infected 
samples (Table 3.3). For the six repeat experiments carried out on uninfected and infected 
plasma pools, there is a similar increase in fibulin 1 expression from uninfected to infected 
samples (average 1.19 for the comparison value based on normalised western blot signals 
which is not as much as the mass spectrometry predicted). For vitamin D binding protein 
there is a consistent decrease in expression, matching the mass spectrometry prediction. 
The comparison value is 0.70. The comparison value for hemopexin is very close to this at 
0.73. This is surprising as although the mass spectrometry predicted both proteins to 
decrease in expression the normalised fold change for each protein are not close. The 
normalised fold change predicted by mass spectrometry for vitamin D binding protein is 0.63 
while for hemopexin it is 0.27. The statistics for the pooled plasma western blots show there 
are significant changes in protein expression. The paired T test for comparison values 
(normalised western blot signal for uninfected and infected pooled plasma) gives a P value 
of 0.0028 for fibulin 1. This is highly significant. For vitamin D binding protein it is 0.007 (very 
significant) and for hemopexin it is 0.06 (borderline significant). 
 
A possible reason for the discrepancy witnessed between the mass spectrometry data and 
the individual plasma blots (uninfected vs infected time points) is the sensitivity of techniques. 
Accuracy of validation, and reproducibility of results, may have been affected by the use of 
different aliquots of plasma used in validation. Although the same sheep were used between 
the pooled and individual samples experiments, different aliquots taken from the sheep 
archive were used. Perhaps there are differences in protein content between stored aliquots 
from the same sheep. This can be determined and accounted for by the microBCA assays 
performed before resolving proteins by SDS-PAGE. It is also possible that multiple freeze 
thawing of these aliquots would have affected protein content, allowing for degradation of 
proteins to occur with ease. In an attempt to prevent this from occurring and alleviate the 
issue, pooled and individual sheep plasma aliquots were diluted in RIPA buffer (with 
protease inhibitor) prior to western blotting. Another possible reason for the magnitude of 
difference between the mass spectrometry data and the western blot results is the use of 
ProteoMiner. ProteoMiner was only applied to pooled samples sent for mass spectrometry 
analysis and not on pooled samples or individual samples used in western blot validation. 
ProteoMiner may have altered the proteins of interest. Thus the magnitude of differential 
expression seen in the untreated samples would not completely reflect the mass 
spectrometry samples. Furthermore, differences between the mass spectrometry data and 
the individual sheep blots may be explained by the natural complexity of blood, the 
thousands of proteins present contribute to its dynamic composition. This would be unique 
from sheep to sheep. The individual sheep have been taken as biological replicates, 
however it is possible that protein expression would vary widely from sheep to sheep. This 
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would be affected by genetics, hormone levels, concurrent infections, stress responses or 
even the time of day when blood was taken. 
 
Technical reasons may also account for the differences seen in the predicted protein 
expression by mass spectrometry and the results obtained from western blotting. A major 
issue with the experiments performed using the individual sheep samples is the LI-COR 
analysis of the Coomasie Instant BlueTM stained gels. Although there is supposed to be 
equal loading between lanes (with the same concentration of loaded for each sample), there 
is some variability between samples (as can be seen by comparing lanes from gels in Figure 
3.16). Hence, consistant signals in the total protein gels were not achieved, allowing 
differential exposure to be normalised. Although two gels are run in parallel to measure 
protein content of samples and account for any slight differences between them, the 
accuracy of reading the whole protein signal per lane is affected by over spillage from 
neighbouring lanes. Overloaded lanes could be underestimated (due to signal outside of the 
boxes), and neighbouring lanes being overestimated this overspill. It may be a result of how 
well the samples were resolved by SDS-PAGE or discrepencies in sample loading. In 
addition, the whole protein concentrations from the LI-COR anlaysis of the Coomasie Instant 
BlueTM stained gels are heavily skewed by albumin. This is because albumin makes up 
about 80% of total protein in plasma. If there are individual expression variations in albumin 
betweem sheep it would heavily affect the quantification of specifiic proteins. A closer 
attention to the protein concentration calculations measured by microBCA assay is required 
to resolve this issue. Additionally, analysis of the whole protein gel could have been 
performed useing averages of sections for each lane (avoiding the strong albumin band).       
 
 
In an attempt to account for the shortcomings in the technical procedure of the individual 
sample blots further experiments were performed. The pooled plasma was prepared from 
prechallenge (uninfected) and 12 months (infected) time point samples. Thus the best 
comparison with the pooled plasma western blots are individual values at prechallenge and 
12 months for the nine infected sheep.  Having samples from the same sheep at different 
time points on the same gel is a better comparison. This seems to have rectified the previous 
issues seen with the large scale experiment of individual sheep samples analysed across 
seven time points, as the results here align with those from the pooled plasma western blots 
and the mass spectrometry predictions. The results for fibulin 1 clearly show a statistically 
significant increase in protein expression when comparing the same sheep at prechallenge 
and 12 months post infection time points (paired T test P value = 0.0055). Likewise, for 
vitamin D biding protein there was a statistically significant decrease in protein expression in 
the same sample sets (paired T test P value = 0.0113). In the case of hemopexin, although 
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there was a decrease in mean protein levels in 12 months compared to prechallenge 
samples, there was a greater spread in the data points for the individual samples at both 
time points, and the difference was not statistically significant (p = 0.1767). In addition to 
these comparisons, the difference between 12 months and prechallenge was calculated 
(normalised western blot signal of prechallenge was subtracted from 12 moths). This 
difference between protein expression at the two time points was then compared for control 
and infected sheep. The T test P value for fibulin 1 was significant at 0.0165, while those for 
vitamin D binding protein and hemopexin were almost significant (P = 0.0763 and P = 0.0655 
respectively). This highlights that there was a clear change (either increased or decreased 
protein expression) between the control and infected sheep for each biomarker.   
 
In a similar study, where ARQ/ARQ sheep were orally infected with 5 g brain tissue from 
BSE infected cattle, there was no detectable presence of PrPSc in the CNS 10 months after 
inoculation. It is only at 16 months that disease specific PrP accumulation was detectable in 
the lymphoreticular tissue and CNS (Jeffrey, Ryder, et al. 2001); (Bellworthy et al. 2005). 
The infected samples used to provide the plasma pool prepared for mass spectrometry were 
collected from nine sheep at 12 months post inoculation. Although at this point it may not be 
possible to identify PrPSc by immunohistochemistry, this may be due to the sensitivity of the 
technique. There may be exceptionally low levels beginning to build up, or other changes 
and pathological processes occurring that do not produce lesions that can be measured by 
immunohistochemistry. Furthermore, Bellworthy et al. (2005) show that despite the lack of 
detectable PrPSc at 10 months following infection the spleen was positive by mouse bioassay. 
This highlights that there is the presence of infectivity at 10 months and suggests that 
infectivity precedes the presence of PrPSc. It can be expected that this is also the case for 
spleen tissue at 12 months (for the transfusion study sheep). The spleen is the largest 
lymphatic organ, one of its key roles is in filtering blood, removing old red blood cells and 
storing platelets and white blood cells (Tarantino, Scalera, and Finelli 2013). The 
experiments performed here specifically look at the proteins in the plasma fraction of blood. 
The full list of differentially regulated proteins during disease as predicted by mass 
spectrometry is outlined in table 3.3. The proteins can be categorised into the following 
processes: regulation of the immune system, cell signalling, protein transport, cell structure 
and cell movement. 
 
A number of the proteins chosen as potential biomarkers showed differential regulation that 
opposed findings from previous studies on prion or neurodegenerative diseases. This may 
be due to experimental design (how analysis was performed), the type of sample 
investigated (genes, mRNA, brain tissue, CSF, blood serum or plasma), the study 
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participants (rodent, macaque or human) or even the type of disease and clinical stage. 
Patient preparation, sample collection, sample preparation and sample storage can all play a 
role in proteomic variations (Apweiler et al. 2009). There are limitations to the information 
derived from DNA/RNA analysis and although genomics provides a vast amount of 
information linking gene activity to disease it is incapable of showing a complete and 
accurate profile of protein abundance or final state of activity. Multiple proteins may be 
generated from each gene through post-translational modification and mRNA splicing (Cho 
2007). mRNA levels also do not always reflect protein expression (Gygi et al. 1999). 
Additionally, there will be disparity in sample complexity when comparing different protein 
sources. Plasma or serum has the advantage of being easily accessible but has a high 
dynamic range, the presence of abundant proteins mask more conservatively expressed 
molecules (Moxon et al. 2009). Withdrawing CSF is a more invasive procedure, less volume 
may be obtained at a time and there may also be contamination by blood-derived proteins. 
However, CSF has the advantage of proximity to region of disease, it is less complex with 
easier identification of proteins low in abundance and also identification of peptides that are 
biologically active (Caudle et al. 2008). Despite this, the overlap between the brain proteome 
and the CSF proteome is quite low, about 34% (Macron et al. 2018). Further challenges are 
involved in extrapolating findings from animal studies to human cases, there will be species 
differences that have not been taken into account (Bracken 2009). Since there is an overlap 
in pathophysiological mechanisms between dementia, AD, PD and prion diseases there may 
also be an overlap in protein expression in early disease stages (Castellani, Perry, and 
Smith 2004).  
 
C1QB, C5, C3, C1S, C4BPA, CD5L are all involved in the complement and coagulation 
cascades. Their up or down regulation in the dataset is varied and may be a result of the 
complexes they form and consequential pathways they are involved in. It is has been 
established that innate immunity is key for prion disease progression. Abnormal prions 
replicate in follicular dendritic cells of the small intestine and B cells play a vital role in 
dissemination through circulation of infectivity in the body (Bradford and Mabbott 2012). The 
blood of the sheep used in this study was able to cause infection when transfused into 
recipient sheep at 10 months post inoculation. This means that at 12 months post inoculation 
the blood was definitely infectious. The immune proteins with differential expression as 
highlighted by mass spectrometry may be involved in initial coordination of the immune 
system allowing the build up and spread of prions to take place. For example, C1Q and C3 
opsonize prions via the classical complement activation pathway, which may aid in their 
targeting of the agent to lymphoid follicles. Mice lacking complement components C1Qa, C2 
or C3 were deficient in peripheral prion pathogeneses under specific conditions (Klein et al. 
2001; Mabbott et al. 2001). C1Q also regulates dendritic cell development from monocytes 
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via DC-SIGN (Hosszu et al. 2010) and enhances receptor mediated uptake of PrPSc by 
dendritic cells (Flores-Langarica et al. 2009).  
 
A number of the mass spectrometry determined dataset proteins are primarily expressed in 
the liver (e.g. paraoxonase 1, hemopexin). Perhaps this is a clue to the organs involved in 
preclinical prion infection or an indication that acute phase reactants are also involved in 
preclinical prion disease. Acute phase proteins (APPs) include complement proteins, 
antiproteases and clotting factors with the function to isolate and neutralize pathogens and 
proteases, opsonize and clear debris, as well as to attenuate the local inflammatory 
response in order to minimize damage to healthy tissue and mediate a return to homeostasis 
(Ramadori and Christ 1999). The association between APPs and prion diseases have been 
highlighted by their elevated presence in the sera of CJD patients (Fratini et al. 2012); 
(Volkel et al. 2001). APPs (including transthyretin) were also detectable in serum during the 
asymptomatic phase of scrapie in sheep (Batxelli-Molina et al. 2010). The synthesis of 
cytokines and APPs are proposed to be a systemic response to non-CNS aspects of prion 
disease pathology, such as PrPSc accumulation in the spleen or lymph organs. Increased 
protease activity may be a necessary response to the extracellular protein deposition seen 
during prion disease (Cunningham et al. 2005). Furthermore, analysis of the peripheral 
tissues of an asymptomatic vCJD-infected patient showed PMCA detectable seeding activity 
by the liver (and lungs) when none was seen by brain material of the same patient (Douet et 
al. 2017). Hence, PMCA amplification determined presence of vCJD prions in the liver early 
in the preclinical stage of disease before involvement of the brain and preceding neurological 
symptoms. 
 
One of the most down regulated proteins on the list in Table 3.3 is SERPINA3, a member of 
the serine protease inhibitor family of APPs. Serpins are predominantly produced in the liver, 
however they are also synthesized in the brain and have been shown to be involved in 
neuroinflammation and neurodegeneration (Baker et al. 2007). Contrasting to my dataset, 
upregulation of SERPINA3 mRNA has been found in human prion disease brain samples 
(Vanni et al. 2017). Upregulation of SERPINA3 gene expression of BSE infected macaque 
brains has also been reported (Barbisin et al. 2014). This suggests SERPINA3 may be 
involved in the pathogenesis and progression of prion disease. Perhaps low levels are seen 
at the preclinical stage of disease and high levels during clinical disease.  
 
Many of the differentially regulated proteins have links to protein transport or the movement 
of proteins from one location to another. Fibulin 1 is one of the top upregulated proteins in 
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the list. It binds to fibrinogen and is incorporated into fibronectin-containing matrix fibers. It 
has a role in cell adhesion and migration along protein fibers within the extracellular matrix 
(ECM). Hence it is important for developmental processes and also contributes to the 
supramolecular organization of ECM architecture (Tran et al. 1995). It has been suggested 
that ECM genes control susceptibility to prion infection as prion-susceptible cells have poorly 
developed ECM structure and more PrPC deposition in that matrix (that can be converted to 
PrPSc thus facilitating future infection) (Linden et al. 2008); (Imberdis and Harris 2014). 
Another protein from the dataset which is important for protein and cell transport is vitamin D 
binding protein. A key function of vitamin D binding protein is in sequestering actin (Krishnan 
and Moens 2009). Actin is (usually in association with myosin) is responsible for cell 
movement (Dominguez and Holmes 2011). Decrease in expression in vitamin D binding 
protein, and thus decreased activity of the actin scavenger system would result in higher 
levels of actin and thus intensification of cell motility. The ability of cells to move freely may 
be key for preclinical infection. It has been shown that the actin-cytoskeleton dramatically 
changes during B cell activation and impaired actin cytoskeleton can devastate the normal 
activation of B cells (Keppler et al. 2018); (Li et al. 2018). Immune cells, specifically B cells, 
are important for peripheral prion pathogenesis (Aguzzi et al. 2003). Hence, the actions of 
vitamin D binding protein and its impact on actin may lay the foundation for resulting 
dissemination of prions around the body. Additionally, during cell motility the cell movement 
and shape changes require active restructuring of the actin (Chhabra and Higgs 2007). 
These are high energy demanding circumstances that directly rely on ATP availability 
(Balaban 1990); (van Horssen et al. 2009). Within the plasma dataset there is consistent 
upregulation of proteins such as MT-ND1, ATP6V1A and ATP5H. ATP6V1A is a component 
of vacuolar ATPase, ATP-driven proton pumps that function to acidify intracellular 
compartments and transport protons across the plasma membrane (Forgac 2007).  ATP5H 
is a subunit of the enzyme mitochondrial ATP synthase which catalyses ATP synthesis by 
oxidative phosphorylation. Energy generated by hydrolysis of ATP is used for all cellular 
processes (Jonckheere, Smeitink, and Rodenburg 2012). MT-ND1 is part of NADH 
dehydrogenase, one of the complexes involved in the electron transport chain of oxidative 
phosphorylation (Yusnita, Norsiah, and Rahman 2010). The involvement of these proteins in 
energy pathways and their upregulation in infected plasma suggests enhanced cell energy 
levels, perhaps facilitating increased cell movement during the preclinical disease stage. 
 
There are some similarities in the plasma dataset to findings of other studies that look at 
differential expression (gene or protein) in blood or other tissues during prion disease or 
other neurodegenerative diseases. Sui et al. (2014) found both transthyretin and hemopexin 
(as well as a number of apolipoproteins) to be down regulated in the serum of transgenic AD 
mice compared to wild type mice. Similarly, Castano et al. (2006) found transthyretin to be 
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reduced and hemopexin increased (alongside differential expression of a range of 
apolipoproteins) in CSF from AD patients. Brechlin et al. (2008) identified transthyretin as a 
potential marker of CJD through analysis of patient CSF and serum. Yu et al. (2003) 
analysed plasma from patients with AD and found enriched levels of hemopexin. These 
studies also show changes in blood proteins may reflect what is occurring in the brain or hint 
at activities leading to disturbances with normal brain function. Differences in up or down 
regulation of a particular protein may reflect a signature unique to blood borne proteins of 
preclinical prion infection in the BSE infected sheep of this study (Rubenstein, 2012). To 
expand on the current work and establish reasons for discrepancies with other studies, in the 
future it would be ideal to also have a list of differentially expressed proteins at the clinical 
stage of disease in these sheep. Expression of overlapping proteins would then give an 
indication of disease progression.  
 
When comparing uninfected and infected plasma there were 153 proteins modulated. Given 
that not all of the chosen proteins for biomarker validation could be identified by antibody 
detection it would be difficult to assemble a panel of markers that would be necessary for 
unambiguous identification of preclinical disease. However, the western blot data for the 
three biomarkers that could be further investigated using pooled plasma samples validate 
the mass spectrometry data to a great extent. This provides evidence for the changes being 
true and not just a result of any possible biases introduced by use of ProteoMiner (as 
ProteoMiner was only used on samples prior to mass spectrometry analysis). Although there 
were some variable results from the individual sheep samples, this can be attributed to 
differences in experimental design and execution. When comparing the same two time 
points used for mass spectrometry, clear trends with significant difference can be seen. Thus, 
it can be said with some confidence that these proteins may be exploited for diagnostic 
purposes. A biomarker panel consisting of multiple proteins, used in conjunction with 
detection of PrPSc would greatly enhance sensitivity and specificity of a diagnostic test. The 
next step would be to design specific probes against the biomarkers and optimise bioassay 
conditions. A comparison of protein profiles with other forms of neurodegenerative disorders 
would depict the selectivity of the bioassay. A large scale validation using preclinical blood 
samples (combined with or confirmed by PMCA) would ensure the diagnostic value of the 
bioassay. Furthermore, this would establish that protein expression is not highly variable 
between individuals thus preventing their usefulness as accurate biomarkers (Huzarewich, 
Siemens, and Booth 2010). 
 
This will provide preliminary data on determining a protein biomarker panel associated with 
prion infection in blood of asymptomatic patients. This may be of importance for future 
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diagnostics as there is currently no effective preclinical test available. A non-invasive test (on 
readily accessible body fluids) with the ability to detect the early stages of vCJD is critical in 
identifying people who are infected but appear completely healthy and to follow disease 
progression. The ultimate end-goal of developing preclinical, diagnostics and biomarkers is 
that they are able to facilitate detection of disease before possible contaminated blood 
products can enter circulation. Furthermore, the ability to detect and quantify progression 
over the course of the disease would allow for the evaluation of therapeutic strategies 
(Rubenstein, 2012). An important issue to consider is the ethical dilemma that a successful 
diagnostic test would create in identifying people at risk. While blood can be identified to 
prevent onward transmission through blood transfusion, there is no cure, no available 
treatment and no way of telling if and when the disease will manifest for preclinical patients. 
Additionally, a test with 99.9% specificity would still result in 0.1% of people with a positive 
result not actually being infected, so 1000 people out of 1 million who donated blood would 
incorrectly be told they potentially had vCJD. Such an outcome is unjustifiable when a 
positive test result would have such an enormous and devastating effect on patients, as well 
as their families (Tabrizi, Elliott, and Weissmann 2003); (Growdon 2011). 
 
To expand on the work in this chapter, some of the problems described here in data analysis 
would need to be rectified. The initial large scale experiment looking at individual sheep 
samples across seven time points did not work. Looking at the data, substantial deviations 
can be seen between experiments. As some time point samples were analysed later than 
other it may be that slightly different conditions in experimental procedure from day to day 
have had an effect on the results., yielding variable blot development. It implies a batch bias 
in the outcome and highlights the difficulty in interpreting the results. Only after all 
experiments were performed a mechanical problem with the western blot transfer machine 
was discovered. It may account for this discrepancy. The uninfected pooled plasma sample 
was used as an additional control and positive indicator. Unfortunately, it did not work for 
many of the blots (bands were not quantifiable) thus was not a good comparison. Had time 
allowed and once technical issues were resolved, repeating the analysis of the longitudinal 
sample series would have been critical in providing provided details on changes in the 
protein biomarker expression across the course of disease from preclinical to the 
symptomatic stage (and show variation from sheep to sheep).  
The small cohort of sheep investigated also warrants caution. In order to differentiate 
between normal or healthy, preclinical and pathological a larger number of study participants 
would be necessary. In an ideal scenario (without time or money limitations), this experiment 
would have involved performing mass spectrometry on plasma for each individual sheep at 
both uninfected/prechallenge and infected/12 month time points. Following this proteins that 
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consistently display the highest or lowest expression change, across the nine sheep, would 
be chosen for further validation. It may be a good idea to test more time points during the 
transfusion study (if archived samples are available and easily accessible). It would also be 
of interest to test plasma samples from humans or other more accessible samples, such as 
urine. One possible avenue to improve on our data would be to look at other fractions of 
blood. Protein expression changes in cells associated with efficient disease transmission 
may be of particular importance in the identification of preclinical biomarkers. White blood 
cells have been shown to be the most efficient blood cells in transmitting infection via the 
transfusion route (Andreoletti et al. 2012), therefore this approach was extended to reach the 
























Blood is essential for transfusions and is the basis for various other life-saving products. 
There is currently no screening test to detect donors who may be incubating prion disease or 
in the early clinical stages. A reliable blood test for the early diagnosis is needed to both 
exclude infected blood and prevent onward transmission but also identify asymptomatic 
individuals. In Chapter 3 I investigated proteomic markers of preclinical infection. Testing, 
archived BSE infected sheep plasma, 44 differentially regulated proteins were identified by 
mass spectrometry and three were validated by western blotting. Here, the same procedure 
was repeated but on the buffy coat fraction of blood from the same sheep.  
 
Although not seen in BSE or atypical scrapie cases, prion infection of the lymphoreticular 
system is necessary for neuroinvasion in many prion diseases (Sigurdson et al. 1999); 
(Andreoletti et al. 2000); (Bartz et al. 2005). PrPSc is initially present in lymphoreticular tissue 
prior to accumulation in the central nervous system and the development of clinical signs 
(Andreoletti et al. 2000); (Aguzzi, Nuvolone, and Zhu 2013). Hence, for the development of a 
preclinical test it may be advantageous to look for blood-based markers of infection rather 
than focussing on markers associated with neurodegeneration. Circulating immune cells 
have the ability to carry of PrPSc and thus traffic infectious prion agent around the body. 
Although prion infection still occurs in the absence of follicular dendritic cells (FDCs), it is 
severely delayed suggesting that FDCs are significant cellular sites of peripheral replication  
(Brown et al. 1999); (Mabbott, Mackay, et al. 2000). Targeting cells that may be involved in 
prion replication may increase the chance of picking up disease specific changes (Rhiannon 
et al. 2010). Furthermore, it has previously been established that WBCs are the most 
infectious component of blood. Intracerebral inoculation of rodent models has shown that 40% 
of the blood infectivity titre is associated with the buffy coat (Brown et al. 1998); (Gregori et al. 
2006). The intravenous administration of just 105 WBCs is sufficient to cause scrapie in 
recipient sheep (Douet et al. 2016). Additionally, transmission of experimental BSE and 
natural scrapie has occurred following the transfusion of buffy coat from asymptomatic 
incubating sheep (Houston et al. 2000); (Hunter 2002). In this chapter I will look at the 




4.1.1 Aims of work 
 
The aim of this work is to establish differences in protein expression between uninfected and 
infected buffy coat samples. In doing so, provide preliminary evidence for a blood based 
diagnostic test centred on a panel of biomarkers that could be used to identify individuals 
























Figure 4.1: Initial gel of pooled uninfected buffy coat sample. In order to 
assess if it was necessary to use ProteoMiner on the buffy coat samples a test 
gel was performed. Here a 1/100 and 1/10 dilution of uninfected pooled buffy coat 
were resolved by SDS PAGE and stained with Coomassie InstantBlueTM.  
4.2 Results 
 
4.2.1 Use of ProteoMiner to deplete high abundant proteins in buffy coat  
 
In order to identify potential biomarkers, uninfected and infected buffy coat samples were 
compared for differential protein expression by mass spectrometry. Western blotting of 
specific proteins was then performed to validate the mass spectrometry predicted results. If 
confirmed, any specific changes in protein expression may be exploited as a signature for 
the disease and be beneficial in a diagnostic setting (Xerxa et al. 2016). The buffy coat 
samples used in Chapter 4 were taken from the same nine BSE infected sheep from which 
plasma samples were taken in Chapter 3. These sheep are from the transfusion study 
(Houston et al. 2008), details of which can be found in Chapter 2 Materials and Methods 
(2.1.1).  
 
The buffy coat portion of blood contains the highest concentration of WBCs (as well as 
platelets) and thus represents the cells with the most infectious capability. An initial SDS 
PAGE of uninfected buffy coat sample was resolved to determine whether protein depletion 
was a necessary step. The results depict the presence some large bands that represent 
highly abundant proteins (Figure 4.1). These include albumin (50 kD), transferrin (76kD) and 
haptoglobin (23 kD). Highly abundant proteins may be obscure the detection of less 
abundant proteins. Hence it was decided to proceed with ProteoMiner.  
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To simplify blood buffy coat samples, ProteoMiner technology was utilized (as previously 
described on plasma in Chapter 3). Highly abundant proteins were depleted while 
simultaneously enriching for less abundant proteins using columns containing high affinity 
ligands. Hence, the presence of highly abundant proteins would not obscure the detection of 
less abundant proteins that may be of interest as disease biomarkers. Initially the pooled 
uninfected buffy coat samples were put through the small capacity kit to ensure compatibility 
with the kit and optimise the procedure. The gel in Figure 4.2 shows a reduction in highly 
abundant proteins in the enriched elution lane compared to the original sample lane. Many 
fine bands now appear in the enriched elution sample lane. Hence, less abundant proteins 
are more readily detected. The pooled uninfected buffy coat and the pooled infected buffy 
coat were put through two separate ProteoMiner columns but the samples collected were 
resolved on the same gel. 
 
The small ProteoMiner kit requires a total protein load of >10 mg, the large capacity kit 
processes samples at >50 mg. Having proven the buffy coat samples were compatible with 
the small capacity kit the experiment was scaled up to the large capacity kit. 1 mL of 
undiluted buffy coat sample is added the ProteoMiner large capacity kit column. Two 
separate columns are used for uninfected and infected samples. The large capacity kit 
requires three rounds of 100 µL of elution buffer to be added to the column to elute the final 
sample. This results in three 100 µL elutions (elution 1, 2 and 3). Following 30 µL removal for 
microBCA assay, these elutions are combined to give enriched elution 4. A microBCA was 
performed to calculate volumes of each sample required to load 10 µg of protein on the 
SDS-PAGE gel (along with microBCA determined 10 µg of the original sample for 
comparison). Table 4.1 shows the protein concentrations for the original sample (before use 
of ProteoMiner) and elution 4. There is a 99-97% reduction in protein concentration achieved 
from use of the ProteoMiner kit. This is similar to what was seen with the plasma samples.  
The results for uninfected pooled buffy coat and infected pooled buffy coat can be seen in 
Figure 4.3. In the enriched elutions the presence of less abundant proteins is depicted by the 
appearance of multiple fine bands. Reduction, alkylation and tryptic digestion was performed 
on pooled uninfected and pooled infected buffy coat samples before they were passed on for 
mass spectrometry analysis. 
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Figure 4.2: Small capacity ProteoMiner enrichment kit results. SDS-PAGE gel 
showing samples collected from use of the small capacity kit. Bands of low abundant 
proteins clearly become evident in the lane of the enriched fraction. The original 
uninfected sample in the first lane of the gel was diluted 1/10 (whereas the infected 
original sample was diluted 1/100). 
 
Table 4.1: Protein concentrations of buffy coat samples.  
Total Protein (µg) 
Uninfected Buffy 
coat 
Original  82373 
Enriched Elution 4 3213 
Infected Buffy 
coat 
Original  78039 
Enriched Elution 4 6588 
Total protein concentrations for the original sample (before ProteoMiner) and Enriched 





B.      
 
Figure 4.3: Pooled uninfected and infected buffy coat were run on separate 
ProteoMiner large capacity kit columns. Samples were collected at each stage when 
using the ProteoMiner kit, following a microBCA to determine protein concentration, 10 
µg of each sample was then resolved by SDS-PAGE. Separate gels for uninfected (A) 
and infected (B) pooled buffy coat samples are shown. The three enriched elutions 
(enriched Elution 1, 2 and 3) obtained from the column were combined to create Elution 
4. The gels show the appearance of multiple fine bands representing low abundant 
proteins that may now be detected following removal of some of the high abundant 
proteins.  
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4.2.2 Mass spectrometry of buffy coat  
 
Buffy coat samples from the same BSE infected sheep as the plasma samples in Chapter 3, 
were analysed by liquid chromatography-tandem mass spectrometry (LC-MS) in the same 
manner as described previously. LC-MS is a highly sensitive and powerful tool for large 
scale identification of peptides. Uninfected (taken before BSE exposure) and infected 
samples (12 months later) were labelled with light (L) and heavy (H) isotopic labels 
respectively. Mass spectrometry data was filtered by ensuring the median H/L chain isotopes 
was set to >1.5 and <0.666, the coefficient variation was less than 100% and that 
identification was based on more than one peptide. The original dataset of 1148 proteins 
(Appendix 2) was reduced to 124 (Appendix 3).  
 
Comparing both the buffy coat and plasma datasets for differentially expressed proteins 
shows that there are six overlapping proteins (6/35 for plasma and 6/122 in buffy coat). Four 
of the six were up or down regulated in the same manner in both datasets (Table 4.2). The 
Venn diagram (Figure 4.4) visually depicts that 6 proteins are common between buffy coat 
and plasma, whereas 116 and 29 proteins are unique for buffy coat and plasma respectively. 
They differ substantially, with 87 buffy coat proteins not identified in the plasma samples.  
Out of the six proteins identified in both datasets, two (transthyretin and alpha-1B-
glycoprotein) had already been picked out as candidate biomarkers for further validation. 
Their expression changes are essentially reversed in the two datasets (Table 4.2). 
Expression of transthyretin and alpha-1B-glycoprotein increased in the buffy coat dataset 
and decreased in the plasma dataset. This is consistent with redistribution of these proteins 
from the plasma to buffy coat cells. Unfortunately, the antibodies tested for these proteins 
were unable to produce clear signals by western blot and so further validation was not 
possible. The remaining four proteins (serum amyloid A protein, ATP synthase subunit D, 
 
Figure 4.4: Venn diagram demonstrating the overlap between the buffy coat and 
plasma filtered datasets. 
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Fold change in 
Buffy coat data 
Fold change in 
Plasma data 
SAA1  Serum amyloid A protein 0.56 0.25 
TTR Transthyretin (Prealbumin)* 2.87 0.25 
A1BG Alpha-1B-glycoprotein* 2.26 0.34 
ATP5H ATP synthase subunit D, 
mitochondrial 
0.66 0.38 
CDH5 Cadherin-5 0.43 0.41 
ITIH1 Inter-alpha-trypsin inhibitor 
heavy chain H1 
1.74 1.25 
 *Candidate proteins chosen for validation 
Mass spectrometry indicated that these six proteins as being differentially expressed in 
both the buffy coat and plasma samples when comparing uninfected to infected. Both 
transthyretin and alpha-1B-glycoprotein were previously considered for further validation 
on the plasma samples, however results could not be quantified. 
cadherin-5, inter-alpha-trypsin inhibitor heavy chain H1) have very similar fold change values 
thus there is an agreement in expression between the two datasets.  
 
The list of 124 differentially regulated proteins and their functions (Appendix 3) suggest that 
metabolic processes take place during the preclinical prion disease. Many of the proteins are 
involved in metabolism or energy conversion pathways, such as T complex protein 1 subunit 
epsilon, proteasome subunit beta 10, mitochondrial ATP synthase subunit 5H, Isocitrate 
dehydrogenase [NADP]. Furthermore, a number of proteins are associated with cell structure 
Table 4.3: Serpin peptidase inhibitor proteins identified in buffy coat or plasma 
datasets. 
Buffy coat dataset Plasma dataset 
Gene Protein Normalised 
fold change 





























1.58 IPSP Serpin 
family A 
0.25 
















and motility including integrin beta chain-2, actin alpha 1 and myosin light chain 6. A number 
of serpin family proteins appear in the buffy coat and plasma datasets (Table 4.3). Serpins 
are the broadest and largest family of proteins with protease inhibitor activity, with over 1,500 
members identified to date (Law et al. 2006). The Human Protein Atlas lists 43 different 
serpins in blood (https://www.proteinatlas.org/search/serpin). They make up 2.4 % of 
differentially expressed buffy coat proteins and 14.3 % of differentially expressed plasma 
proteins. Considering that more than 10.5 thousand blood-plasma proteins that have been 
detected (Ponomarenko et al, 2016), it is 0.4% likely (very unlikely) that this identification of 
serpin is due to chance. As mentioned in the previous chapter, differential overexpression of 
SERPINA3 has been identified in human prion disease (Vanni et al, 2017) and strongly 
upregulated in brains of scrapie infected mice (Barbisin et al. 2014). However SERPINA3 is 
down regulated in the plasma dataset. This may be due to the infected plasma in my study 
being from a preclinical time point, before PrPSc accumulation in the brain that may have 
contributed to the affects on SERPINA3 expression seen in these studies. However, the 
changes in protein expression seen in this study between uninfected and infected time points 
may induce greater disease susceptibility. 
 
4.2.3 Bioinformatic analysis and selection of potential biomarkers 
 
Two free online bioinformatic tools previously utilised for investigating the plasma dataset in  
Chapter 3 were also applied to the buffy coat dataset. Reactome is an open-source, peer-
reviewed pathways database which provides basic visualisation and interpretation of 
pathway knowledge. The relevant pathways identified by analysis of the buffy coat protein 
expression data by Reactome are listed in Table 4.4. Five out of nine are related to 
metabolism, two to DNA repair and one to cell cycle. The P value gives the probability that 
the overlap between the query dataset and the pathway occurred by chance. DAVID 
Bioinformatics Resources provides functional analysis tools to understand the biological 
meaning behind lists of genes or proteins. Pathways interpreted by DAVID as important for 
the buffy coat data are listed in Table 4.5. Out of the fifteen that are highlighted, nine are to 
do with metabolism. Others include Parkinson’s disease and leukocyte transendothelial 
migration. The P value is a measure of a given protein in a dataset belonging to a particular 
pathway due to chance. The smaller this score the more the dataset is specifically 
associated (enriched) with the pathway. A P value that is equal to or smaller than 0.05 is 
considered strongly enriched (DAVID 2007). As all the pathways score small P values it 
indicates that the result is non-random and potentially interesting or worth following up in 
closer detail. The information provided by Reactome and DAVID gives an indication for the 
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involvement of energy related pathways during preclinical infection. Proteins significant to 
other neurodegenerative diseases may also be affected during preclinical prion disease. To 
investigate the data further and determine potential biomarkers, additional analysis was 
required. 
 
With a greater number of proteins available in the buffy coat dataset than the plasma dataset, 
network analysis could be employed. IPA is a functional analysis tool which is used to help 
Table 4.5: The top functional pathways suggested by DAVID Bioinformatics 
Resources (https://david.ncifcrf.gov). ‘Count’ refers to the number of genes present in 
the dataset that are relevant to the suggested pathway, it must be greater than 1 and 
the default is 2. The ‘P value’ refers to the modified Fisher extract P-value, Enrichment 
score. 
DAVID Pathways 
Pathway  P value 
Carbon metabolism  7.1E-8 
Biosynthesis of antibiotics  2.0E-7 
Biosynthesis of amino acids  1.1E-5 
Metabolism pathways  7.5E-4 
Porphyrin and chlorophyll metabolism  2.2E-3 
Spliceosome  2.4E-3 
Glycolysis/Gluconeogenesis  1.1E-2 
Pentose phosphate pathway  1.6E-2 
Citrate cycle (TCA cycle)  2.0E-2 
Tryptophan metabolism  4.4E-2 
Ameobiasis  4.8E-2 
Arginine and proline metabolism  5.1E-2 
Leukocyte transendothelial migration  5.2E-2 
Glutathione metabolism  5.9E-2 
Parkinson’s disease  9.9E-2 
 
 
Table 4.4: Reactome predicted functional pathways for differentially expressed 
buffy coat proteins (https://reactome.org/). ‘Entities P value’ is a calculation of the 
proteins appearing in a particular pathway by chance. 
Reactome pathways 
Description Origin Entities P value 
Association of TriC/CCT with target 









DNA Damage Recognition in GG-NER DNA repair 5.43E-4 
Citric acid cycle (TCA cycle) Metabolism  1.48E-4 
Formation of TC-NER pre-incision 
complex 
DNA repair 2.54E-4 
mRNA splicing  Metabolism of RNA 2.82E-10 
Deposition of new CENPA-containing 
nucleosomes are the centromere 
Cell cycle 4.11E-5 
Heme degradation Metabolism 3.04E-5 




search for and discover targeted information on genes, proteins, chemicals and drugs using 
extensive biological knowledge. Complex searches are made for prediction of biomarkers 
and enable disease specific hypothesises to be generated. Canonical pathways are deemed 
significant to the input data set by testing two parameters. First, a ratio of the number of 
proteins from the data set that map to the pathway divided by the total number of proteins 
that map to the canonical pathway. Secondly, a P value is calculated using Fisher’s exact 
test to determine the probability that the association between the proteins in the data set and 
the canonical pathway is due to chance alone. The smaller the P value the less likely that the 
association is random (Qiagen 2012). Protein expression direction is not taken into account 
for this calculation. A Z score is a statistical measure of the match between expected 
relationship direction and observed protein expression. It gives a prediction for the activation 
state of a particular pathway (as well as the magnitude of increase or decrease). A Z score 
>2 or <-2 is considered significant. Out of the 191 canonical pathways suggested by IPA, the 
top 3 based on P value and ratio of proteins are LXR/RXR Activation –log(p value) = 5. 28, 
Acute Phase Response Signalling –log(p value) = 4.33 and Mitochondrial Dysfunction –log(p 
value) = 4.31. Out of these, only a Z score for LXR/RXR Activation was achieved (Z score = -
0.378). The lack of Z score for the other pathways may due to conflicting directions in which 
proteins are regulated. It may also be down to IPA not having enough information on the 
molecules involved in each pathway compared to those of the dataset to make a valid 
judgment. In comparison the Z score for Leukocyte Extravasation Signalling is 0.447, 
indicating upregulation.  
 
From this it can seen that there is a suggestion here of the involvement of the immune 
system in the early stages of prion infection. LXR/RXR activity has been shown to regulate 
the immune response, for example in macrophages LXRs inhibit proinflammatory gene 
expression (Schulman 2017). The acute phase response is part of the innate immune 
system creating a systemic reaction (Gruys et al. 2005b). Mitochondrial dysfunction has also 
been linked to activation of innate immunity (Carney 2018). Leukocyte extravasion refers to 
the migration of leukocytes across the endothelium (Middleton et al. 2002). It is known that 
the immune system plays an important role in peripheral replication of infectious prion 
protein before its efficient spread toward the CNS and to the brain (Aguzzi et al. 2003); 
(Beekes and McBride 2007). Providing further evidence for this, the buffy coat dataset is 
indicating activity in immune cells during the preclinical time point.  
 
The fifty-one canonical pathways presented by IPA as relevant for the buffy coat data set 
were narrowed down to key five canonical pathways. This was done by conducting an in 
depth literature search. Only pathways that have previously been identified as potentially 
 128 
significant in prion or neurodegenerative diseases were selected. Table 4.6 displays these 
five canonical pathways and their proteins that map to the buffy coat data set. The ratio 
refers to the number of proteins in the dataset that map to the pathway.  As the ratio for all 
pathways is <0.05, this signifies that the presence of these proteins in their associated 
pathways are not due to chance. Out of these proteins candidate biomarkers were chosen 
for Western blot based validation. To identify the relevant proteins from each pathway a 
search of published literature was performed to evaluate previous association with prion or 
neurodegenerative diseases.  
 
An ideal non-invasive, easily applicable blood test for prion diseases would have practical 
applications in a clinical setting. A good biomarker panel is one that can discriminate 
between states and provide accurate information on subsequent clinical outcome. It would 
be able to differentiate between healthy patients and those with prion disease at both a 
preclinical and clinical stage. This can be addressed by assessing deregulation of several 
biological systems rather than focussing on just one. In doing so, better detection is 
facilitated as it takes into account the heterogeneous blood protein composition and 
individual variability between patients. The inclusion of several biological pathways or 
processes that may be involved in disease pathogenesis is a common feature of many blood 
based biomarker panel studies. Ray et al. 2007 proposed a panel of 18 plasma proteins 
involved in numerous pathways altered early in AD pathogenesis including inflammation, cell 
growth, angiogenesis, stress response, lipid metabolism, oxidative stress and antioxidant 
response. It was able to distinguish AD patients from healthy controls with 89% accuracy, 
Table 4.6: Shortlist of IPA canonical pathways. For each pathway chosen for 
the biomarker panel, the table lists proteins present in the dataset obtained from 




































confirm the prospective power of multiple blood biomarkers incorporated into a panel for 
accurate diagnosis. However, including a smaller number of predictors will both reduce the 
efforts and costs for measurement as well as reduce the statistical problems associated with 
evaluation of the results.  
 
Specific proteins from each pathway were chosen as potential biomarkers for their IPA 
confirmed relevance (as part of important biological pathways), previous association to prion 
or neurodegenerative diseases (from published literature), but also due to the availability of 
antibodies (antibodies are only available for a limited number of proteins). Reviewing the 
current literature ensures no prospective candidates are ignored. It also ensures that the 
chosen biomarkers can be measured in medical departments across diverse patient 
populations and are not reliant on the development of new technology or statistical methods.   
 
Additionally a panel of biomarkers rather than a single protein are more likely to be 
implemented in diagnostic screening. This would be so as to balance time and cost concerns 
with high specificity and accuracy. Table 4.7 lists the potential biomarkers for validation of 
the mass spectrometry analysis; the proteins presented offer a wide coverage of potentially 
relevant biological pathways. This is a fundamental step in beginning to understand what 
differs between healthy and diseased individuals.  
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Protein Pathway Examples of relevant studies showing relation to neurodegenerative 
diseases 
0.33 SMS 
spermine synthase Spermine Biosynthesis Antony et al. (2003); Bera and Nandi (2007); Speldewinde and Grant 
(2015); Phadwal et al. (2018). 
0.64 hnRNP K 
heterogeneous 
nuclear 
ribonucleoprotein K  
Acute Phase Response 
Signalling 






chain H2  
Acute Phase Response 
Signalling 
Okroj et al. (2012); Ashton et al. (2015); Dieks et al. (2013); Meier et al. 
(2015); ; Watanabe et al. (2019). 
1.58 PARK7 
Parkinson disease 
protein 7  
Mitochondrial 
Dysfunction 
Kiachopoulos et al. (2004); Winklhofer and Tatzelt (2006); Nguyen et al. 
(2014); Prusiner et al. (2015). 
1.59 MSN 
moesin Leukocyte Extravasation 
Signalling 
Riemer et al. (2004); Xiang et al. (2004); Chadwick et al. (2010); 
Jayasena et al. (2015).  
2.84 s100A8 S100 
s100A8 S100 
calcium binding 
Acute Phase Response 
Signalling 
Beekes et al. (1999); Xiang et al. (2004); Cristóvão and Gomes (2019); 
Spratt et al. (2019).  
2.87 TTR 
transthyretin LXR/RXR Activation Yu et al. (2003); Riemer et al. (2004); Rubenstein (2012); Lim et al. 
(2016); Dasari et al. (2019). 
 
The table depicts the change in protein expression from pooled uninfected to infected buffy coat samples. The fold change refers to the H/L ratio, 
proteins with a value <1 are down regulated in the infected sample. There is no change in expression for proteins with a value of 1, and 
upregulated proteins have a value 1>. Out of the chosen potential buffy coat biomarkers two show decreased expression in infected samples, while 




4.2.4 Biomarker validation 
 
Antibodies for each of the selected candidate biomarker proteins were tested on uninfected 
buffy coat samples, however the only one that appeared to bind specifically to its target was 
the anti-moesin antibody. This is likely down to most commercial antibodies recognising 
human proteins, while the samples used here are from sheep. Although only antibodies for 
proteins with high sequence similarity (as verified by human and ovine alignment using 
UniProt) or predicted to work with ovine samples were ordered, all but one did not work. 
Moesin has a 99% protein identity when comparing the amino acid similarity between human 
and sheep proteins; this indicates that the target human and sheep sequences are highly 
similar. The molecular weight of moesin is predicted to be 70-78 kD, and the antibody used 
detects a protein of this weight. Initial experiments were performed using pooled uninfected 
buffy coat. For efficient quantification, where changes in expression may be monitored easily, 
a thin western blot band is ideal. It was found that 8 µg of protein gave rise to consistent 
results. 
 
Table 4.8 lists the antibodies tested for the chosen buffy coat biomarkers. It is important to 
be consistent when conducting antibody trials, thus rigorous western blotting procedures 
were instated. Following protein transfer, nitrocellulose membranes were blocked in 
commercial blocking buffer (containing bovine serum albumin). Membranes were then fully 
immersed in primary antibody (by placing them on rollers in individual falcon tubes) and 
incubated overnight. All membranes were thoroughly washed in PBS-T before use of 
secondary antibody. All primary antibodies were rabbit polyclonal, thus the same secondary 
antibody (Donkey anti-Rabbit IgG ThermoFisher Scientific 31238) and western blotting 
chemiluminescence detection kit (Roche BM) could be utilised. All primary antibodies were 
initially applied at the manufacturer’s recommended dilution, with a range of sample protein 
concentration (uninfected pooled buffy coat). To enhance detection of western blot bands, a 
range of antibody dilutions were then tried. The recommended dilution for the secondary 
antibody is 1:10 000 - 1:200 000. The different concentrations of secondary antibody, 




Table 4.8: List of antibodies for buffy coat potential biomarkers. In order to validate the findings from mass spectrometry where the protein 
expression of uninfected and infected buffy coat samples were compared, 7 candidate proteins were chosen for further testing. Most antibodies 
are produced to react with human samples. To ensure that these antibodies have a high chance of working on the sheep blood samples, a 
comparison was made between the human and ovine target peptide sequence on UniProt (https://www.uniprot.org/). The result is an amino acid 
sequence similarity (protein identity %), which is the overlap in similarity for protein. If there is a high level of identity between human and sheep 
proteins, then the antibody is more likely to cross-react with both human and sheep samples. However, after testing all of these antibodies, only 
moesin presented a quantifiable band pattern.   
Protein Western blot compatible 
Antibody Name 
Company Reference Human and sheep amino acid 















PA5-27522 74% Human, mouse 
Inter-alpha-
trypsin inhibitor 
heavy chain H2 
ITIH2 Polyclonal Antibody Invitrogen PA5-13670 78% Human 
Parkinson 
disease protein 7 








Moesin Moesin Antibody Novusbio NBP1-90372 99% Human, mouse, rat 
S100A8 S100 
calcium binding 
Rabbit IgG polyclonal 





AMS.ABO12428 64% Human, mouse, rat 
Transthyretin Transthyretin Rabbit 
Polyclonal Antibody 





Table 4.9: Testing conditions for potential buffy coat biomarkers. In order to optimise the use of each antibody a series of experiments 
were performed. A working antibody with a positive result would yield a reliable (consistently quantifiable) western blot band signal. Listed 















Protein Load tested 
(µg) 














1:200 000  
























































2, 4, 6, 8, 10, 12 Good band signal 
achieved with 
8 µg of buffy coat 
sample, 1:2500 primary 
































Buffy coat samples from nine sheep at an uninfected time point (prechallenge) were pooled, 
and buffy coat samples from the same nine sheep at an infected time point (12 months) were 
pooled. Portions of these were used for uninfected and infected samples used in mass 
spectrometry analysis, the remainder stored at -80 oC. Once the moesin antibody had been 
optimised (tested for consistent and quantifiable results) validation of the mass spectrometry 
predictions began. Pooled uninfected and infected buffy coat samples were removed from -
80 oC storage, diluted in RIPA buffer (to prevent protein precipitation) and samples taken for 
microBCA assay. After calculating protein concentration, stock dilutions and aliquots in 
sample buffer were prepared. For the pooled buffy coat experiments four replicate pairs of 
uninfected and infected pooled samples were then resolved side by side on the same gel 
(thus moesin expression for each experiment is an average between 4 repeat comparisons). 
Two gels were generated at the same time in one tank. One gel was stained Coomassie 
InstantBlueTM for analysing whole protein content of the lanes. The second gel was taken 
through the western blot procedure and moesin bands for individual sheep captured by LI-
COR scanning. Six experiments were performed and to plot the graph in Figure 4.5 a ratio of 
the normalized signal for infected samples to uninfected samples was calculated. The value 
for uninfected samples is set to 1 to reflect what the value for infected samples are in relation 
(values >1 for moesin indicate increased expression). Figure 4.6 show example gels for 
measuring moesin expression in pooled buffy coat samples from one of the experiment. 
Across the 6 repeat experiments the standard deviation calculated on comparison values is 
low (table in Figure 4.5). This indicates that the data is not widely spread but all values are 



















Std Dev 0.070 
SEM 0.029 
 
Figure 4.5 Results for moesin expression in pooled uninfected and infected buffy 
coat samples. Uninfected and infected buffy coat samples were resolved side-by-side 4 
times on the same gel. The mass spectrometry data predicted an increase in moesin in 
the infected buffy coat sample. Across 6 repeat experiments (where 4 replicate 
comparisons of uninfected and infected buffy coat moesin expression was averaged per 
gel), the expression of moesin was shown to increase. The graph shows a ratio of the 
normalized signal for infected samples to uninfected samples (values >1 for moesin 
indicate increased expression). The table illustrates that the results between 
experiments are similar. Across the six repeat experiments the standard deviation 
(0.070) is very low. The SEM, an indicator for the precision of the estimated mean, is 
also low. It is thus likely that these findings accurately reflect differences in moesin 











































Comparison (Normalised Western) between 
normalised western blot signals for pooled infected 




































Figure 4.6: Example western blots of pooled buffy coat samples with 8 µg loaded 
per lane. Four repeat pairs of uninfected and infected pooled samples are resolved side 
by side on the same gel. The first gel (A) was stained Coomassie InstantBlueTM for 
determining the whole protein content of the lanes. The second gel (B) was taken 
through the whole western blot procedure and antibody probed to obtain a specific 
western blot band signal. The molecular weight for moesin is 70-78 kD as depicted here. 




Upregulation of moesin in the infected pooled buffy coat was reported from the mass 
spectrometry analysis. This is successfully validated in western blotting of the pooled buffy 
coat samples. Validation using individual sheep samples was the next step. Buffy coat 
samples from the same nine sheep as those used in the pooled buffy coat experiments (at 
the same two time points) were taken from -80 oC storage and diluted in RIPA buffer. 
Following microBCA assay to calculate the protein concentration of each sample, stock 
solutions were prepared and samples made ready for gel electrophoresis. Samples from 
three control sheep (age-matched but not exposed to BSE) were resolved on all gels. Gels 
were processed with samples from the same sheep at two time points (prechallenge and 12 
months) resolved side by side for better comparison. As before, two gels are resolved at the 
same time. One is stained over night in Coomassie Instant BlueTM  to quantify the whole 
protein content per lane and the other gel is antibody probed to obtain a western blot band 
signal. To plot the graph in Figure 4.7 A a normalised western blot signal is calculated. A 
ratio value is obtained by dividing the whole protein signal (from the Coomassie Instant 
BlueTM stained gel) by the highest whole protein signal across the gel (as the same protein 
concentration for each of the nine sheep samples should have been loaded, thus taking into 
account loading discrepancies). The western blot signal (detected from LI-COR scanning the 
antibody probed, chemiluminescence stained nitrocellulose membrane) is then divided by 
the ratio and this ‘normalised’ value plotted. The results are an average of two repeat 
experiments (of all nine sheep at the two time points), the data values were under 4% 
difference from each other. Highlighted on Figure 4.7 A are comparisons with significant 
values. The paired T test result for control sheep at prechallenge and at 12 months gives a P 
value of 0.2687. This shows that there is not a significant difference in protein expression for 
control sheep. The paired T test for infected sheep at prechallenge and 12 months gives a P 
value of 0.0001. This is very significant. It highlights that there is definitely a difference in 
protein expression at the two time points for infected sheep. The unpaired T test P value of 
control and infected sheep at the prechallenge time point is 0.1165 (this is not significant and 
no difference in expression between the groups are expected at this stage). The unpaired T 
test P value for controls and test sheep at 12 months is 0.0021 (a significant result reflecting 
change in moesin expression before and after sheep are exposed to BSE). To plot Figure 
4.7 B the normalised western blot band signal at the prechallenge time point is subtracted 
from the normalised western blot band signal at 12 months. This gives a comparison or 
difference in moesin expression for control and infected sheep at the two time points. It is a 
significant difference and the T test P value is 0.0255.Example gels for the individual sheep 











Figure 4.7: Moesin expression in individual sheep at Prechallenge compared to 12 
months. This plotted data is an average of two repeat experiments (results varied by 
4%). Graph (A) depicts an increase in moesin expression in infected sheep at the 12 
months time point compared to at Prechallenge. A paired T test with a significant result 
(P=<0.0001) is seen between Prechallenge and 12 months for infected samples. 
Another comparison with a statistically significant T test result is that of moesin 
expression in control sheep at 12 months and infected sheep at 12 months (0.0021). 
Graph (B) is the difference between 12 months and Prechallenge (normalised western 
blot band signal subtracting the prechallenge values from the 12 month value) plotted for 
control sheep and infected sheep. A significant value was calculated in the T test 










































Figure 4.8: Example western blots of moesin expression for individual sheep buffy 
coat samples with 8 µg of protein loaded per lane. Two gels resolved at the same 
time, with UN or uninfected (Prechallenge) and IN or infected (12 month) placed side by 
side for easy comparison. The first (A) is Coomassie Blue stained to obtain the whole 
protein signal. Protein on the second gel is transferred to a membrane, which is then 








Through identification of novel biomarkers proteomic analysis has clear potential in aiding 
the development of a highly sought after preclinical prion disease diagnostic test to 
complement detection of PrPSc. While the list of potential biomarkers is growing, validation 
studies are not being carried out at the same pace. This is due to some of the inherent 
problems of prion disease such as the small number of clinical cases, long incubation period 
and limited availability of preclinical human samples (Huzarewich et al. 2010). Additionally 
there are technical issues of readiness of compatible assays or working antibodies. Many 
proteomic studies of prion diseases focus on the analysis of brain or CNS tissues, here I 
present presymptomatic changes in protein expression from the buffy coat blood fraction of 
sheep exposed to BSE. By utilising IPA analysis and reported associations in published 
literature, the list of 124 mass spectrometry identified differentially regulated buffy coat 
proteins were shortlisted to seven biomarkers. These were spermine synthase, 
heterogeneous nuclear ribonucleoprotein K, inter-alpha-trypsin inhibitor heavy chain H2, 
Parkinson disease protein 7, moesin, s100A8 S100 calcium binding and transthyretin. After 
attempting validation by western blotting, only moesin was successfully validated using the 
original pooled sheep buffy coat samples. These findings were then found to be reflected in 
the individual sheep buffy coat samples from the same time points. 
 
4.3.1 Biological interpretation  
 
A number of problems were encountered during attempted validation of the seven 
biomarkers chosen from the buffy coat dataset, this is predominantly down to the antibodies 
not being compatible with sheep samples. However, there are examples of previously 
published proteomic/genomic studies on blood that present findings similar to my work. To 
detect gene expression changes with microarray analysis, Panelli et al. (2011) fractionated 
WBCs from the blood of cattle one year after oral BSE challenge. The majority of 
differentially regulated proteins were related to immune function, with significantly modified 
expression of genes linked to T and B cell development and activation, as well as 
inflammatory responses. Xerxa et al. (2016) performed whole blood gene expression 
profiling from preclinical and clinical cattle infected with atypical BSE. Gene enrichment 
analysis (performed using DAVID bioinformatics tool) revealed that the preclinical stage was 




matrix, immune response, B cell proliferation and RNA metabolic process. These studies 
corroborate our findings and give a degree of confidence in what we are seeing. 
 
At the 10 month time point post after exposure to BSE, where the mass spectrometry 
analysed infected samples were taken from, PrPSc accumulation is not detectable in the brain 
or lymphoid tissues of the sheep (Jeffrey, Martin, et al. 2001). However, prion misfolding and 
PrPSc replication is undoubtedly taking place as the blood is infectious at this stage (as 
shown by transmission of disease to blood recipient sheep). By reviewing the association to 
neurodegenerative diseases of the IPA suggested pathways, as well as the functions of the 
differentially regulated buffy coat proteins, a picture of what may be occurring at the 
preclinical stage of infection can be formed. Proteins of the immune system are highly 
featured. This may indicate that preclinical prion infection is associated with low level 
activation of the body’s early defence mechanism or innate immunity. The responses taking 
place are unlikely to be that of adaptive immunity this is because PrPSc is tolerated by the 
host immune system due to the widespread expression of PrPC throughout the body. Thus 
specific cell-mediated activity and antibody production, which normally respond to and 
remove foreign viruses or bacteria, is prevented (Furr, Young, and Richt 2012).  
 
Immune cells are critical for prion disease propagation. PrPSc accumulate first upon follicular 
dendritic cells (FDCs) as they make their way from the site of infection to the CNS (Mabbott, 
Mackay, et al. 2000); (Montrasio et al. 2000); (McCulloch et al. 2011). Their importance has 
been established by the lack of PrPSc accumulation in the spleen and subsequent 
neuroinvasion in immunodeficient mice lacking FDC (Klein et al. 2001). B cells regulate FDC 
maturation but also are likely to be responsible for movement of PrPSc (Mackay and 
Browning 1998); (Cinamon et al. 2008); (Mok et al. 2012). Conventional dendritic cells are 
able to capture and retain intact pathogens and migrate into B cell follicles, hence PrPSc may 
exploit them for propagation (Huang et al. 2002); (Raymond, Aucouturier, and Mabbott 2007); 
(Sethi et al. 2007). Within a matter of weeks of their initial multiplication within the draining 
lymphoid tissue, PrPSc are subsequently propagated to most other secondary lymphoid 
tissues (SLO), including the spleen. This implies dissemination via the blood and lymph 
(Mohan, Bruce, and Mabbott 2005); (Glaysher and Mabbott 2007).  
 
One of the key pathways highlighted by IPA analysis of the buffy coat dataset was the 
leukocyte extravasation signalling pathway. Also called diapedesis, it is the process whereby 
leukocytes move out of the circulatory system, cross blood vessels and head towards the 




borders (paracellular transmigration) and in some cases, through the endothelial cells 
themselves (transcellular migration) (Muller 2013). Moesin is one of the proteins of this 
pathway. It orchestrates complex procedures involved in cell shape changes. The ERM 
protein family (erzin and radixin, moesin) regulates cortical morphogenesis and cell adhesion 
through connection of membrane adhesion receptors to the actin-based cytoskeleton. Both 
moesin and ezrin interact with the vascular cell adhesion molecule (VCAM)-1 during 
leukocyte adhesion and transendothelial migration. Moesin thus plays an essential role in the 
firm adhesion of leukocytes to the endothelium (Barreiro et al. 2002). Up regulation of 
moesin was observed in the pooled, infected buffy coat samples. Previous studies have also 
shown upregulation of moesin in prion disease states (Xiang et al. 2004; Chadwick et al. 
2010; Jayasena et al. 2015). The increase in moesin may be facilitating movement of 
leukocytes through an enhanced ability to connect cells. This would enable their migration to 
lymphoid organs in the early stage of disease and mediate effective dissemination of PrPSc.  
 
Due to the crucial role the immune system plays in peripheral pathogenesis of prion disease, 
it could be argued that it promotes rather than protects against the disease. This is 
supported by the finding that repetitive immunization enhances susceptibility of mice to 
intraperitoneal administration of scrapie (Bremer et al. 2009). Acute phase signalling is an 
essential part of innate immunity which include vascular permeability and leucocytosis (Lu et 
al. 2011). The presence of acute phase proteins in the buffy coat dataset and the 
identification of the acute phase response signalling pathway by IPA suggests an occurrence 
of inflammation or inflammation-like incidents at the preclinical time point. Host inflammation 
has been shown to significantly influence prion disease pathogenesis, through enhancing 
PrPSc uptake or expanding their tissue distribution (Heikenwalder et al. 2008); (Sigurdson et 
al. 2009). During inflammation, dilation and increased permeability of blood vessels leads to 
increased local blood flow and the leakage of fluid results in heat, redness and swelling. 
Cytokines and complement fragments have significant affects on the adhesive properties of 
the endothelial cells of the blood vessel wall, causing circulating leukocytes to stick to the 
endothelium and migrate between them to the site of infection to which they are attracted to 
by chemokines (Janeway CA Jr 2001). Stimulation of leukocytes and their change in shape 
and adhesiveness is a prerequisite to the entry of effector cells such as neutrophils, 
monocytes and effector T cells to sites of infection, injury and stress (Nourshargh and Alon 
2014). Thus, these activities promote cell movement, which is important for the spread of 
PrPSc. 
 
In omic based searches for non-PrPSc markers of prion diseases there are many genes and 




occurrence of an acute phase response has been detected in sheep with clinical scrapie 
(Meling, Bårdsen, and Ulvund 2012). Serum transthyretin has been found to discriminate 
healthy from scrapie infected sheep both at preclinical and clinical stages of disease 
(Batxelli-Molina et al. 2010). Serum amyloid P is increased with the onset and progression of 
clinical signs in an experimental scrapie murine model (Coe, Race, and Ross 2001). Protein 
C-reactive protein (CRP) was increased in the plasma samples of CJD patients compared to 
healthy controls (Volkel et al. 2001).  
 
The three proteins from the buffy coat dataset chosen for further validation were S100A8 
calcium binding protein, heterogeneous nuclear ribonucleoprotein K and inter-alpha-trypsin 
inhibitor heavy chain H2, all were identified by IPA as belonging to the acute phase response 
signalling pathway. S100A8 plays a prominent role in the regulation of inflammatory 
processes (Ryckman et al. 2003),this is achieved by stimulating leukocyte recruitment and 
inducing cytokine secretion (Wang et al. 2018). Heterogeneous nuclear ribonucleoprotein K 
is one of the major RNA-binding proteins and is involved in many processes that compose 
nucleic acid metabolism and gene expression, including mRNA processing and translation 
(Geuens, Bouhy, and Timmerman 2016). Not much is known about inter-alpha-trypsin H2 
but it is down regulated during an inflammatory response (Daveau et al. 1993). Although 
there is a mix of up/down regulation of these proteins in the buffy coat dataset, their 
involvement further suggests immune effects, such as movement of WBCs, occurring at the 
preclinical stage of prion infection. Perhaps activities occurring at the preclinical phase are 
characterised by a systemic acute phase response.  
 
The stimulation of immune cells and their movement or circulation around the body requires 
a vast amount of energy, hence a number of proteins involved in energy pathways and 
metabolic processes are upregulated in the dataset. Bioinformatic analysis of the mass 
spectrometry data suggests an involvement of cellular energy pathways, such as 
glycolysis/gluconeogenesis. While, FDCs are major cell populations in lymphoid nodules 
(Manuelidis et al. 2000), macrophages are also present throughout the lymphoid nodule and 
ingest apoptotic B cells. Cells of myeloid lineages depend almost exclusively on glycolysis to 
derive their energy. In comparison lymphocytes utilize predominantly oxidative 
phosphorylation (Fox, Hammerman, and Thompson 2005). T and B cells exploit amino acids, 
glucose and lipids as energy sources during oxidative phosphorylation. Stimulated 
proliferation can result in nearly twenty-fold increase in glucose (Kominsky, Campbell, and 
Colgan 2010). Perhaps metabolic reprograming (and regulation of cellular energy pathways) 




uptake, transport and elimination of PrPSc, culminating in accumulation of PrPSc within the 
lymph nodules and ultimately aiding neuroinvasion later during disease.  
 
Another key pathway identified by IPA analysis of the buffy coat data is the LXR/RXR 
activation pathway. It has also been described as a top canonical pathway from gene 
expression profiling of BSE infected macaques (Barbison et al. 2014) as well as of potential 
importance in AD (Bogdanovic et al. 2001); (Patel and Forman 2004). The liver X receptors 
(LXRs) and the retinoid X receptors (RXRs) are central to lipid metabolism. LXRs regulate 
the expression of several genes involved in reverse cholesterol transport in peripheral cells 
such as macrophages (Castrillo and Tontonoz 2004). This is done not only by inducing 
cholesterol transporter proteins (ABCA1 and ABCG1) but also through increased production 
of cholesterol acceptors (apoE and apoCs) and lipoprotein remodelling proteins (PLTP and 
LPL) (Beaven and Tontonoz 2006). The RXRs also act as negative regulators of the immune 
responses (inflammatory response and macrophage activation). RXR is able to control 
macrophage gene transcription through its hetrodimerisation with other nuclear receptors 
(Roszer et al. 2013). In addition to the role as cholesterol sensors, LXRs have also been 
shown to be implicated in modulating the innate and adaptive immune response suggesting 
a crosstalk between inflammatory and metabolic pathways. It has been shown that LXRs 
dependent gene expression is important for macrophage survival, there is an LXR-
dependent repression of inflammatory gene expression in activated macrophages. LXRs 
inhibit inflammatory genes after LPS, TNF-α or IL-1β stimulation (Joseph et al. 2003). IPA 
analysis has suggested a downregulation in LXR/RXR activation during preclinical prion 
disease. It is possible that there is a suppression of negative regulation of the immune 
system during preclinical infection, thus leading to heightened macrophage activity. The 
increased macrophage activity may relate to enhanced accumulation of the infectious prion 
agent, transport and delivery to neuronal cells (Carp and Callahan 1981); (Jeffrey et al. 
2000); (Mabbott and MacPherson 2006).  
 
Bioinformatic analysis of the buffy coat data also revealed spermine biosynthesis as an 
important biological pathway. The candidate biomarker chosen for further investigation was 
spermine synthase which converts spermidine into spermine. Both are present in millimolar 
concentrations in almost all cells as they are inherently involved in cellular metabolism 
(Coffino 2000). Spermine has been shown to be able to inhibit nucleic acid induced 
polymerisation of prion protein, acting as a protective agent. Through induction of autophagy 
and other stress response pathways, spontaneous prion formation is prevented (Bera and 
Nandi 2007). The mass spectrometry data suggests a decrease in spermine synthase (and 




protective agents during disease progression promoting PrPSc production at the early, 
preclinical stage of disease.  
 
The final IPA pathway further looked at in this chapter was mitochondrial dysfunction. 
Mitochondria are able to stimulate the innate immune signalling cascade to intensify 
inflammation, through distinct stress signals or damage associated molecular patterns 
(DAMPs) such as reactive oxygen species (ROS) (Chen, Zhou, and Min 2018). Keller et al. 
(2019) found that in genetic prion disease (using mice modelling E200K CJD) oxidative 
damage, associated with mitochondrial dysfunction, is initiated well before clinical 
manifestations. Furthermore, gene expression changes associated with mitochondrial 
dysfunction have been detected in the blood of patients with early AD using microarray 
technology (Lunnon et al. 2012). Hence, altered changes are not just restricted to the brain 
in such neurodegenerative disease and they may prove to be sufficient to specifically classify 
disease before diagnosis. IPA of the buffy coat dataset identified Parkinson disease protein 7 
as part of the mitochondrial dysfunction pathway. Defects in the gene cause autosomal 
recessive, early onset Parkinson’s disease. Parkinson disease protein 7 plays an important 
part in regulation of the ROS production through interaction with the p47phox, a subunit of 
NADPH oxidase (Liu et al. 2015; Cheng et al. 2018). ROS are key mediators in initiating toll-
like receptor (TLR) signalling pathways to activate macrophages (Gallego et al. 2011); (West 
et al. 2011). In the buffy coat data there is an increase in Parkinson disease protein 7 in the 
infected samples, perhaps indicating activation and activity of leukocytes.  
 
Even though further studies are required to investigate the specific involvement of all the 
identified protein biomarkers, the mass spectrometry identified proteins in the buffy coat 
samples show an important role for immune system regulation in prion pathogenesis of BSE-
infected sheep. This is perhaps reflected in other prion and neurodegenerative diseases in 
general. In fact, immune markers such as increased TREM2 in CSF, have been 
predominantly and reproducibly associated with the early presymptomatic stages of AD 
(Villegas-Llerena et al. 2016); (Brosseron et al. 2019); (Falcon et al. 2019); (Nordengen et al. 
2019); (Suarez-Calvet et al. 2019). It suggests that the innate immune system may undergo 









spectrometry buffy coat dataset and its suggested ingenuity pathways. The proteins chosen 
for validation came from pathways with significant scoring P values as calculated by IPA 
using a Right-Tailed Fisher’s Exact Test. It is unlikely that the proteins appear in these 
pathways due to random chance. Although there are similarities to other published studies 
on prion disease, focusing on the proteins previously identified as of interest may show some 
bias and result in missing potential proteins of interest. Due to the lack of preclinical samples 
many studies are not focused on this stage of disease so may not pick up on specific 
preclinical proteins. A lot of prion disease biomarker studies also only look at brain-derived 
material so may not be as relevant. Furthermore, as infectivity has not been found in the 
blood of cattle with BSE and atypical BSE, studies focused on these samples may be 




The aim of this work is to look for proteins besides PrP that may be utilised for following 
prion infection in blood of sheep orally infected with BSE. While it likely that at the time when 
infected blood was taken during the transfusion study (12 months) there would not have 
been an accumulation of abnormal prion protein in the brain, there is likely to be other events 
occurring in the body in response to infection. It may be possible to identify changes in 
protein expression for use as diagnostic markers and to indicate disease status. However, 
the identification of non-prion protein biomarkers from blood remains challenging due to the 
inherent complexity and vast dynamic range of proteins present. In addition, a key issue with 
using blood for biomarker discovery is that its cellular components may change dramatically 
during infection or inflammation. Mass spectrometry based proteomics technology has been 
utilized to aid biomarker discovery and propel advancements in diagnostics. Here, alterations 
in protein expression of infected buffy coat samples were established by mass spectrometry.  
IPA analysis was able to predict a number of disease pathways of interest and the potential 
involvement of an active immune response has been highlighted. Seven proteins were 
suggested for a biomarker and validation of moesin by western blotting was achieved with 
both pooled and individual buffy coat samples. 
 
4.3.4 Future work 
 
The strong data generated from mass spectrometry of comparing uninfected and infected 
buffy coat samples requires further exploration. This work presents an array of relevant 
proteins, provides theories for their particular involvement in disease progression and gives 




validation, it essential that other proteins of the pathways highlighted as important by IPA are 
also tested. Validation of a full biomarker panel is the first step in a premortem test and 
would prevent the inadvertent transfusion of infected blood, enable accurate prediction of 
TSE epidemics as well as allow for greater understanding of disease pathogenesis (Wei et al. 
2011a). However, it would be necessary to overcome the issues faced here in finding 
antibodies compatible with sheep blood. Repeat experiments would better confirm the mass 
spectrometry predicted trends and including a greater number of control sheep would also 
strengthen the statistical comparison between the two groups. Performing mass 
spectrometry on individual sheep buffy coat samples or from more time points across the 
transfusion study would indicate which proteins have the greatest differential expression and 
when this occurs along the time the course of disease progression. For further work, 
validation on clinical samples to confirm application to human blood is crucial.  
 
Additionally, investigation of the biochemical properties of moesin may provide a greater 
insight into the mechanism of prion diseases by further defining the physiological process 
through cellular interaction and protein function. Overall, this will help in progressing the field 
of neurodegenerative diseases as a more comprehensive understanding of the molecular 



























In Chapter 4 I explored how WBCs were important for prion disease pathogenesis and 
proposed a biomarker panel based on the buffy coat proteome of BSE-infected sheep for 
diagnostic purposes. The objective of the work in this chapter was to develop a system to 
study the processes by which live WBCs transfer infection to other cells, and then to 
investigate if they are more efficient than infection by brain homogenate. Blood derived PrPSc 
and brain derived PrPSc are likely to have different properties in regards to aggregate size, 
solubility and even resistance to PK digestion. The brain is a solid organ that permits 
aggregate accumulation on infected nerve cells. It has been suggested that the large 
amyloid fibrils seen in the brains of patients with prion disease are actually protective agents, 
sequestering the more hazardous smaller fibrils into innocuous deposits (Caughey and 
Lansbury 2003); (Piccardo et al. 2007). Smaller, non-fibrillar PrPSc containing aggregates are 
more efficient initiators of prion disease (Silveira et al. 2005); (Chiovitti et al. 2007), as they 
provide an increased number of multiplication seeds. With blood being a fluid, moving 
medium and having a high cell turn over, it does not allow for the build up of the large 
aggregate deposits seen in the brain. Thus, as blood borne PrPSc is predominantly found in 
smaller aggregates (Chang et al. 2007); (Bannach et al. 2012) it may actually be more 
infectious.   
 
5.1.1 Current cell lines 
 
Cell lines were initially used to explore PrPSc propagation, in recent years they have been 
used as models for screening therapeutic compounds. However, cell lines pose a difficulty in 
that many are not permissive to prion infection or replication. Even those that can be infected 
are not necessarily permissive to infection by all prion agents and strains. Table 5.1 gives 
examples of some cell lines and the prion strains which they can replicate. The mouse 
neuroblastoma N2a cell line is the most extensively used cell line to date (Race, Fadness, 
and Chesebro 1987). Klöhn et al. (2003) isolated N2a cells (fast growing mouse 
neuroblastoma) highly susceptible to RML scrapie prions thus allowing the study of scrapie 
infectivity. 
 
The RK13 cell line are rabbit kidney epithelial cells which do not express endogenous rabbit 
PrPC. To achieve a high level of ovine PrP expression, the Rov9 cell line was created by 
transfection of RK13 with plasmid vectors containing the tetracycline-inducible (tet-on) 




Table 5.1: Cell lines permissive to prion infection. Below is a list with examples of 
current cell lines used to study prions in vitro (van der Merwe et al. 2015). 
 
Cell Designation Species Origin Prion Strain 
Neuronal 
N2a Mouse Neuroblastoma Chandler, RML, 139A, 22L, C506, Fukuoka-1, FU CJD 
GT1 Mouse Hypothalamic Chandler, RML, 139A, 22L, FU CJD, M1000 
SMB Mouse Scrapie-infected 
mesodermal cells 
Chandler, 139A, 22F, 79A 
SN56 Mouse Cholinergic septal 
cells 
Chandler, ME7, 22L 
CAD Mouse Catecholaminerguc RML, 22L, ME7, 301C 
PC12 Rat Pheochromocytoma 139A, ME7 
Non-Neuronal Cell Lines 
C2C12 Mouse Myotubes RML, ME7, 22L 
NTH/3T3 Mouse Fibroblast 22L 
moRK12 Rabbit Epithelial cell line 
expressing mouse 
PrPC 
22L, Chandler, M1000, mo sCJD, Fukuoka-1 
voRK13 Rabbit Epithelial cell line 
expressing vole PrPC 
Vole-adapted BSE 
OvRK13/Rov9 Rabbit Epithelial cell line 
expressing ovine 
PrPC 
PG127, LA404, SSBP/1, scrapie field isolates 
SSCA Cell Lines 
PK1 Mouse N2a RML, 22L 
R33 Mouse N2a RML, 22L 
CAD5 Mouse CAD RML, 22L, me7, 301C 
LD9 Mouse L929 RML, 22L, ME7 
L929 Mouse Fibroblast RML, 22L, ME7 
Elk21 Rabbit RK12: epithelial cell 













first cell model that can be infected by natural scrapie isolates which have not been 
previously passaged and adapted to rodents. In the presence of the antibiotic tetracycline (or 
one of its derivatives such as doxycycline), the cell line synthesises highly glycosylated PrP 
at levels similar to that seen in sheep brain (Neale et al. 2010). The susceptibility of sheep to 
scrapie is mediated by PRNP, the allele VRQ confers high susceptibility combined with a 
short incubation time for sheep exposed to the scrapie agent. In contrast ARR is associated 
with clinical resistance to the disease (Hunter 1997). Rov9 cells were used in the 
experiments for this chapter. 
 
5.1.2 Factors that affect cell line susceptibility and propagation of prions in culture 
 
It is apparent that one cell line can be infected by several prion strains. Conversely, it is clear 
that one strain can infect several different cell lines. There are likely to be several factors that 




PrP molecules expressed affects the cell line susceptibility to carry infection. Additionally, the 
general trafficking of PrP (such as the endogenous cleavage and degradation pathways of 
PrP) may be involved (Solassol, Crozet, and Lehmann 2003). Additionally, C1 cleavage is 
associated with resistance of cell lines to prion infection, while susceptible cell lines have a 
greater proportion of full length PrPC (Lewis et al. 2009). Another potentially important factor 
is the varying expression of co-factors necessary for replication of the agent (Telling et al. 
1994). Two types of cofactors, lipids and polyanions, have been identified as influencing 
prion propagation and infectivity, however the precise mechanism remains unclear (Ma 
2012); (Supattapone 2014). 
 
The formation of PrPSc in cell culture is initiated following the translocation of PrPC to the cell 
surface (Caughey and Raymond 1991). However PrPSc uptake is independent of PrPC 
expression and does not indicate a productive infection as it is also observed in 
nonpermissive cell lines (Paquet, Daude, et al. 2007). The continuous presence of PrPSc 
over multiple cell passages is indicative of a productive infection of the cell culture. This may 
be detected by western blot analysis of cell lysates treated with PK (50 μg/mL, 37°C, 1 hr) or 
by indirect immunofluorescence in fixed cells following antigen retrieval by denaturants such 
as guanidinium hydrochloride (Taraboulos, Serban, and Prusiner 1990); (Veith et al. 2009). 
 
The vertical spread from mother to daughter cells where cell division occurs affects the 
aggregate load of the cell, diluting the number of infectious particles by half. The continuous 
prion propagation in cell culture implies that there are fragmentation mechanisms in place for 
seed multiplication. The mechanical force of endocytosis possibly segregates large PrPSc 
aggregates, alternatively unidentified cofactors catalyse the fragmentation of larger 
aggregates (Krauss and Vorberg 2013). Prions are not only transmitted to progeny cells but 
are also spread to adjacent cells. Horizontal transmission by contact of neighbouring cells 
induces a prion phenotype in the recipient cells that again spreads vertically and horizontally. 
It has been shown that direct proximity between donor and recipient cells greatly increases 
infection (Kanu 2002).  
 
5.1.3 PK digestion and glycosylation pattern of prion protein 
 
There are a number of different ways to identify the presence of abnormal prion protein, the 
method used in this chapter is a well-characterised western blot. The key to a western blot 
assay for PrPSc is the use of proteinase K (PK). Normal PrPC is sensitive to PK digestion 
while PrPSc is resistant to PK digestion. Based on these differences, it is possible to 
unambiguously distinguish between the cellular form and abnormal form of prion protein in a 
sample by western blot. PrPC resolves as a triplet on SDS-PAGE gels, showing three distinct 




absence of these bands in PK treated samples containing PrPC as the procedure results in 
small peptides. Conversely, in PK treated samples containing PrPSc the bands remain 
although shifted to a lower molecular weight (Riesner 2003b). These are the N-terminally 
truncated forms of PrPSc, Figure 5.1 shows how PrP is cleaved resulting in this fully 
infectious amino acid sequence (of approximately 142 amino acids) referred to as PrP 27-30. 
 
Although the diagnosis of prion disease by detection of PrPSc using PK is a well-established 
method, studies have shown that PK sensitive pathological isoforms of PrP also play an 
important role in disease pathogenesis (Tzaban et al. 2002); (Tremblay et al. 2004); 
(Pastrana et al. 2006). 
 
5.1.4 Peripheral Blood Mononuclear Cells (PBMCs)  
 
Further to investigating the infectious nature of blood, this chapter looks at the particular 
ability of certain blood components to infect the Rov9 cell line. PBMCs refer to all blood cells 
with a round nucleus. These include monocytes, T cells, B cells, natural killer cells and a 
small number of dendritic cells. Hence, the PBMC portion of the blood contain cell types vital 
for immune monitoring events (Koncarevic et al. 2014). As mentioned in previous chapters, 
these cells have a critical role in the early pathogenesis of peripherally acquired prion 
disease particularly due to their function within the lymphoreticular system and sequential 
dissemination of prions throughout the body (Andreoletti et al. 2000). Previous studies 
indicate that PrPC surface expression and thus potential infectivity is associated with 
peripheral blood mononuclear cells (PBMC) (Herrmann et al. (2001); (Andreoletti et al. 2012; 
Halliday, Houston, and Hunter 2005). The presence of prion infectivity in different PBMC 
populations, such as lymphocytes and monocytes has been reported in scrapie-infected 
sheep (Lacroux, Vilette, et al. 2012). The ability to transmit disease by blood transfusion 
correlated with the presence of infectivity in WBCs and PBMCs as detected by bioassay in 
tg338 mice and with PrPSc identification using PMCA (Lacroux et al. 2012). 
Figure 5.1: Example of PK treated PrP. Western blot of PrPC and PrPSc following PK 






It is known that as little as 0.1 mL of whole blood from an asymptomatic scrapie infected 
sheep can transmit the disease and that 105 were the minimal number of WBCs required to 
transfer infection (Douet et al. 2016). Douet et al. (2016) also assessed the capacity of 
different PBMC subpopulations to transmit scrapie. They found that the intravenous 
administration of 106 CD45/B220+ (predominantly B lymphocyte) cells resulted in 
transmission in all recipient sheep, however the same number of CD14+ cells (monocyte 
lineage) failed to infect any recpients. Only some recipients of 106 CD4+/8+ (T lymphocytes) 
were positive, while none of the sheep that received 105 cells (CD45/B220+, CD14+ or 
CD4+/8+) developed clinical scrapie or accumulated PrPSc in their tissues. This suggests 
PBMC populations display different abilities to transmit scrapie and that CD45/B220+ and 
CD4+/8+ are not responsible for the entire capacity of WBCs to transmit blood-borne prion 
disease but instead that the other cell populations participate in this process.  
 
Further to these findings, live WBCs seem to be important for efficient transmission of 
scrapie by intravenous transfusion. When blood components from preclinical VRQ/VRQ 
sheep infected with the PG127 scrapie strain were administered intravenously to VRQ/VRQ 
TSE free recipients, WBCs displayed the same ability as whole blood to infect recipients. 
Fixation of WBCs with paraformaldehyde impaired disease transmission by transfusion in 
sheep. Whereas all recipient who received fresh WBCs succumbed to clinical disease, only 
two out four recipient sheep given PFA fixed WBCs became infected and had longer 
incubation periods than those transfused with live WBCs. This suggests that PFA fixation 
reduces the WBC associated infectivity. However, Andreoletti et al. (2012) also found that 
PFA fixation did not affect infectivity titre as measured by intracerebral inoculation in tg338 
mice (transgenic for the VRQ allele of ovine PrP). From this it can be determined that 
although the transmission of prion disease by blood transfusion is highly efficient, it is 
dependent on the viability of transfused cells rather than their infectious titre. Treatment with 
formaldehyde crosslinks cell membrane surface proteins (chemically bonding adjacent 
molecules). This impairs cellular interactions as it prevents the cell from making changes to 
its membrane. As demonstrated in cell culture studies conversion of PrPC to PrPSc during 
transmission of infection, is critically dependent on cell to cell contact (Kanu 2002).  Perhaps 
the ability of blood to efficiently transmit disease via the blood transfusion route depends on 
the ability of blood cells to interact with the host. 
 
5.1.5 Aims of work 
 
It is previously been shown that the Rov9 cell line is capable of supporting infection from 
scrapie source material. SSBP1 brain homogenate (an experimental scrapie strain) and 




shown to infect Rov9 cells (Salamat, MFK; unpublished data). Halliez et al. (2014) 
demonstrated that the Rov9 cell line can be infected with WBC homogenates 
from sheep inoculated with PG127 scrapie strain. The question raised here is whether the 
differential treatment of PBMCs from scrapie infected sheep affects their infectivity ability.  
 
The aim of this work is to develop an in vitro system in which to understand the processes by 
which live scrapie-infected WBCs transfer infection to other cells. The initial objective was to 
establish whether WBCs from scrapie infected sheep of the Roslin Scrapie Flock can infect 
the Rov9 cell line. This would reinforce the findings of Halliez et al. (2014) (who used the 
experimental scrapie source PG127), but with a natural scrapie isolate.  
 
The second aim of the work was to investigate whether live PBMC are more efficient at 
infecting Rov9 cells than either lysed PBMC or fixed PBMC. This may shed light on how 
intact (non-fixed) cells initiate infection and whether cellular interactions based on cell 
membrane surface proteins are detrimental to passing disease. The hypothesis for the 
experiments performed in this chapter is that PBMCs from infected (VRQ/VRQ) sheep will be 
able to cause infection in the Rov9 cell line but that their treatment with PFA will reduce the 



























5.2.1 Experiment 1 
 
Rov9 cells were thawed and cultured until they reached confluency in a 6 well plate, as 
described in Methods chapter (section 2.2.1). The inoculum was prepared by isolating 
PBMCs from 50 mL blood from a sheep in the Roslin Scrapie Flock, which had the PRNP 
genotype VRQ/VRQ and was showing clinical signs of scrapie, by density gradient 
centrifugation (as described in Methods 2.2.2). 
Pellets of 1 x 107 PBMCs were freeze thawed (10 mins on ice, 10 mins at room temperature) 
three times in succession to lyse cells before being taken up in 1 mL of Opti-Mem media 
warmed to 37 oC. Two wells of the 6 well plate coated in Rov9 cells were inoculated with 1 
 
Figure 5.2: Plate outline for preliminary experiment. Rov9 cells were inoculated with 
freeze-thawed 1x107 PBMC pellets or SSBP1 brain homogenate. Two methods were 
compares, the first set of cells were passaged after 4 days of incubation with the 





mL of PBMC lysate. The negative control refers to plate wells of Rov9 cells where no 
PBMCs were added. The positive controls are Rov9 cells infected with SSBP1 brain 
homogenate (1% final concentration in the same medium as used for the cells). This is 
illustrated in Figure 5.2. At Day 2, all wells were provided with fresh Opti-Mem medium 
supplemented with doxycycline.  
Two methods of passaging cells were then tested. In the first method cells were infected at 
day 0 and left in contact with the inoculum for 4 days before passaging. In the second 
method cells were in contact with the inoculum for 7 days before passaging weekly as 
described in Materials and Methods 2.2.1. Samples were collected, PK treated and Western 
blotted (Materials and Methods 2.2.4), 
 
5.2.2. Experiment 2 
 
In this experiment, PBMC were prepared in three different ways before being used as 
inoculum for the Rov9 cell line: lysed (freeze thawed, as in Experiment 1), fresh (live), or 
PFA fixed. Rov9 cells were thawed and grown to confluency in two 12 well plates, as 
previously described (Methods 2.2.3). PBMC isolated from two sheep were used in this 
experiment, one with the resistant genotype ARR/ARR (as an uninfected negative control) 
and one with the scrapie susceptible genotype VRQ/VRQ, which was showing clinical signs 
of scrapie. PBMC were isolated by density gradient centrifugation as previously described. 
Following counting, fresh PBMC were suspended in Opti-Mem medium warmed to 37 oC and 
diluted to final concentrations of 1 x 107 cells/mL, 1x 106 and 1x 105 cell/mL, and 1 mL of 
each cell concentration added to individual wells of the 12 well plate. For preparation of fixed 
PBMC, aliquots of PBMC (uninfected and infected) were suspended at 1 x 107, 1 x 106, and 
1 x 105 cells/mL in 2 % PFA diluted in Opti-Mem medium and placed on ice for 10 mins. 
They were washed three times in PBS before being added to wells of the 12 well plate. 
Lysed PBMC were prepared from suspensions of 1 x 107, 1 x 106, and 1 x 105 cells/mL by 
freeze thawing, as described for Experiment 1, and 1ml of each cell lysate added to 
individual wells of the 12 well plate. Figure 5.3 is a flowchart of events and Figure 5.4 depicts 
the plate layout. For a positive control Rov9 cells were inoculated with SSBP1 brain 
homogenate (1 % final concentration). Rov 9 cells were also inoculated with natural scrapie 
(NS) brain homogenate (1% final concentration). As a negative control Rov9 cells inoculated 
with uninfected PBMC and Rov9 cells with no PBMCs (or any additional cells) were used. 
Cells were passaged up to passage 9 (Materials and Methods 2.2.1). Cell lysates were 










Figure 5.3: Flowchart of events. The series of preparation steps involved in upscale of 
the experiment. Different sized pellets of fresh, whole PBMCs were used to inoculate the 
Rov9 cell line. For comparison and to test levels of infectivity, pellets of different sized 
PBMCs were differentially treated (either fixed in 2% PFA on ice or freeze thawed three 
times on ice and at room temperature) and also added to the Rov9 cell line. Following 
passages and collection of cell lysate, PK digestion and western blotting was used to 
determine infectivity of the PBMCs. 
 
 
Figure 5.4: Plate outline for Experiment 2. PBMCs that were treated in three different 
ways (fresh, freeze thawed and PFA fixed) were used to inoculate the Rov9 cell line to 
assess how infectivity is passed between cells. Rov9 cells were initially grown up in 12 
well plates. PBMC pellets of three sizes were used (107, 106 and 105 cells). The positive 
control was Rov9 cells inoculated with 1% SSBP1 brain homogenate, Rov9 cells were 
also inoculated with 1% natural scrapie brain homogenate and the negative control were 






5.2.3 Experiment 3 
 
This was essentially a repeat of Experiment 2, except that Rov9 cells were inoculated only 
with 1 x 107 fresh, PFA fixed, or lysed PBMC isolated from scrapie-resistant (ARR/ARR) or 
susceptible (VRQ/VRQ) sheep. For this experiment, the VRQ/VRQ sheep used was not 
showing clinical signs of scrapie (as for the previous 2 experiments) but was predicted to be 
in the late preclinical phase of infection. The plate plan for how the Rov9 cells were 
inoculated is shown in Figure 5.5.  Following transfer of cells lines into T25 flasks and a 
week of growth (as previously described), cell lines were passaged into T75 flasks. 400 µL of 
1x trypsin was added to T25 flasks and flasks were incubated for 5 mins at 37 oC. Cells were 
then disrupted with a stripette, 3.6 mL of fresh Opti-Mem media added and this cell 
suspension added to T75 flasks containing 15 mL of fresh Opt-Mem media with Doxycycline 
(1 µg/mL). Cells were passaged after a week, 1.5 mL of 1x trypsin was added to each T75 
flask and flasks incubated at 37 oC for 5 mins. Cells were then disrupted with a stripette and 
7.5 mL of fresh Opti-Mem media added. 1 mL of this cell suspension was frozen and stored 
at -80 oC, 4 mL was treated with TL1 buffer to collect samples for western blotting and the 
remaining 4 mL of cell suspension was carried forward for passaging (placed into fresh 
flasks containing 15 mL Opti-Mem with Doxycycline (1 µg/mL). This was repeated weekly 
until passage 7 (Materials and Methods 2.2.1). Cell lysates were immunoblotted after PK-




Figure 5.5: Plate outline for Experiment 3. Pellets of 1x107 PBMCs (fresh, freeze 
thawed and PFA fixed) were used to inoculate the Rov9 cells. SSBP1 brain homogenate 







5.3.1 Optimisation steps 
 
5.3.1.1 Rov9 cell line 
 
Before inoculation of Rov9 cells with PBMC, initial experiments were performed to test the 
procedure for passaging, PK digestion and western blotting. Two methods of Rov9 cell 
collection were compared using uninfected Rov9 cell frozen stock. Cells were thawed, grown 
to confluency and after the addition of doxycycline to induce PrP expression, two different 
methods of cell collection were implemented and samples processed for comparison by 
western blotting. One method of harvesting cells was by using RIPA buffer and a scraper. 
The second method was with incubation with TL1 buffer (Figure 5.6). Little difference was 
seen between the two cell collection methods but the TL1 buffer method was continued with. 
From this work it was found that cell lysate collected from a 25 cm2 flask in 1.5 mL TL1 buffer 
is equivalent to 1 mg/mL protein content. It was decided that loading 12 μg in 2X sample 
buffer gave precise and clear bands so was used for all future work (taking into account the 
maximum loading of 24 μL in 20 well gels). The concentration of PK required for PrPC 
digestion was also tested (Figure 5.7), 4 μg/mL was found to be optimal at all exposure times. 
A.   
 
B.   
 
Figure 5.6: Comparison of two alternative Rov9 cell harvesting methods. In order 
to determine which method of cell collection was more efficient Rov9 cells were 
removed with RIPA buffer and scrape inside flask (A) or incubated with TL1 buffer (B). 









The effect of increasing PK concentrations on PrPSc was tested using infected cell lysate 
(Figure 5.8). It was found that 4 μg/mL of PK did not digest PrPSc. 
 
 
5.3.1.2 Positive control 
 
RecPrP, scrapie-infected brain homogenate and Rov9 cells infected with brain homogenate 
were all tested for use as positive controls. The process of protein purification to obtain 
recPrP from bacterial glycerol stocks and NanoDrop to determine protein concentration, as 
well as the procedure used to prepare brain homogenate is detailed in the Methods chapter 
(Methods 2.2.6 and 2.2.5 respectively). The loading concentrations of each material, along 
 
Figure 5.7: Testing a range of PK concentrations for PrPC digestion. In order to 
determine the correct PK concentration to use on uninfected Rov9 cell lysate a range of 








Figure 5.8: Testing the effect of increasing PK concentrations on PrPSc. To 
investigate the effect of PK digestion on PrPSc, increasing concentrations of  





with western blot procedure (time and type of washing, blocking and transfer buffer) and PK 
digestion were refined alongside the type and concentration of antibody and xograph film 
exposure time (Figures 5.9, 5.10 and 5.11 show some example western blots). The final 







 A.      B. 
       
Figure 5.9: Western blots for the comparison of different antibodies for recPrP. 
Duplicate gels resolved with recPrP dilutions (concentration determined by NanoDrop) 
were processed simultaneously, however one was probed with BC6 antibody (A) and 




A.  B.  
Figure 5.10: Western blots for trialling different antibodies on uninfected brain 
homogenate. Following preparation of brain homogenate and microBCA for protein 
concentration, BC6 (A) and FH11 (B) were tested on dilutions of brain homogenate 








































Figure 5.11: PK digestion of Rov9 cells infected with brain homogenate. Initial 
experiments were performed where Rov9 cells were inoculated with SSBP1 brain  


















Figure 5.12: Preliminary experiment results. Rov9 cell line was infected with lysed, 
freeze thawed PBMC (1x107). Positive signal was achieved after passage 4. The image 
shows band pattern for PrPSc in PK treated cell lysates collected at passage 4 (P4) and 
passage 5 (P5) as well as the positive control (cells infected with SSBP1 brain 
homogenate). No signal is seen for uninfected cell lysate, where no PrPC or PrPSc is 
present following PK digestion. The western blot shows comparison of cells passaged 
after 4 days and after 7 days of incubation with inoculum. 
5.3.2 Experiment 1 
 
The initial aim of this work was to repeat Halliez et al. (2014) work of infecting the Rov9 cell 
line with scrapie infected WBCs. Rather than use sheep infected with the PG127 isolate, 
here the WBCs were from a flock with natural scrapie. In the Experiment 1, Rov9 cells were 
inoculated with freeze thawed PBMCs isolated on the same day from blood of a VRQ/VRQ 
sheep with clinical signs of scrapie then incubated for either 4 or 7 days before washing and 
passaging at weekly intervals. This was to test whether increasing the contact time of Rov9 
cells with the inoculum would improve efficiency of infection and conversion of PrPC to PK 
resistant PrPSc. The results for Rov9 cells infected with freeze thawed PBMCs in the 
preliminary experiment were positive after passage 4. Figure 5.12 shows the western blot of 
PK treated cell lysates. The banding pattern is similar to that of the positive control (PK 
treated SSBP1 brain homogenate). This confirms that lysed, disrupted PBMC from a 
scrapie-infected sheep are capable of initiating infection not only in those cells infected with 
usual method of infection of 4 days (Salamat et al. 2011) but also in a longer incubation with 
inoculum (7 days). No bands were observed for the negative control (cell lysate collected 







5.3.3 Experiment 2 
 
In order to replicate the findings of Experiment 1 and to determine whether live PBMCs were 
more efficient at infecting the cell line than lysed or PFA fixed PBMCs, a larger-scale 
experiment was performed. Here, PBMCs prepared by three different methods (fresh/live, 
PFA fixed, and lysed) were used to inoculate Rov9 cells at three different concentrations: 1 x 
107, 1 x 106 and 1 x 105 PBMC/well. For the negative control, cells inoculated with PBMC 
from an ARR/ARR scrapie resistant sheep were used. As an additional negative control, no 
PBMCs were added to the Rov9 cells (referred to as ‘uninfected Rov9’). For the positive 
controls Rov9 cells were inoculated with 1 % SSBP1 brain homogenate or 1 % natural 
scrapie brain homogenate and passaged weekly alongside other cell lines.  
 
Each cell line was passaged 9 times, and cell lysates from each passage were analysed for 
the presence of proteinase K (PK) resistant PrPSc by western blotting. Figure 5.13 shows the 
results of PK treated samples at passage 5. The only bands present are those for recPrP 
and 1% SSBP1 brain homogenate (Control 1) and Rov9 cells inoculated with 1% SSBP1 
brain homogenate cells. Figure 5.14 shows results obtained at passages 6 and passage 9. 
From passage 6 to passage 9 a positive signal was achieved for Rov9 cells infected with 1% 
SSBP1 brain homogenate and Rov9 cells inoculated with 1% natural scrapie brain 
homogenate.  None of the Rov9 cell cultures inoculated with PBMC preparations from either 
scrapie susceptible (VRQ/VRQ) or scrapie resistant (ARR/ARR) sheep showed a positive 
signal for PrPSc in any passage up to passage 9. 
 
The results of Experiment 2 were unexpected since it was partly a repeat of Experiment 1. 
Both Experiment 1 and Experiment 2 used 107 lysed PBMC as inoculum (which did infect the 
Rov9 cells in Experiment 1). However, the major differences between the two experiments 
were the sheep (it is possible that their blood titre was significantly different) and also the 
size of flasks and method of passaging the cells. Experiment 2 was repeated but stopped 
before reaching passage 9 due to contamination and death of cell lines. PK digestion of cells 
at passage 4 of the Experiment 2 repeat showed no positive results (none of the PBMC 







Figure 5.13: PK treated samples at passage 5. RecPrP is not PK treated. Control 1 is 
1% SSBP1 brain homogenate on its own which has been PK treated. The western blot 
shows the first appearance of a positive signal in the Rov9 treated cell lines is at 
passage 5. The bands are for Rov9 cells inoculated with 1% SSBP1 brain homogenate. 
No bands appear for Rov9 cells inoculated with differentially treat PBMC (fresh, freeze-











Figure 5.14:  Non-PK and PK treated samples at passage 6 and passage 9, 5 min 
exposure. RecPrP is not PK treated. Control 1 is 1% SSBP1 brain homogenate on its 
own which has been PK treated. Passages 6 to 9 show positive signals for Rov9 cells 
inoculated with 1% SSBP1 brain homogenate and Rov9 cells inoculated with 1% Natural 
Scrapie brain homogenate. No bands show for PK treated Rov9 cells inoculated with 






5.3.4 Experiment 3 
 
In Experiment 3, three types of PBMCs were used to evaluate the efficiency of live WBCs in 
initiating infection: fresh, freeze-thawed and PFA-fixed. 1x 107 uninfected cells and 1x 107 
infected cells (for each of the three PBMC types) were used to inoculate Rov9 cells. Only 
after passage 5 was a positive signal following PK digestion seen for Rov9 cells inoculated 
with 1% SSBP1 brain homogenate. At passage 6, PrPSc was detected in cell cultures 
inoculated with fresh, fixed and lysed PBMC from an infected sheep indicating that they had 
became infected, but also (unexpectedly) the lines inoculated with fixed and lysed PBMC 
from the uninfected scrapie resistant, negative control sheep also became infected (Figure 
5.15). For all samples equal volumes were loaded, the lack of bands for samples not PK 
treated may be due to poor technique in sample preparation, uneven cell collection or 
improper solubilisation of cell pellets. However, due to the results being similar in both 
passages it may be attributed to a much lower number of cells present in these samples, or 




Figure 5.15: Non-PK and PK treated samples for passage 6 and 7, 5 minute 
exposure. Rov9 cells inoculated with differentially treated PBMCs (fresh, freeze-thawed 
or PFA fixed).  Infected (IN) PBMC are from a scrapie-positive VRQ/VRQ sheep and 
uninfected (UN) from a scrapie-resistant ARR/ARR sheep. Both non-PK and PK treated 
samples are resolved on the same gel. For positive controls Rov9 cells inoculated with 
either natural scrapie brain homogenate  (natural scrapie BH) or SSBP1 brain 
homogenate (SSBP1 BH) were passaged weekly alongside experimental cell lines. As a 
negative control Rov9 cells with no inoculum were used (ROV9 UN) (P7 western blot 







Measuring prion infectivity is a necessary requirement for various procedures, such as 
determining the efficacy of a treatment or infectivity of a prion purification procedure. Cell line 
assays allow for quantitative in vitro analysis of prion strains, titres and biological properties. 
Here the Rov9 cell line is used to investigate the infectivity of PBMCs that have been 
differentially treated. I confirmed that lysed PBMC from a scrapie-infected sheep of the 
Roslin Cheviot Scrapie Flock were able to infect Rov9 cells. These results confirm that of 
Halliez et al. (2014) where disrupted PBMCs from sheep with PG127 classical scrapie were 
capable of passing infection to the Rov9 cell line. 
 
In Experiment 2, PBMC pellets of different sizes were differentially treated and added to 
plates of Rov9 cells. Collection and analysis of PK treated samples up to passage 9 
achieved no positive results. This is unexpected following the successful infection of the 
Rov9 cell line in the preliminary experiment. A key difference between Experiment 1 and 
Experiment 2 was the sheep that was used. It is possible that they had different titres of 
scrapie infectivity in their blood. Additionally, the method of passaging was different (T25 
flasks used in Experiment 1 compared to T75 flasks in Experiment 2). The advantage of 
using T75 flasks for continuing the passage of cells is that it prevents changes to the cell line 
being missed by using flasks that are passaged but not analysed by western blot. 
 
For Experiment 3, it was decided to run a simpler version of the second experiment. Only 
one size of PBMC pellet was utilized and focus was given to inoculum preparation. To avoid 
clumping (and any suppression of infectivity) each inoculum was added to the plate as soon 
as it was prepared. Rov9 cells inoculated with scrapie infected fresh, lysed and fixed PBMC 
became infected. The Rov9 cells inoculated with uninfected lysed or fixed (but not fresh) 
PBMC from the scrapie resistant sheep became infected. No evidence of infection in the cell 
lines inoculated with PBMC is seen until passage 6. SSBP1 brain homogenate inoculated 
Rov9 cells were positive at passage 5. This possibly indicates that the T25 passage method 
may result in more efficient infection of the cell line (as in Experiment 1 infection with the 
SSBP1 control can be detected at passage 4). This may be due to the two ways that 
infection can spread within a cell culture, either passed from an infected cell to an uninfected 
cell or when an infected cell replicates. Using a larger flask would allow for a greater portion 
of the cell suspension to be passaged rather than discarded, thus a greater number of the 
few infected cells may be retained and are able to pass on infection. Although, perhaps 
uninfected cells replicate at a faster rate than infected cells and compete for presence within 






This is an unexpected result as uninfected blood should not be able to pass infection. There 
may have been cross contamination, perhaps cells inoculated with the SSBP1 brain 
homogenate positive control got mixed with those of differentially treated PBMCs before or 
after passaging. To determine if this is the case, the experiment would need to be repeated 
to see if the same results would be achieved, rule out cross contamination and see and if 
this was a genuine finding. Although ARR/ARR sheep appear to be resistant to infection, as 
they do not develop scrapie following exposure to infection, if their WBCs are shown to 
transmit infection it may indicate that they can actually be carriers of infection. Previous 
studies have indicated the possibility of ARR/ARR sheep carrying infection. Classical scrapie 
of ARR/ARR sheep has been reported in three sheep of Germany and France (Groschup et 
al. 2007) as well as one in Japan (Ikeda et al. 1995). PrPSc was present in buccal swabs 
from ARR/ARR sheep, although at lower levels than sheep of other genotypes. Their 
presence indicate that orally available prions may be a common feature in these sheep but 
will never progress to clinical scrapie (Gough et al. 2012). However, due to the low number 
of positive results in ARR/ARR sheep, positive results could possibly be attributed to 
environmental contamination of the infected farm. Thus conclusions made from such results 
should be looked at with caution. Though, Jeffrey et al. (2014) have also shown incidence of 
infection in ARR/ARR sheep after experimental inoculation or natural exposure to classical 
scrapie and Nor98 scrapie cases have been reported in ARR/ARR sheep (Le Dur et al. 
2005). Le Dur et al. (2005) demonstrated that 3 ARR/ARR sheep efficiently transmitted 
Nor98 scrapie to transgenic mice expressing ovine PrP. It is important to note however, that 
these incidents in ARR/ARR sheep are very rare and that the evidence for their occurrence 
is not as strong as that compared to ARR/ARR sheep being resistant (Goldmann 2008). 
 
Understanding how prions move from cell to cell and progressively spread within infected 
tissue is critical for developing an intervention or delay in disease progression. Cell to cell 
transmission of infectious prions (and the conversion of PrPC to PrPSc) may occur via a 
number of different pathways, such as cell-cell contacts (Kanu 2002); (Paquet, Daude, et al. 
2007), cytoplasmic bridges or tunnelling nanotubes (Gousset et al. 2009) and also contact 
independent mechanisms via secretion of extracellular vesicles (Vilette et al. 2018; Fevrier 
and Raposo 2004). From work with Rov9 and MovS (another non-neuronal cell line derived 
from peripheral neuroglial cells, Schwann cell type) cell lines, it has been suggested that the 
cell to cell spread of prions, and progression of infection, results mainly through infection of 
neighbouring cells despite the presence of extracellular, cell-free infectivity. Analysing the 
spatial distribution of newly infected cells revealed cells proximal to the infected donor cells 
consistently accumulated more PrPSc (Paquet, Langevin, et al. 2007). An additional study 
that highlights the need for cell contact in order for a scrapie prion infected cell to convert a 




were able to convert target cells by coculture. Even when SMB cells were killed by fixation in 
aldehyde they were found to retain conversion activity. This aligns with the ability of scrapie 
infectivity to be resistant in conditions of aldehyde fixation, which is capable of killing cells 
(Pattison 1965). 
 
Although the underlying mechanisms involved in dissemination of infection among living cells 
is not clear, some active biological processes may be required to also occur during contact 
between closely apposed PrPC and PrPSc. For instance, in trogocytosis there is transfer of 
plasma membrane fragments which may also allow PrPSc to be incorporated in the 
membrane of apposed acceptor cells. This process occurs at the immune synapse during 
the interaction between antigen presenting cells and T cells but it has also been suggested 
that circulating dendritic cells (DCs) exploit the same pathway to transmit PrPSc (Klohn, 
Castro-Seoane, and Collinge 2013). In some cell culture models, prions are secreted into the 
cell culture supernatant (Baron et al. 2006); (Maas et al. 2007). A few studies have 
demonstrated that prions are often associated with exosomes released by donor cells and 
these exosomes containing PrPSc have been shown to efficiently intiate prion propagation in 
recpient cells (Kanu 2002). How exosomes make contact and how incorporated prions then 
induce infection is not currently know. It is unclear if the observed differences in spreading 
mechanisms are due to different cell culture models or strain-specific dissemination 
strategies (Krauss and Vorberg 2013). 
 
There are several activities of live cells that could initiate infection after close apposition, 
such as the release of PrPSc and its GPI-anchor with the subsequent insertion into the target 
cell membrane, a process referred to as ‘painting’ (Kooyman, Byrne, and Logan 1998). 
Studies of prion liposome complexes may provide an explanation for the activity of PrPSc in 
intact cells. There is evidence that when prion rods are solubilised and incorporated into lipid 
vesicles, there is an increase of infectivity of about 100-fold (Gabizon et al. 1988). The 
presentation of smaller, monomeric or oligomeric PrPSc embedded or anchored in a lipid 
membrane is more effective at converting cells than presentation of aggregates in 
suspension. Within the cell culture a template mechanism for conversion of PrPC may be 
taking place. The PrPSc of an infected cells may be able to act on PrPC of the target 
uninfected cell, either directly or through cleavage and transfer to the target cell. This in itself 
would catalyse the process, promoting further interaction between PrPSc and other PrPC 
along the target membrane.  
 
In conclusion, I was able to show that the Rov9 cell line could be infected using PBMC 
isolated from the Roslin natural scrapie flock. However, the results presented here are 
preliminary findings and more work is required to optimise the cell culture system. Repeat 




undertaken to confirm the results seen here. It may shed light on the requirement of ‘live’ 
(fresh not fixed) cells to pass infection and help to investigate the mechanisms of PrPSc 
propagation within cell culture. A possible way of exploring the mixed results seen in 
Experiment 3 would be to use PBMC from sheep susceptible but not exposed to scrapie, 
such as the New Zealand flock of sheep. Following this, it may be possible to compare the 
efficiency of blood and brain material to pass infection through inoculation of Rov9 cells. 
In order to explore blood-borne infectivity it would be potentially interesting to further 
separate the PBMCs into distinct cell populations (T cells, B cells NK cells and monocytes) 
and see which of the individual cells are the carriers or transmitters of prion infection in cell 
culture. Additionally, as we know plasma and platelets can pass infection (Mathiason et al. 
2010); (Andreoletti et al. 2012) it may be of interest to look at the susceptibility of Rov9 cells 
to different blood component fractions. As highlighted previously, BSE-infected sheep show 
signs of infection in their blood that may be used as an important model in the study of 
human blood product safety. The experiments may be repeated using blood from animals 
with various prion diseases (scrapie, BSE, CWD) to assess differences in their ability to 
transmit infection. Alternative model systems may also be implemented to investigate activity 
of blood derived PrPSc and if PBMCs are able to initiate infection more efficiently than brain 
homogenate. Examples of such models include be cath–a-differentiated or CAD cells (a 




























The UK population was exposed to a significant level of BSE infectivity when it entered the 
food chain in the 1980s and early 1990s. Until 2015 where there was an incident of vCJD in 
a heterozygous individual (MV), all cases had been MM at codon 129 (Mok et al. 2017). It 
raises the possibility of a further outbreak so although the vCJD epidemic is clearly in decline, 
it may be premature to be complacent about concerns for public health. Furthermore, the 
secondary transmission of vCJD through transfusion of non-leucodepleted blood has 
resulted in three clinical cases of vCJD (donations were from recipients who later went on to 
develop vCJD themselves) (Urwin et al. 2016). The incidence of vCJD in the general UK 
population has been studied via immunohistochemistry of appendectomy samples. This has 
lead to an estimation of the prevalence being 1 in 2000 of the relevant age group (Gill et al. 
2013b). It is a matter of concern since the incubation period of vCJD may be over a decade, 
resulting in an asymptomatic state (which cannot yet be identified), representing the 
unintentional risk of horizontal transmission of vCJD infection by blood transfusion, blood 
products or contaminated surgical instruments (Ironside et al. 2006).  
 
The development of a blood test to ensure the safety of blood transfusions is top priority for 
public health and the prevention of further infections. As yet there is no operational test and 
this is due to the numerous difficulties that need to be overcome. While blood from vCJD 
patients has been proven to be infectious, the concentration of infectious material is much 
lower than that of central nervous system tissue. Several studies have determined that the 
bulk of infectivity is associated with white blood cells, however plasma is also clearly 
infectious (Halliez et al. 2014; Andreoletti et al. 2012). Very little is known about the 
biochemical properties of the PrPSc in the different blood fractions, for instance the size of the 
formed aggregates and whether they are resistant to proteinase K digestion (a treatment on 
which most current rapid tests are based) (Sajnani and Requena 2012).  
 
In terms of diagnostics, there are a few methods available. Currently there is a reliance on 
tests typically performed post-mortem with the use of immunohistochemistry or enzyme-
linked immunosorbent assay (ELISA) to detect abnormal prion protein from diseased brains 
or lymphoid tissues. However, an ante-mortem method of diagnosis that could be performed 
using body fluid is highly desirable. PrPSc was detectable by PMCA in plasma from patients 
with clinical vCJD and additionally, in preclinical blood samples from two vCJD patients who 
donated blood prior to onset of their symptoms (Moda et al. 2014; Concha-Marambio et al. 




blood is not feasible by PMCA and routine use is limited by the procedure being technically 
challenging and involving long incubation periods.  
 
An alternative to identifying PrPSc is to look for other disease associated markers. It is 
imperative to find non-PrP changes relating to preclinical prion infection that can be detected 
and easily exploited for diagnostic use or for monitoring responses to treatment. Elevated 
levels of 14-3-3, S100b and tau in cerebrospinal fluid (CSF) are the current clinical 
biomarkers in use for patients with CJD (Green et al. 2001). Protein biomarkers may be 
established by proteomic profiling and mass spectrometry is a popular tool for biomarker 
discovery due to its properties of high sensitivity, speed, chemical specificity and capability 
for processing complex mixtures. However, there are a number of issues to consider when 
analysing proteomic mass spectrometric data for classification such as analyte suppression 
from highly abundant species that may obscure detection of low abundant analytes of 
interest in a highly complex mixture (Herbst et al. 2009). Mass spectrometry has previously 
been used to determine non-prion biomarkers for the diagnosis of prion disease, for example 
apolipoprotein E (ApoE) was identified as upregulated in plasma samples from C57/B16 
mice intraperitoneally inoculated with brain homogenate from mice clinically affected with 
RML prion strain (compared to those inoculated with brain homogenate from control 
unaffected mice) (Wei et al. 2011a). ApoE functions as a component of lipoproteins, 
transporting lipids through the bloodstream among various cells and tissues of the body 
(Herz and Bock 2002); (Huang and Mahley 2014).  
 
In order to tackle these issues regarding diagnostics, archived samples from the transfusion 
study on BSE infected sheep have been used. Investigating the differential expression of 
proteins occurring at a preclinical stage compared to an infectious time point may shed light 
on changes occurring in biological systems and highlight alternative markers of infection with 
potential diagnostic use.   
 
6.2 Proteomic markers that distinguish prion infected and uninfected blood   
 
Following mass spectrometry analysis of plasma and buffy coat samples at preclinical and 
infectious time points, three potential protein biomarkers were validated in plasma and one 
potential biomarker validated in buffy coat by western blotting and LI-COR imaging. The four 
proteins that have been successfully validated here demonstrate that this approach to 
biomarker identification works and that the infection specific changes in protein concentration 
identified through mass spectrometry can be verified through western blotting. However, 
further proteins of interest have been highlighted in the mass spectrometry datasets and had 




of the buffy coat dataset suggested involvement of multiple preclinical, biological pathways 
as supported by published literature on prion and neurodegenerative diseases. 
 
The three biomarkers validated in plasma were fibulin 1, vitamin D binding protein and 
hemopexin. Moesin was validated in buffy coat samples. Fibulin 1 is an extracellular matrix 
protein involved in matrix organization. Fibulin 1 associated with fibronectin modulates cell 
interactions, orientation, adhesion, spreading and motility (Twal et al. 2001). It is likely to 
contribute to prion infection susceptibility of cells through its role in the molecular 
organisation of the extracellular matrix (ECM). Cells with poorly developed ECM have more 
PrPC deposition in their matrix that may be converted to PrPSc and thus facilitate further 
infection (Imberdis and Harris 2014). The key role of vitamin D binding protein is in the 
transport of vitamin D metabolites (Chun 2012), high concentrations of vitamin D binding 
protein in serum affects T cell differentiation and responses (Kongsbak et al. 2014). It has 
previously been established as a serum biomarker for Alzheimer’s disease (AD), where 
levels were elevated in CSF (Bishnoi, Palmer, and Royall 2015). Hemopexin has previously 
been shown to be upregulated in CSF of patients with AD (Castano et al. 2006). It is the 
major vehicle for transportation of heme in plasma (preventing oxidative stress), is mainly 
expressed in the liver and is one of the acute phase reactants of which synthesis is induced 
after inflammation (Tolosano and Altruda 2002). The function of moesin is in maintaining 
epithelial integrity by regulating cell signalling events that affect actin organisation and 
polarity (Speck et al. 2003). Previous studies have also shown upregulation of moesin in 
prion disease states (Xiang et al. 2004; Chadwick et al. 2010; Jayasena et al. 2015). It is 
likely to be facilitating the movement of leukocytes and the dispersion of infection within the 
body during the early stages of disease.  
 
One of the key functions highlighted through Ingenuity Pathway Analysis (IPA) of the buffy 
coat data was the involvement of an immune response. A number of studies have also 
identified a significant number of genes associated with the immune response, including 
genes involved in the complement activation and inflammatory response pathways. Xiang et 
al. (2004) showed increased expression of genes in these pathways when analysing scrapie 
infected mouse brains. It has been suggested that the enhancement of complement proteins 
and inflammatory factors and the subsequent glial activation in the diseased brain are 
important pathogenic events in prion disease (Giese and Kretzschmar 2001). A number of 
complement proteins (C1QB, C5, C3, C1S) were also shown to have expression changes in 
the plasma dataset. C3 has previously been identified in the serum and plasma of AD and 
Parkinson’s (Zhang et al. 2004; Goldknopf et al. 2006). Riemer et al. (2004) also show a role 
for immune and inflammatory response in the scrapie infected brain. Among the genes 




C1qb, C3, C4) and markers for microglial activation and differentiation. This is confirmation 
of the results from mass spectrometry relating to other prion diseases and provides further 
evidence for the involvement of inflammatory processes, such as complement activation, in 
neurodegenerative disorders. However, Riemer et al. (2004) suggest the proinflammatory 
response is a result of peptide fragments that contribute to neuronal damage shown to be 
implicated in the pathogenesis of stroke and AD (Huang et al. 1999; McGeer and McGeer 
2002). It is unlikely that this is occurring at the 12 months post inoculation, when blood was 
taken for the infected samples of BSE infected sheep in this study, as this is early during 
disease progression. 
 
Another critical pathway identified by IPA was leukocyte extravasation signalling. A key 
feature of the inflammatory processes (and also normal immune surveillance) is the 
migration of leukocytes from circulation, across the endothelium and basement membrane 
into affected tissue. The mechanism of extravasation is induced by proinflammatory 
chemokines. For this to take place, leukocytes must first adhere to the luminal surface of the 
endothelium via integrins and their ligands, including immunoglobulin like intracellular 
adhesion molecules (Middleton et al. 2002). Leukocyte transendothelial migration, 
complement and coagulation cascades as well as chemokine signalling pathways were 
identified by analysis of differentially expressed genes from different mouse strain-prion 
combination models as biologically important pathways by Newaz, Sriram, and Bera (2015). 
They concluded that the transcriptomic data showed neuronal dysfunction in prion disease is 
strongly related to the immunological pathways. IPA of proteins associated with the amyloid 
and nonamyloid disease phenotypes depicted an association with pathways related to 
transport, cell morphology, maintenance and assembly (Moore et al. 2014). Localisation and 
metabolic processes were found to be important in bioinformatics analysis of plasma from 
mice intraperitoneally inoculated with brain homogenate from mice clinically affected with the 
RML prion strain (Wei et al. 2011b). Furthermore, leukocyte extravasation has previously 
been reported by Hwang et al. (2009). Prion infected mouse brain genes involved in this 
process include selectin ligands, adhesion molecules, chemokines and their receptors, 
transendothelial migration genes and intracellular signalling molecules. Activation of 
endothelial cells from microglia and astrocytes would enhance migration of leukocytes from 
blood and their differentiation into microglia. Genes related to cell adhesion and cell 
movement were also identified by Almeida et al. (2011) from the gene expression study of 
BSE infected medulla tissue. Hence, this is not a unique finding but instead shows that it 
may be a common feature amongst prion diseases. 
 
A number of proteins in the plasma and buffy coat datasets were acute phase proteins 
and/or implemented in the acute phase response signalling pathway. The acute phase 




microbial growth and help to restore homeostasis. Some acute phase proteins opsonize 
microorganisms and activate complement and others scavenge cellular remnants or 
neutralize proteolytic enzymes (Gruys et al. 2005a). Riemer et al. (2004) also identified acute 
phase proteins that were strongly induced in their dataset. Most strongly induced was serine 
proteinase inhibitor 2 (SPI-2). Barbisin et al. (2014) showed that acute phase signalling was 
an important function conveyed by the genes with differential expression from 
transcriptionally profiling brains of BSE infected macaques. They showed an upregulation in 
TTR which has been shown to have a neuroprotective role in AD brains (Buxbaum et al. 
2008), suggesting it may be marker of neurodegenerative disease.  
 
Analysis of the buffy coat dataset showed downregulation of the LXR/RXR activation 
pathway. It has been shown that LXR dependent gene expression is important for 
macrophage survival and the innate immune response (Joseph et al. 2003). The inhibition of 
inflammatory gene expression has been reported to occur when LXR ligands inhibit LPS- or 
cytokine- induced expression of inflammatory genes such as iNOS and IL-6 by interfering 
with NF-kB signalling (Joseph et al. 2004). A downregulation of this inhibition may lead to 
reduced inflammation. LXRs also play an important role in cholesterol uptake. The top 
canonical pathway from differentially expressed genes of BSE infected macaques in a study 
performed by Barbisin et al. (2014) was also LXR/RXR activation. They concluded that lipid 
transport is deregulated in prion infected macaques. Brown et al. (2005) show an activation 
of cholesterol biosynthesis pathways or upregulation of their genes. This suggests that 
alterations in cholesterol metabolism may be a common consequence of amyloidgenic 
process in AD and prion diseases. 
 
Some of the proteins identified in the buffy coat proteins have a link to metabolism and 
energy conversion pathways, such as PSMB10, ATP5H and IDH2. This link between 
metabolism and prion diseases has previously been suggested. From their list of 
differentially expressed proteins in the blood of BSE infected cattle, Xerxa et al. (2016) 
propose that there is a switch from glucose catabolism to fatty acid utilization, with increased 
production of ketone bodies during prion disease. It has been shown that these molecules 
are able to cross the blood brain barrier, thus Xerxa et al. (2016) suggest that during prion 
disease the concentration of ketone bodies would rise and act in the brain as neuroprotective 
molecules to prevent the neurodegeneration induced by prions. In accordance to the finding 
in this study of a number of proteins to do with energy pathways in the datasets from BSE 
infected sheep, Skretting et al. (2004) revealed genes involved in ATP production in their 
study of cDNA from the Peyer’s patches of lambs with scrapie. Chen et al. (2014) showed 
that the most affected pathways of genes differentially expressed in the CSF of patients with 





IPA also highlighted mitochondrial dysfunction to be a major pathway associated with the 
proteins in the buffy coat dataset. Mitochondria are double membrane bound organelles 
involved in ATP generation, programmed cell death and signal transduction (Friedman and 
Nunnari 2014; Shadel and Horvath 2015). Mitochondrial dysfunction has previously been 
shown to be a trigger of innate immune responses and inflammation. Due to the pleiotropic 
roles for mitochondria in cellular physiology, their dysfunction can drastically alter cell and 
tissue homeostasis and has thus been implemented in a number of diseases including 
neurodegeneration, cancer and inflammatory disorders (Dromparis and Michelakis 2013; 
Nunnari and Suomalainen 2012; Wallace 2005). Brown et al. (2005) analysed gene 
expression from mice with scrapie infected brains, the results showed activated ER and 
mitochondrial apoptosis pathways. Neuronal loss in prion disease has been documented to 
be, at least in part, associated with apoptosis (Hetz et al. 2003; Lucassen et al. 1995; Puig 
and Ferrer 2001; Williams et al. 1997). The caspase-dependent apoptotic cascade can be 
initiated by cell surface receptors, mitochondrial stress or by ER stress (Szegezdi et al. 2006; 
Senft and Ronai 2015). Perhaps dysfunction of mitochondrial activity is an early event in the 
disease process. A study performed by Skinner et al. (2006a) also showed major alterations 
in genes to with the mitochondria, they highlighted that energy production is critical for 
neuronal survival.   
 
These are important findings in dissecting the molecular mechanisms that underline early 
prion disease pathogenesis and the eventual neurotoxicity. Visualization of gene or protein 
expression changes in critical biological modules indicate what is occurring in cellular and 
subcellular compartments over the course of disease. They offer a dynamic scheme for the 
processes that characterise an early disease response. Further validation of the roles of 
specific proteins and of identified disease pathways in the definable stages of disease 
progression may yield greater insights into the importance of these processes for 
transmission of infection. For instance, epigenomic analysis will inform gene regulation, while 
proteomic and metabolomics will confirm and reveal new downstream effector pathways and 
potential molecular targets for therapeutics and preventative interventions (Omenn 2009).  
 
In regards to an ante-mortem prion disease test, it is likely that a panel of different proteins, 
rather than use of just one protein, would be the most efficient route. Combined signatures of 
multiple biomarkers can take into account patient heterogeneity and thus, provide a more 
accurate indication of patient health. Perhaps at least one protein from each pathway 
identified by IPA analysis and shown by other prion studies, would be beneficial. Blood from 
different disease stages during the transfusion study are available in the archive, they could 
be further compared by performing mass spectrometry and analysing the resulting datasets. 
Validation of results from these transfusion experiments performed with BSE infected sheep 




may be confirmed by looking at blood from other prion disease models which could be used 
to find distinctions between strains.  
 
To strengthen the preclinical test and improve the pre-mortem assay, the panel of biomarker 
proteins may be paired with microRNAs (miRNAs). These are a small class of non-coding 
RNAs that regulate protein levels post-transcriptionally (Etheridge et al. 2011). They are 
ideal biomarkers for studying normal cellular processes, pathological conditions and 
response to therapeutic intervention (Rifai, Gillette, and Carr 2006). They have a presence in 
plasma thus can be accessed through non-invasive methods and are highly stable in 
circulation. Their tissue specific expression patterns have been shown to fluctuate in 
response to inflammation, acute and chronic tissue injury and even cancer. While the low 
abundance of some proteins significantly hinder their detection, most circulating miRNAs can 
be detected by PCR. Hence, miRNAs possess many desirable properties that can only 
strengthen diagnostics when combined with protein biomarkers (Moldovan et al. 2014) Most 
recently, Norsworthy et al. (2020) identified blood miRNA signatures that were able to 
discriminate patients with sCJD from AD patients.  
 
There may be challenges of translating these experimental findings into a routine diagnostic 
test to be used in hospitals and transfusion service laboratories. The test would need to be 
robustly sensitive and specific when implemented on a large scale with a high throughput of 
samples (Rifai, Gillette, and Carr 2006). New biomarkers are only likely to be introduced into 
clinical biochemistry departments if there is strong evidence the results will improve patient 
management and outcome (Sturgeon et al. 2010). A test such as this would meet the criteria. 
A robust assay would identify silent carriers of infection and prevent transmission of disease 
by blood transfusion. In the case of blood based biomarkers for other neurodegenerative 
diseases, much progress is still required for the identification of asymptomatic individuals 
(Lashley et al. 2018). For comparison, in AD amyloid β can be measured in plasma but their 
correlation with cerebral β-amyloidosis is weak when assessed immunochemically (Olsson 
et al. 2016). However, clinically significant correlations between amyloid β and cerebral β-
amyloidosis has been measured by mass spectrometry (Kaneko et al. 2014; Nakamura et al. 
2018; Ovod et al. 2017). 
 
6.3 Development of an in vitro assay for blood borne prion infectivity 
 
It is striking that although prion infection by blood transfusion is efficient, the titres of 
infectivity in blood is much lower than that of the brain. This may be due to how cells transfer 
infection. Live white blood cells (WBCs) seem to be important for efficient transmission of 
disease via the transfusion route as illustrated by Andreoletti et al. (2012) with the use of 




paraformaldehyde (PFA) seemed to impair disease transmission, with fewer recipient 
VRQ/VRQ, prion disease free sheep succumbing to scrapie. Andreoletti et al. (2012) 
however also found that PFA fixation did not affect infectivity titre as measured by 
intracerebral inoculation in tg338 mice. From this, it can be hypothesised that transmission of 
prion disease is dependent on the viability of transfused cells. Treatment with PFA impairs 
cell to cell interactions by crosslinking cell surface proteins (Kim et al. 2017). Interaction of 
blood cells with the host is potentially vital for efficient transmission via the transfusion route. 
A viable cell culture system may help to explore these issues by comparing the efficiency of 
infection transmission of different cell types or treated cells.  
 
This work has established that the Rov9 cell line (rabbit kidney cells modified to overexpress 
VRQ sheep PrP) can be infected with lysed PBMC from blood of the Roslin Natural Scrapie 
Flock sheep. If more time was available the cell culture system could be further used to 
investigate whether involvement of cellular membrane protein interactions is necessary for 
efficient infection. The experiments would need to be repeated to clearly establish the effects 
of differential treatment (fresh, lysed, PFA fixed) on PBMCs ability to pass infection. Potential 
future work with this cell line in exploring of blood borne prion infectivity is to look at different 
PBMC populations (B cells, T cells, NK cells, monocytes), different blood components 




The outbreak of BSE and the following vCJD epidemic in the UK have prompted the need for 
a rapid, reliable and inexpensive screening method of blood. Current diagnostic tests for 
prion diseases have focused on detection of the causal agent, or neurological proteins that 
correlate with the neurological disease. The tests are inadequate because they are post-
mortem, low throughput and/or not sensitive enough to detect infection early on, in the 
preclinical stage of the disease. There have been a wide range in approaches used to 
identify viable prion disease markers that permit testing of blood samples. By comparing 
uninfected and infected sheep blood samples from a previous transfusion study, mass 
spectrometry has been able to identify a panel of potential biomarkers. Early physiological 
changes associated with prion infection (before the accumulation of PrPSc in the blood and 
the brain) have been hypothesised. This is one of the few studies to focus on changes 
detectable in blood rather than the brain, and to also to use blood of known infectivity. Thus, 
it is crucial for further work to be conducted in order for the development of a rapid and 
sensitive ante-mortem, preclinical test (Parveen et al. 2005).  
 
In experimental scrapie infection of an animal, the initial inoculum of PrPSc is rapidly cleared. 




convert uninfected target cells to produce PrPSc (Kanu 2002). However, the mechanism of 
this cell based infection is not understood. Investigating the dissemination of infection 
amongst cells may shed light on disease processes and help in the development of 
interventions or treatments to stop disease progression. This may be done through 
experiments using infectious blood components and cell assays, such as PBMC from the 
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Appendix 1: Plasma mass spectrometry results 
Accession Median(H/L) Gene Name 
ENSOARP00000016410.1 0.21875 SERPINA3 
ENSOARP00000019654.1 0.265625 HPX  
ENSOARP00000009904.1 0.265625 IPSP 
ENSOARP00000009080.1 0.28125 TF 
ENSOARP00000004002.1 0.3125 HP 
ENSOARP00000015963.1 0.359375 SERPINA1  
ENSOARP00000013350.1 0.359375 IGL@  
ENSOARP00000002222.1 0.359375 Q86SX2 
ENSOARP00000010561.1 0.390625 SAA1 
ENSOARP00000006793.1 0.390625 TTR 
ENSOARP00000009964.1 0.390625 IPSP 
ENSOARP00000014782.1 0.40625 ALB  
ENSOARP00000001046.1 0.421875 A2M  
ENSOARP00000019505.1 0.46875 IGL@  
ENSOARP00000004100.1 0.53125 A1BG  
ENSOARP00000000762.1 0.5625 C3 
ENSOARP00000008560.1 0.5625 C1QB  
ENSOARP00000020933.1 0.578125 ATP6V1A  
ENSOARP00000013478.1 0.59375 IGL@ 
ENSOARP00000012213.1 0.59375 ATP5H  
ENSOARP00000006008.1 0.59375 C5  
ENSOARP00000000757.1 0.609375 ITIH4 
ENSOARP00000013750.1 0.625 GC 
ENSOARP00000000921.1 0.625 MT-ND1  
ENSOARP00000001942.1 0.640625 CDH5  
ENSOARP00000000771.1 0.65625 C3 
ENSOARP00000001973.1 1.515625 C4A 
ENSOARP00000005881.1 1.546875 GSN  
ENSOARP00000015280.1 1.546875 SERPINF1  
ENSOARP00000006714.1 1.578125 BPIA2 
ENSOARP00000021893.1 1.609375 APOD  
ENSOARP00000003016.1 1.640625 IGHM  
ENSOARP00000016297.1 1.6875 SHBG  
ENSOARP00000004994.1 1.78125 C1S  
ENSOARP00000004316.1 1.796875 F2 
ENSOARP00000010848.1 1.890625 CONG 
ENSOARP00000013455.1 1.90625 HABP2  
ENSOARP00000001607.1 1.953125 ITIH1 




ENSOARP00000014654.1 2.015625 ITIH2 
ENSOARP00000007943.1 2.15625 C4BPA  
ENSOARP00000007474.1 2.265625 CD5L  
ENSOARP00000016248.1 2.375 SERPINA5  































Appendix 2: Buffy coat mass spectrometry results 
Accession Median(H/L) Gene Name 
ENSOARP00000017452 0.33 SMS 
ENSOARP00000007752 0.36 ISG15 
ENSOARP00000016735 0.36 PRPF19 
ENSOARP00000020212 0.39 LBP 
ENSOARP00000000988 0.43 CFHR4 
ENSOARP00000001942 0.43 CDH5 
ENSOARP00000010561 0.44 SAA2 
ENSOARP00000010686 0.48 SAA3 
ENSOARP00000000559 0.49 PZP 
ENSOARP00000001687 0.51 TIMM8A 
ENSOARP00000014091 0.52 RNF114 
ENSOARP00000006406 0.53 PAICS 
ENSOARP00000013476 0.53 RUVBL2 
ENSOARP00000015311 0.56 CCT5 
ENSOARP00000015112 0.56 SERPINF2 
ENSOARP00000010581 0.56 SAA1  
ENSOARP00000003455 0.57 PSMB10 
ENSOARP00000012339 0.57 ALDH9A1 
ENSOARP00000003727 0.58 SPTBN1 
ENSOARP00000010495 0.59 SPTAN1 
ENSOARP00000002026 0.59 COPS3 
ENSOARP00000016820 0.59 PDIA6 
ENSOARP00000015018 0.59 LYPLA1 
ENSOARP00000022524 0.6 TMOD3 
ENSOARP00000009527 0.6 SH3GLB2 
ENSOARP00000015560 0.61 CCT8 
ENSOARP00000008923 0.61 SRSF1 
ENSOARP00000022764 0.62 ACTN1 
ENSOARP00000010798 0.63 MYL6 
ENSOARP00000012882 0.63 IDH2 
ENSOARP00000000794 0.63 GLUD1 
ENSOARP00000005333 0.64 RUVBL1 
ENSOARP00000004266 0.64 HNRNPF 
ENSOARP00000010661 0.64 SMARCC2 
ENSOARP00000022149 0.64 STRAP 
ENSOARP00000014561 0.64 SRSF3 
ENSOARP00000014259 0.64 RBBP7 
ENSOARP00000009376 0.64 FH 




ENSOARP00000006283 0.65 HNRNPL 
ENSOARP00000013029 0.65 SUB1 
ENSOARP00000022478 0.65 RBBP4 
ENSOARP00000004520 0.65 CCDC6 
ENSOARP00000006306 0.66 KHSRP 
ENSOARP00000001874 0.66 PRDX3 
ENSOARP00000012213 0.66 ATP5H 
ENSOARP00000004875 0.66 TCP1 
ENSOARP00000018724 0.66 PDLIM5 
ENSOARP00000014672 0.66 LMNB2 
ENSOARP00000010106 0.66 CS 
ENSOARP00000011580 1.5 PRDX2 
ENSOARP00000018140 1.5 TSC22D4 
ENSOARP00000005022 1.5 CYB5 CYB5A 
ENSOARP00000018174 1.5 BLVRA 
ENSOARP00000011646 1.5 GSS 
ENSOARP00000013845 1.51 SERPINC1 
ENSOARP00000017187 1.52 UBE2L3 
ENSOARP00000003070 1.53 PCMT1 
ENSOARP00000000187 1.53 CIAPIN1 
ENSOARP00000022054 1.53 FETUB 
ENSOARP00000014553 1.53 PURA 
ENSOARP00000003883 1.53 PSMD7 
ENSOARP00000013259 1.53 ITGB2 
ENSOARP00000009446 1.54 HSPA1A 
ENSOARP00000010804 1.54 EFHD2 
ENSOARP00000014654 1.56 ITIH2 
ENSOARP00000002904 1.56 GBP1 
ENSOARP00000012635 1.56 PRDX6 
ENSOARP00000007392 1.57 COPS7A 
ENSOARP00000010837 1.58 PARK7 
ENSOARP00000012677 1.58 CCT7 
ENSOARP00000005414 1.59 MSN 
ENSOARP00000002274 1.59 CAMP 
ENSOARP00000001333 1.62 MAP 
ENSOARP00000013895 1.62 PITPNA 
ENSOARP00000012513 1.62 BCCIP 
ENSOARP00000011651 1.63 LCN2 
ENSOARP00000021664 1.65 CAP1 
ENSOARP00000010475 1.66 RAD23A 
ENSOARP00000011240 1.66 PGLYRP1 
ENSOARP00000017958 1.68 TKT 




ENSOARP00000018006 1.71 FRZB 
ENSOARP00000020200 1.74 PGK1 
ENSOARP00000006715 1.74 ALAD 
ENSOARP00000018863 1.74 APOL3 
ENSOARP00000001607 1.74 ITIH1 
ENSOARP00000016173 1.74 GBP1 
ENSOARP00000014964 1.75 ARG1 
ENSOARP00000018674 1.75 IGHG2 
ENSOARP00000009256 1.76 LTF 
ENSOARP00000022574 1.77 COPS2 
ENSOARP00000008093 1.78 TSC22D1 
ENSOARP00000004221 1.79 NUCB2 
ENSOARP00000021574 1.8 UBE2N 
ENSOARP00000022329 1.81 PLBD1 
ENSOARP00000012500 1.82 AKR1C3 
ENSOARP00000004816 1.82 NAMPT 
ENSOARP00000007182 1.83 OLFM4 
ENSOARP00000002425 1.84 RETN 
ENSOARP00000006648 1.87 C1orf123 
ENSOARP00000009374 1.88 PGK2 
ENSOARP00000013912 1.88 HMBS 
ENSOARP00000009640 1.88 FABP5 
ENSOARP00000004428 1.9 ALDOA 
ENSOARP00000008717 1.93 C8B 
ENSOARP00000021247 1.94 AAK1 
ENSOARP00000010386 1.94 PRTN3 
ENSOARP00000009955 1.96 AKR1C1 
ENSOARP00000017956 2.03 UQCRC1 
ENSOARP00000009967 2.23 MPO 
ENSOARP00000017556 2.24 PGLS 
ENSOARP00000004100 2.26 A1BG 
ENSOARP00000013929 2.6 ANG 
ENSOARP00000019468 2.62 TIMM10B 
ENSOARP00000019931 2.7 CAT 
ENSOARP00000000416 2.77 S100A9 
ENSOARP00000007106 2.79 BLVRB 
ENSOARP00000000449 2.84 S100A8 
ENSOARP00000006793 2.87 TTR 
ENSOARP00000008379 2.89 INMT 
ENSOARP00000019194 3.14 TXNRD2 
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